INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38001, 2305, 'Celecoxib', 'Hypertension', 'Nonsteroidal anti-inflammatory drugs (NSAIDs), including topicals, can lead to new onset of hypertension or worsening of preexisting hypertension, either of which can contribute to the increased incidence of cardiovascular events.  NSAIDs should be used with caution in patients with hypertension.  Blood pressure should be monitored closely during the initiation of NSAID therapy and throughout the course of therapy.', '2', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):|"Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38002, 2321, 'Celecoxib', 'Hypertension', 'Nonsteroidal anti-inflammatory drugs (NSAIDs), including topicals, can lead to new onset of hypertension or worsening of preexisting hypertension, either of which can contribute to the increased incidence of cardiovascular events.  NSAIDs should be used with caution in patients with hypertension.  Blood pressure should be monitored closely during the initiation of NSAID therapy and throughout the course of therapy.', '2', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):|"Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38003, 2909, 'Celecoxib', 'Hypertension', 'Nonsteroidal anti-inflammatory drugs (NSAIDs), including topicals, can lead to new onset of hypertension or worsening of preexisting hypertension, either of which can contribute to the increased incidence of cardiovascular events.  NSAIDs should be used with caution in patients with hypertension.  Blood pressure should be monitored closely during the initiation of NSAID therapy and throughout the course of therapy.', '2', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):|"Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38004, 4483, 'Celecoxib', 'Hypertension', 'Nonsteroidal anti-inflammatory drugs (NSAIDs), including topicals, can lead to new onset of hypertension or worsening of preexisting hypertension, either of which can contribute to the increased incidence of cardiovascular events.  NSAIDs should be used with caution in patients with hypertension.  Blood pressure should be monitored closely during the initiation of NSAID therapy and throughout the course of therapy.', '2', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):|"Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38005, 4484, 'Celecoxib', 'Hypertension', 'Nonsteroidal anti-inflammatory drugs (NSAIDs), including topicals, can lead to new onset of hypertension or worsening of preexisting hypertension, either of which can contribute to the increased incidence of cardiovascular events.  NSAIDs should be used with caution in patients with hypertension.  Blood pressure should be monitored closely during the initiation of NSAID therapy and throughout the course of therapy.', '2', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):|"Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38006, 14448, 'Celecoxib', 'Hypertension', 'Nonsteroidal anti-inflammatory drugs (NSAIDs), including topicals, can lead to new onset of hypertension or worsening of preexisting hypertension, either of which can contribute to the increased incidence of cardiovascular events.  NSAIDs should be used with caution in patients with hypertension.  Blood pressure should be monitored closely during the initiation of NSAID therapy and throughout the course of therapy.', '2', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):|"Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38007, 16084, 'Celecoxib', 'Hypertension', 'Nonsteroidal anti-inflammatory drugs (NSAIDs), including topicals, can lead to new onset of hypertension or worsening of preexisting hypertension, either of which can contribute to the increased incidence of cardiovascular events.  NSAIDs should be used with caution in patients with hypertension.  Blood pressure should be monitored closely during the initiation of NSAID therapy and throughout the course of therapy.', '2', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):|"Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38008, 16085, 'Celecoxib', 'Hypertension', 'Nonsteroidal anti-inflammatory drugs (NSAIDs), including topicals, can lead to new onset of hypertension or worsening of preexisting hypertension, either of which can contribute to the increased incidence of cardiovascular events.  NSAIDs should be used with caution in patients with hypertension.  Blood pressure should be monitored closely during the initiation of NSAID therapy and throughout the course of therapy.', '2', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):|"Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38009, 16087, 'Celecoxib', 'Hypertension', 'Nonsteroidal anti-inflammatory drugs (NSAIDs), including topicals, can lead to new onset of hypertension or worsening of preexisting hypertension, either of which can contribute to the increased incidence of cardiovascular events.  NSAIDs should be used with caution in patients with hypertension.  Blood pressure should be monitored closely during the initiation of NSAID therapy and throughout the course of therapy.', '2', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):|"Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38010, 16088, 'Celecoxib', 'Hypertension', 'Nonsteroidal anti-inflammatory drugs (NSAIDs), including topicals, can lead to new onset of hypertension or worsening of preexisting hypertension, either of which can contribute to the increased incidence of cardiovascular events.  NSAIDs should be used with caution in patients with hypertension.  Blood pressure should be monitored closely during the initiation of NSAID therapy and throughout the course of therapy.', '2', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):|"Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38011, 16096, 'Celecoxib', 'Hypertension', 'Nonsteroidal anti-inflammatory drugs (NSAIDs), including topicals, can lead to new onset of hypertension or worsening of preexisting hypertension, either of which can contribute to the increased incidence of cardiovascular events.  NSAIDs should be used with caution in patients with hypertension.  Blood pressure should be monitored closely during the initiation of NSAID therapy and throughout the course of therapy.', '2', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):|"Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38012, 26014, 'Celecoxib', 'Hypertension', 'Nonsteroidal anti-inflammatory drugs (NSAIDs), including topicals, can lead to new onset of hypertension or worsening of preexisting hypertension, either of which can contribute to the increased incidence of cardiovascular events.  NSAIDs should be used with caution in patients with hypertension.  Blood pressure should be monitored closely during the initiation of NSAID therapy and throughout the course of therapy.', '2', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):|"Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38013, 29532, 'Celecoxib', 'Hypertension', 'Nonsteroidal anti-inflammatory drugs (NSAIDs), including topicals, can lead to new onset of hypertension or worsening of preexisting hypertension, either of which can contribute to the increased incidence of cardiovascular events.  NSAIDs should be used with caution in patients with hypertension.  Blood pressure should be monitored closely during the initiation of NSAID therapy and throughout the course of therapy.', '2', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):|"Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38014, 30297, 'Celecoxib', 'Hypertension', 'Nonsteroidal anti-inflammatory drugs (NSAIDs), including topicals, can lead to new onset of hypertension or worsening of preexisting hypertension, either of which can contribute to the increased incidence of cardiovascular events.  NSAIDs should be used with caution in patients with hypertension.  Blood pressure should be monitored closely during the initiation of NSAID therapy and throughout the course of therapy.', '2', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):|"Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38015, 32620, 'Celecoxib', 'Hypertension', 'Nonsteroidal anti-inflammatory drugs (NSAIDs), including topicals, can lead to new onset of hypertension or worsening of preexisting hypertension, either of which can contribute to the increased incidence of cardiovascular events.  NSAIDs should be used with caution in patients with hypertension.  Blood pressure should be monitored closely during the initiation of NSAID therapy and throughout the course of therapy.', '2', '"Product Information. Indocin (indomethacin)." Merck & Co., Inc  (2002):|"Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc  (2002):|"Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals  (2001):|"Product Information. Relafen (nabumetone)." SmithKline Beecham  (2001):|"Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Dolobid (diflunisal)." Merck & Co., Inc  (2001):|"Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn  (2001):|"Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Daypro (oxaprozin)." Searle  (2001):|"Product Information. Celebrex (celecoxib)." Searle  (2001):|"Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc  (2012):|"Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38016, 2292, 'Cefuroxime', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38017, 2293, 'Cefuroxime', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38018, 2414, 'Cefuroxime', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38019, 2417, 'Cefuroxime', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38020, 6146, 'Cefuroxime', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38021, 12874, 'Cefuroxime', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38022, 16071, 'Cefuroxime', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38023, 20292, 'Cefuroxime', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38024, 20293, 'Cefuroxime', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38025, 20294, 'Cefuroxime', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38026, 20486, 'Cefuroxime', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38027, 24493, 'Cefuroxime', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38028, 24494, 'Cefuroxime', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38029, 29872, 'Cefuroxime', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38030, 29873, 'Cefuroxime', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38031, 29874, 'Cefuroxime', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38032, 29918, 'Cefuroxime', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38033, 29919, 'Cefuroxime', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38034, 29920, 'Cefuroxime', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38035, 29921, 'Cefuroxime', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38036, 29927, 'Cefuroxime', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38037, 29984, 'Cefuroxime', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38038, 2292, 'Cefuroxime', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased, and the half-lives prolonged, in patients with impaired renal function.  Neurotoxic reactions (e.g., encephalopathy, asterixis, myoclonus, seizures, coma) have been reported in such patients treated parenterally with these agents.  Dosage adjustments may be necessary, and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Staphcillin (methicillin)." Apothecon Inc  (2002):|"Product Information. Pfizerpen (penicillin)." Roerig Division  (2001):|"Product Information. Pipracil (piperacillin)." Lederle Laboratories  (2001):|"Product Information. Ticar (ticarcillin)." SmithKline Beecham  (2001):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38039, 2293, 'Cefuroxime', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased, and the half-lives prolonged, in patients with impaired renal function.  Neurotoxic reactions (e.g., encephalopathy, asterixis, myoclonus, seizures, coma) have been reported in such patients treated parenterally with these agents.  Dosage adjustments may be necessary, and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Staphcillin (methicillin)." Apothecon Inc  (2002):|"Product Information. Pfizerpen (penicillin)." Roerig Division  (2001):|"Product Information. Pipracil (piperacillin)." Lederle Laboratories  (2001):|"Product Information. Ticar (ticarcillin)." SmithKline Beecham  (2001):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38040, 2414, 'Cefuroxime', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased, and the half-lives prolonged, in patients with impaired renal function.  Neurotoxic reactions (e.g., encephalopathy, asterixis, myoclonus, seizures, coma) have been reported in such patients treated parenterally with these agents.  Dosage adjustments may be necessary, and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Staphcillin (methicillin)." Apothecon Inc  (2002):|"Product Information. Pfizerpen (penicillin)." Roerig Division  (2001):|"Product Information. Pipracil (piperacillin)." Lederle Laboratories  (2001):|"Product Information. Ticar (ticarcillin)." SmithKline Beecham  (2001):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38041, 2417, 'Cefuroxime', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased, and the half-lives prolonged, in patients with impaired renal function.  Neurotoxic reactions (e.g., encephalopathy, asterixis, myoclonus, seizures, coma) have been reported in such patients treated parenterally with these agents.  Dosage adjustments may be necessary, and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Staphcillin (methicillin)." Apothecon Inc  (2002):|"Product Information. Pfizerpen (penicillin)." Roerig Division  (2001):|"Product Information. Pipracil (piperacillin)." Lederle Laboratories  (2001):|"Product Information. Ticar (ticarcillin)." SmithKline Beecham  (2001):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38042, 6146, 'Cefuroxime', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased, and the half-lives prolonged, in patients with impaired renal function.  Neurotoxic reactions (e.g., encephalopathy, asterixis, myoclonus, seizures, coma) have been reported in such patients treated parenterally with these agents.  Dosage adjustments may be necessary, and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Staphcillin (methicillin)." Apothecon Inc  (2002):|"Product Information. Pfizerpen (penicillin)." Roerig Division  (2001):|"Product Information. Pipracil (piperacillin)." Lederle Laboratories  (2001):|"Product Information. Ticar (ticarcillin)." SmithKline Beecham  (2001):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38043, 12874, 'Cefuroxime', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased, and the half-lives prolonged, in patients with impaired renal function.  Neurotoxic reactions (e.g., encephalopathy, asterixis, myoclonus, seizures, coma) have been reported in such patients treated parenterally with these agents.  Dosage adjustments may be necessary, and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Staphcillin (methicillin)." Apothecon Inc  (2002):|"Product Information. Pfizerpen (penicillin)." Roerig Division  (2001):|"Product Information. Pipracil (piperacillin)." Lederle Laboratories  (2001):|"Product Information. Ticar (ticarcillin)." SmithKline Beecham  (2001):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38044, 16071, 'Cefuroxime', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased, and the half-lives prolonged, in patients with impaired renal function.  Neurotoxic reactions (e.g., encephalopathy, asterixis, myoclonus, seizures, coma) have been reported in such patients treated parenterally with these agents.  Dosage adjustments may be necessary, and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Staphcillin (methicillin)." Apothecon Inc  (2002):|"Product Information. Pfizerpen (penicillin)." Roerig Division  (2001):|"Product Information. Pipracil (piperacillin)." Lederle Laboratories  (2001):|"Product Information. Ticar (ticarcillin)." SmithKline Beecham  (2001):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38045, 20292, 'Cefuroxime', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased, and the half-lives prolonged, in patients with impaired renal function.  Neurotoxic reactions (e.g., encephalopathy, asterixis, myoclonus, seizures, coma) have been reported in such patients treated parenterally with these agents.  Dosage adjustments may be necessary, and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Staphcillin (methicillin)." Apothecon Inc  (2002):|"Product Information. Pfizerpen (penicillin)." Roerig Division  (2001):|"Product Information. Pipracil (piperacillin)." Lederle Laboratories  (2001):|"Product Information. Ticar (ticarcillin)." SmithKline Beecham  (2001):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38046, 20293, 'Cefuroxime', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased, and the half-lives prolonged, in patients with impaired renal function.  Neurotoxic reactions (e.g., encephalopathy, asterixis, myoclonus, seizures, coma) have been reported in such patients treated parenterally with these agents.  Dosage adjustments may be necessary, and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Staphcillin (methicillin)." Apothecon Inc  (2002):|"Product Information. Pfizerpen (penicillin)." Roerig Division  (2001):|"Product Information. Pipracil (piperacillin)." Lederle Laboratories  (2001):|"Product Information. Ticar (ticarcillin)." SmithKline Beecham  (2001):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38047, 20294, 'Cefuroxime', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased, and the half-lives prolonged, in patients with impaired renal function.  Neurotoxic reactions (e.g., encephalopathy, asterixis, myoclonus, seizures, coma) have been reported in such patients treated parenterally with these agents.  Dosage adjustments may be necessary, and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Staphcillin (methicillin)." Apothecon Inc  (2002):|"Product Information. Pfizerpen (penicillin)." Roerig Division  (2001):|"Product Information. Pipracil (piperacillin)." Lederle Laboratories  (2001):|"Product Information. Ticar (ticarcillin)." SmithKline Beecham  (2001):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38048, 20486, 'Cefuroxime', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased, and the half-lives prolonged, in patients with impaired renal function.  Neurotoxic reactions (e.g., encephalopathy, asterixis, myoclonus, seizures, coma) have been reported in such patients treated parenterally with these agents.  Dosage adjustments may be necessary, and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Staphcillin (methicillin)." Apothecon Inc  (2002):|"Product Information. Pfizerpen (penicillin)." Roerig Division  (2001):|"Product Information. Pipracil (piperacillin)." Lederle Laboratories  (2001):|"Product Information. Ticar (ticarcillin)." SmithKline Beecham  (2001):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38049, 24493, 'Cefuroxime', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased, and the half-lives prolonged, in patients with impaired renal function.  Neurotoxic reactions (e.g., encephalopathy, asterixis, myoclonus, seizures, coma) have been reported in such patients treated parenterally with these agents.  Dosage adjustments may be necessary, and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Staphcillin (methicillin)." Apothecon Inc  (2002):|"Product Information. Pfizerpen (penicillin)." Roerig Division  (2001):|"Product Information. Pipracil (piperacillin)." Lederle Laboratories  (2001):|"Product Information. Ticar (ticarcillin)." SmithKline Beecham  (2001):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38050, 24494, 'Cefuroxime', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased, and the half-lives prolonged, in patients with impaired renal function.  Neurotoxic reactions (e.g., encephalopathy, asterixis, myoclonus, seizures, coma) have been reported in such patients treated parenterally with these agents.  Dosage adjustments may be necessary, and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Staphcillin (methicillin)." Apothecon Inc  (2002):|"Product Information. Pfizerpen (penicillin)." Roerig Division  (2001):|"Product Information. Pipracil (piperacillin)." Lederle Laboratories  (2001):|"Product Information. Ticar (ticarcillin)." SmithKline Beecham  (2001):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38051, 29872, 'Cefuroxime', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased, and the half-lives prolonged, in patients with impaired renal function.  Neurotoxic reactions (e.g., encephalopathy, asterixis, myoclonus, seizures, coma) have been reported in such patients treated parenterally with these agents.  Dosage adjustments may be necessary, and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Staphcillin (methicillin)." Apothecon Inc  (2002):|"Product Information. Pfizerpen (penicillin)." Roerig Division  (2001):|"Product Information. Pipracil (piperacillin)." Lederle Laboratories  (2001):|"Product Information. Ticar (ticarcillin)." SmithKline Beecham  (2001):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38052, 29873, 'Cefuroxime', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased, and the half-lives prolonged, in patients with impaired renal function.  Neurotoxic reactions (e.g., encephalopathy, asterixis, myoclonus, seizures, coma) have been reported in such patients treated parenterally with these agents.  Dosage adjustments may be necessary, and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Staphcillin (methicillin)." Apothecon Inc  (2002):|"Product Information. Pfizerpen (penicillin)." Roerig Division  (2001):|"Product Information. Pipracil (piperacillin)." Lederle Laboratories  (2001):|"Product Information. Ticar (ticarcillin)." SmithKline Beecham  (2001):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38053, 29874, 'Cefuroxime', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased, and the half-lives prolonged, in patients with impaired renal function.  Neurotoxic reactions (e.g., encephalopathy, asterixis, myoclonus, seizures, coma) have been reported in such patients treated parenterally with these agents.  Dosage adjustments may be necessary, and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Staphcillin (methicillin)." Apothecon Inc  (2002):|"Product Information. Pfizerpen (penicillin)." Roerig Division  (2001):|"Product Information. Pipracil (piperacillin)." Lederle Laboratories  (2001):|"Product Information. Ticar (ticarcillin)." SmithKline Beecham  (2001):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38054, 29918, 'Cefuroxime', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased, and the half-lives prolonged, in patients with impaired renal function.  Neurotoxic reactions (e.g., encephalopathy, asterixis, myoclonus, seizures, coma) have been reported in such patients treated parenterally with these agents.  Dosage adjustments may be necessary, and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Staphcillin (methicillin)." Apothecon Inc  (2002):|"Product Information. Pfizerpen (penicillin)." Roerig Division  (2001):|"Product Information. Pipracil (piperacillin)." Lederle Laboratories  (2001):|"Product Information. Ticar (ticarcillin)." SmithKline Beecham  (2001):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38055, 29919, 'Cefuroxime', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased, and the half-lives prolonged, in patients with impaired renal function.  Neurotoxic reactions (e.g., encephalopathy, asterixis, myoclonus, seizures, coma) have been reported in such patients treated parenterally with these agents.  Dosage adjustments may be necessary, and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Staphcillin (methicillin)." Apothecon Inc  (2002):|"Product Information. Pfizerpen (penicillin)." Roerig Division  (2001):|"Product Information. Pipracil (piperacillin)." Lederle Laboratories  (2001):|"Product Information. Ticar (ticarcillin)." SmithKline Beecham  (2001):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38056, 29920, 'Cefuroxime', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased, and the half-lives prolonged, in patients with impaired renal function.  Neurotoxic reactions (e.g., encephalopathy, asterixis, myoclonus, seizures, coma) have been reported in such patients treated parenterally with these agents.  Dosage adjustments may be necessary, and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Staphcillin (methicillin)." Apothecon Inc  (2002):|"Product Information. Pfizerpen (penicillin)." Roerig Division  (2001):|"Product Information. Pipracil (piperacillin)." Lederle Laboratories  (2001):|"Product Information. Ticar (ticarcillin)." SmithKline Beecham  (2001):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38057, 29921, 'Cefuroxime', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased, and the half-lives prolonged, in patients with impaired renal function.  Neurotoxic reactions (e.g., encephalopathy, asterixis, myoclonus, seizures, coma) have been reported in such patients treated parenterally with these agents.  Dosage adjustments may be necessary, and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Staphcillin (methicillin)." Apothecon Inc  (2002):|"Product Information. Pfizerpen (penicillin)." Roerig Division  (2001):|"Product Information. Pipracil (piperacillin)." Lederle Laboratories  (2001):|"Product Information. Ticar (ticarcillin)." SmithKline Beecham  (2001):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38058, 29927, 'Cefuroxime', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased, and the half-lives prolonged, in patients with impaired renal function.  Neurotoxic reactions (e.g., encephalopathy, asterixis, myoclonus, seizures, coma) have been reported in such patients treated parenterally with these agents.  Dosage adjustments may be necessary, and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Staphcillin (methicillin)." Apothecon Inc  (2002):|"Product Information. Pfizerpen (penicillin)." Roerig Division  (2001):|"Product Information. Pipracil (piperacillin)." Lederle Laboratories  (2001):|"Product Information. Ticar (ticarcillin)." SmithKline Beecham  (2001):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38059, 29984, 'Cefuroxime', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased, and the half-lives prolonged, in patients with impaired renal function.  Neurotoxic reactions (e.g., encephalopathy, asterixis, myoclonus, seizures, coma) have been reported in such patients treated parenterally with these agents.  Dosage adjustments may be necessary, and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Staphcillin (methicillin)." Apothecon Inc  (2002):|"Product Information. Pfizerpen (penicillin)." Roerig Division  (2001):|"Product Information. Pipracil (piperacillin)." Lederle Laboratories  (2001):|"Product Information. Ticar (ticarcillin)." SmithKline Beecham  (2001):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38060, 2292, 'Cefuroxime', 'Diseases requiring dialysis', 'Cefuroxime serum levels can be reduced by hemodialysis and peritoneal dialysis.  A supplemental dose should be given at the end of each hemodialysis session.  There is not enough information regarding the use of cefuroxime in patients on peritoneal dialysis.', '2', '"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38061, 2293, 'Cefuroxime', 'Diseases requiring dialysis', 'Cefuroxime serum levels can be reduced by hemodialysis and peritoneal dialysis.  A supplemental dose should be given at the end of each hemodialysis session.  There is not enough information regarding the use of cefuroxime in patients on peritoneal dialysis.', '2', '"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38062, 2414, 'Cefuroxime', 'Diseases requiring dialysis', 'Cefuroxime serum levels can be reduced by hemodialysis and peritoneal dialysis.  A supplemental dose should be given at the end of each hemodialysis session.  There is not enough information regarding the use of cefuroxime in patients on peritoneal dialysis.', '2', '"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38063, 2417, 'Cefuroxime', 'Diseases requiring dialysis', 'Cefuroxime serum levels can be reduced by hemodialysis and peritoneal dialysis.  A supplemental dose should be given at the end of each hemodialysis session.  There is not enough information regarding the use of cefuroxime in patients on peritoneal dialysis.', '2', '"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38064, 6146, 'Cefuroxime', 'Diseases requiring dialysis', 'Cefuroxime serum levels can be reduced by hemodialysis and peritoneal dialysis.  A supplemental dose should be given at the end of each hemodialysis session.  There is not enough information regarding the use of cefuroxime in patients on peritoneal dialysis.', '2', '"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38065, 12874, 'Cefuroxime', 'Diseases requiring dialysis', 'Cefuroxime serum levels can be reduced by hemodialysis and peritoneal dialysis.  A supplemental dose should be given at the end of each hemodialysis session.  There is not enough information regarding the use of cefuroxime in patients on peritoneal dialysis.', '2', '"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38066, 16071, 'Cefuroxime', 'Diseases requiring dialysis', 'Cefuroxime serum levels can be reduced by hemodialysis and peritoneal dialysis.  A supplemental dose should be given at the end of each hemodialysis session.  There is not enough information regarding the use of cefuroxime in patients on peritoneal dialysis.', '2', '"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38067, 20292, 'Cefuroxime', 'Diseases requiring dialysis', 'Cefuroxime serum levels can be reduced by hemodialysis and peritoneal dialysis.  A supplemental dose should be given at the end of each hemodialysis session.  There is not enough information regarding the use of cefuroxime in patients on peritoneal dialysis.', '2', '"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38068, 20293, 'Cefuroxime', 'Diseases requiring dialysis', 'Cefuroxime serum levels can be reduced by hemodialysis and peritoneal dialysis.  A supplemental dose should be given at the end of each hemodialysis session.  There is not enough information regarding the use of cefuroxime in patients on peritoneal dialysis.', '2', '"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38069, 20294, 'Cefuroxime', 'Diseases requiring dialysis', 'Cefuroxime serum levels can be reduced by hemodialysis and peritoneal dialysis.  A supplemental dose should be given at the end of each hemodialysis session.  There is not enough information regarding the use of cefuroxime in patients on peritoneal dialysis.', '2', '"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38070, 20486, 'Cefuroxime', 'Diseases requiring dialysis', 'Cefuroxime serum levels can be reduced by hemodialysis and peritoneal dialysis.  A supplemental dose should be given at the end of each hemodialysis session.  There is not enough information regarding the use of cefuroxime in patients on peritoneal dialysis.', '2', '"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38071, 24493, 'Cefuroxime', 'Diseases requiring dialysis', 'Cefuroxime serum levels can be reduced by hemodialysis and peritoneal dialysis.  A supplemental dose should be given at the end of each hemodialysis session.  There is not enough information regarding the use of cefuroxime in patients on peritoneal dialysis.', '2', '"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38072, 24494, 'Cefuroxime', 'Diseases requiring dialysis', 'Cefuroxime serum levels can be reduced by hemodialysis and peritoneal dialysis.  A supplemental dose should be given at the end of each hemodialysis session.  There is not enough information regarding the use of cefuroxime in patients on peritoneal dialysis.', '2', '"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38073, 29872, 'Cefuroxime', 'Diseases requiring dialysis', 'Cefuroxime serum levels can be reduced by hemodialysis and peritoneal dialysis.  A supplemental dose should be given at the end of each hemodialysis session.  There is not enough information regarding the use of cefuroxime in patients on peritoneal dialysis.', '2', '"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38074, 29873, 'Cefuroxime', 'Diseases requiring dialysis', 'Cefuroxime serum levels can be reduced by hemodialysis and peritoneal dialysis.  A supplemental dose should be given at the end of each hemodialysis session.  There is not enough information regarding the use of cefuroxime in patients on peritoneal dialysis.', '2', '"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38075, 29874, 'Cefuroxime', 'Diseases requiring dialysis', 'Cefuroxime serum levels can be reduced by hemodialysis and peritoneal dialysis.  A supplemental dose should be given at the end of each hemodialysis session.  There is not enough information regarding the use of cefuroxime in patients on peritoneal dialysis.', '2', '"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38076, 29918, 'Cefuroxime', 'Diseases requiring dialysis', 'Cefuroxime serum levels can be reduced by hemodialysis and peritoneal dialysis.  A supplemental dose should be given at the end of each hemodialysis session.  There is not enough information regarding the use of cefuroxime in patients on peritoneal dialysis.', '2', '"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38077, 29919, 'Cefuroxime', 'Diseases requiring dialysis', 'Cefuroxime serum levels can be reduced by hemodialysis and peritoneal dialysis.  A supplemental dose should be given at the end of each hemodialysis session.  There is not enough information regarding the use of cefuroxime in patients on peritoneal dialysis.', '2', '"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38078, 29920, 'Cefuroxime', 'Diseases requiring dialysis', 'Cefuroxime serum levels can be reduced by hemodialysis and peritoneal dialysis.  A supplemental dose should be given at the end of each hemodialysis session.  There is not enough information regarding the use of cefuroxime in patients on peritoneal dialysis.', '2', '"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38079, 29921, 'Cefuroxime', 'Diseases requiring dialysis', 'Cefuroxime serum levels can be reduced by hemodialysis and peritoneal dialysis.  A supplemental dose should be given at the end of each hemodialysis session.  There is not enough information regarding the use of cefuroxime in patients on peritoneal dialysis.', '2', '"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38080, 29927, 'Cefuroxime', 'Diseases requiring dialysis', 'Cefuroxime serum levels can be reduced by hemodialysis and peritoneal dialysis.  A supplemental dose should be given at the end of each hemodialysis session.  There is not enough information regarding the use of cefuroxime in patients on peritoneal dialysis.', '2', '"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38081, 29984, 'Cefuroxime', 'Diseases requiring dialysis', 'Cefuroxime serum levels can be reduced by hemodialysis and peritoneal dialysis.  A supplemental dose should be given at the end of each hemodialysis session.  There is not enough information regarding the use of cefuroxime in patients on peritoneal dialysis.', '2', '"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38082, 2292, 'Cefuroxime', 'Diabetes Mellitus', 'A false-negative result for blood/plasma glucose may occur with ferricyanide tests in patients receiving cefuroxime; either the glucose oxidase or hexokinase method should be used to determine blood/plasma glucose levels during cefuroxime therapy.  Clinicians should consider the interaction with the ferricyanide test when prescribing or administering cefuroxime to patients with diabetes.', '2', '"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38083, 2293, 'Cefuroxime', 'Diabetes Mellitus', 'A false-negative result for blood/plasma glucose may occur with ferricyanide tests in patients receiving cefuroxime; either the glucose oxidase or hexokinase method should be used to determine blood/plasma glucose levels during cefuroxime therapy.  Clinicians should consider the interaction with the ferricyanide test when prescribing or administering cefuroxime to patients with diabetes.', '2', '"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38084, 2414, 'Cefuroxime', 'Diabetes Mellitus', 'A false-negative result for blood/plasma glucose may occur with ferricyanide tests in patients receiving cefuroxime; either the glucose oxidase or hexokinase method should be used to determine blood/plasma glucose levels during cefuroxime therapy.  Clinicians should consider the interaction with the ferricyanide test when prescribing or administering cefuroxime to patients with diabetes.', '2', '"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38085, 2417, 'Cefuroxime', 'Diabetes Mellitus', 'A false-negative result for blood/plasma glucose may occur with ferricyanide tests in patients receiving cefuroxime; either the glucose oxidase or hexokinase method should be used to determine blood/plasma glucose levels during cefuroxime therapy.  Clinicians should consider the interaction with the ferricyanide test when prescribing or administering cefuroxime to patients with diabetes.', '2', '"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38086, 6146, 'Cefuroxime', 'Diabetes Mellitus', 'A false-negative result for blood/plasma glucose may occur with ferricyanide tests in patients receiving cefuroxime; either the glucose oxidase or hexokinase method should be used to determine blood/plasma glucose levels during cefuroxime therapy.  Clinicians should consider the interaction with the ferricyanide test when prescribing or administering cefuroxime to patients with diabetes.', '2', '"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38087, 12874, 'Cefuroxime', 'Diabetes Mellitus', 'A false-negative result for blood/plasma glucose may occur with ferricyanide tests in patients receiving cefuroxime; either the glucose oxidase or hexokinase method should be used to determine blood/plasma glucose levels during cefuroxime therapy.  Clinicians should consider the interaction with the ferricyanide test when prescribing or administering cefuroxime to patients with diabetes.', '2', '"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38088, 16071, 'Cefuroxime', 'Diabetes Mellitus', 'A false-negative result for blood/plasma glucose may occur with ferricyanide tests in patients receiving cefuroxime; either the glucose oxidase or hexokinase method should be used to determine blood/plasma glucose levels during cefuroxime therapy.  Clinicians should consider the interaction with the ferricyanide test when prescribing or administering cefuroxime to patients with diabetes.', '2', '"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38089, 20292, 'Cefuroxime', 'Diabetes Mellitus', 'A false-negative result for blood/plasma glucose may occur with ferricyanide tests in patients receiving cefuroxime; either the glucose oxidase or hexokinase method should be used to determine blood/plasma glucose levels during cefuroxime therapy.  Clinicians should consider the interaction with the ferricyanide test when prescribing or administering cefuroxime to patients with diabetes.', '2', '"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38090, 20293, 'Cefuroxime', 'Diabetes Mellitus', 'A false-negative result for blood/plasma glucose may occur with ferricyanide tests in patients receiving cefuroxime; either the glucose oxidase or hexokinase method should be used to determine blood/plasma glucose levels during cefuroxime therapy.  Clinicians should consider the interaction with the ferricyanide test when prescribing or administering cefuroxime to patients with diabetes.', '2', '"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38091, 20294, 'Cefuroxime', 'Diabetes Mellitus', 'A false-negative result for blood/plasma glucose may occur with ferricyanide tests in patients receiving cefuroxime; either the glucose oxidase or hexokinase method should be used to determine blood/plasma glucose levels during cefuroxime therapy.  Clinicians should consider the interaction with the ferricyanide test when prescribing or administering cefuroxime to patients with diabetes.', '2', '"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38092, 20486, 'Cefuroxime', 'Diabetes Mellitus', 'A false-negative result for blood/plasma glucose may occur with ferricyanide tests in patients receiving cefuroxime; either the glucose oxidase or hexokinase method should be used to determine blood/plasma glucose levels during cefuroxime therapy.  Clinicians should consider the interaction with the ferricyanide test when prescribing or administering cefuroxime to patients with diabetes.', '2', '"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38093, 24493, 'Cefuroxime', 'Diabetes Mellitus', 'A false-negative result for blood/plasma glucose may occur with ferricyanide tests in patients receiving cefuroxime; either the glucose oxidase or hexokinase method should be used to determine blood/plasma glucose levels during cefuroxime therapy.  Clinicians should consider the interaction with the ferricyanide test when prescribing or administering cefuroxime to patients with diabetes.', '2', '"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38094, 24494, 'Cefuroxime', 'Diabetes Mellitus', 'A false-negative result for blood/plasma glucose may occur with ferricyanide tests in patients receiving cefuroxime; either the glucose oxidase or hexokinase method should be used to determine blood/plasma glucose levels during cefuroxime therapy.  Clinicians should consider the interaction with the ferricyanide test when prescribing or administering cefuroxime to patients with diabetes.', '2', '"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38095, 29872, 'Cefuroxime', 'Diabetes Mellitus', 'A false-negative result for blood/plasma glucose may occur with ferricyanide tests in patients receiving cefuroxime; either the glucose oxidase or hexokinase method should be used to determine blood/plasma glucose levels during cefuroxime therapy.  Clinicians should consider the interaction with the ferricyanide test when prescribing or administering cefuroxime to patients with diabetes.', '2', '"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38096, 29873, 'Cefuroxime', 'Diabetes Mellitus', 'A false-negative result for blood/plasma glucose may occur with ferricyanide tests in patients receiving cefuroxime; either the glucose oxidase or hexokinase method should be used to determine blood/plasma glucose levels during cefuroxime therapy.  Clinicians should consider the interaction with the ferricyanide test when prescribing or administering cefuroxime to patients with diabetes.', '2', '"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38097, 29874, 'Cefuroxime', 'Diabetes Mellitus', 'A false-negative result for blood/plasma glucose may occur with ferricyanide tests in patients receiving cefuroxime; either the glucose oxidase or hexokinase method should be used to determine blood/plasma glucose levels during cefuroxime therapy.  Clinicians should consider the interaction with the ferricyanide test when prescribing or administering cefuroxime to patients with diabetes.', '2', '"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38098, 29918, 'Cefuroxime', 'Diabetes Mellitus', 'A false-negative result for blood/plasma glucose may occur with ferricyanide tests in patients receiving cefuroxime; either the glucose oxidase or hexokinase method should be used to determine blood/plasma glucose levels during cefuroxime therapy.  Clinicians should consider the interaction with the ferricyanide test when prescribing or administering cefuroxime to patients with diabetes.', '2', '"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38099, 29919, 'Cefuroxime', 'Diabetes Mellitus', 'A false-negative result for blood/plasma glucose may occur with ferricyanide tests in patients receiving cefuroxime; either the glucose oxidase or hexokinase method should be used to determine blood/plasma glucose levels during cefuroxime therapy.  Clinicians should consider the interaction with the ferricyanide test when prescribing or administering cefuroxime to patients with diabetes.', '2', '"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38100, 29920, 'Cefuroxime', 'Diabetes Mellitus', 'A false-negative result for blood/plasma glucose may occur with ferricyanide tests in patients receiving cefuroxime; either the glucose oxidase or hexokinase method should be used to determine blood/plasma glucose levels during cefuroxime therapy.  Clinicians should consider the interaction with the ferricyanide test when prescribing or administering cefuroxime to patients with diabetes.', '2', '"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38101, 29921, 'Cefuroxime', 'Diabetes Mellitus', 'A false-negative result for blood/plasma glucose may occur with ferricyanide tests in patients receiving cefuroxime; either the glucose oxidase or hexokinase method should be used to determine blood/plasma glucose levels during cefuroxime therapy.  Clinicians should consider the interaction with the ferricyanide test when prescribing or administering cefuroxime to patients with diabetes.', '2', '"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38102, 29927, 'Cefuroxime', 'Diabetes Mellitus', 'A false-negative result for blood/plasma glucose may occur with ferricyanide tests in patients receiving cefuroxime; either the glucose oxidase or hexokinase method should be used to determine blood/plasma glucose levels during cefuroxime therapy.  Clinicians should consider the interaction with the ferricyanide test when prescribing or administering cefuroxime to patients with diabetes.', '2', '"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38103, 29984, 'Cefuroxime', 'Diabetes Mellitus', 'A false-negative result for blood/plasma glucose may occur with ferricyanide tests in patients receiving cefuroxime; either the glucose oxidase or hexokinase method should be used to determine blood/plasma glucose levels during cefuroxime therapy.  Clinicians should consider the interaction with the ferricyanide test when prescribing or administering cefuroxime to patients with diabetes.', '2', '"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38104, 2292, 'Cefuroxime', 'Epilepsy', 'Several cephalosporins (including cefuroxime) have been implicated in triggering seizures, especially in patients with renal dysfunction when the dosage was not reduced.  If seizures associated with drug therapy occur, cefuroxime should be discontinued.  Anticonvulsant therapy can be administered if clinically indicated.', '2', '"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38105, 2293, 'Cefuroxime', 'Epilepsy', 'Several cephalosporins (including cefuroxime) have been implicated in triggering seizures, especially in patients with renal dysfunction when the dosage was not reduced.  If seizures associated with drug therapy occur, cefuroxime should be discontinued.  Anticonvulsant therapy can be administered if clinically indicated.', '2', '"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38106, 2414, 'Cefuroxime', 'Epilepsy', 'Several cephalosporins (including cefuroxime) have been implicated in triggering seizures, especially in patients with renal dysfunction when the dosage was not reduced.  If seizures associated with drug therapy occur, cefuroxime should be discontinued.  Anticonvulsant therapy can be administered if clinically indicated.', '2', '"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38107, 2417, 'Cefuroxime', 'Epilepsy', 'Several cephalosporins (including cefuroxime) have been implicated in triggering seizures, especially in patients with renal dysfunction when the dosage was not reduced.  If seizures associated with drug therapy occur, cefuroxime should be discontinued.  Anticonvulsant therapy can be administered if clinically indicated.', '2', '"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38108, 6146, 'Cefuroxime', 'Epilepsy', 'Several cephalosporins (including cefuroxime) have been implicated in triggering seizures, especially in patients with renal dysfunction when the dosage was not reduced.  If seizures associated with drug therapy occur, cefuroxime should be discontinued.  Anticonvulsant therapy can be administered if clinically indicated.', '2', '"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38109, 12874, 'Cefuroxime', 'Epilepsy', 'Several cephalosporins (including cefuroxime) have been implicated in triggering seizures, especially in patients with renal dysfunction when the dosage was not reduced.  If seizures associated with drug therapy occur, cefuroxime should be discontinued.  Anticonvulsant therapy can be administered if clinically indicated.', '2', '"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38110, 16071, 'Cefuroxime', 'Epilepsy', 'Several cephalosporins (including cefuroxime) have been implicated in triggering seizures, especially in patients with renal dysfunction when the dosage was not reduced.  If seizures associated with drug therapy occur, cefuroxime should be discontinued.  Anticonvulsant therapy can be administered if clinically indicated.', '2', '"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38111, 20292, 'Cefuroxime', 'Epilepsy', 'Several cephalosporins (including cefuroxime) have been implicated in triggering seizures, especially in patients with renal dysfunction when the dosage was not reduced.  If seizures associated with drug therapy occur, cefuroxime should be discontinued.  Anticonvulsant therapy can be administered if clinically indicated.', '2', '"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38112, 20293, 'Cefuroxime', 'Epilepsy', 'Several cephalosporins (including cefuroxime) have been implicated in triggering seizures, especially in patients with renal dysfunction when the dosage was not reduced.  If seizures associated with drug therapy occur, cefuroxime should be discontinued.  Anticonvulsant therapy can be administered if clinically indicated.', '2', '"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38113, 20294, 'Cefuroxime', 'Epilepsy', 'Several cephalosporins (including cefuroxime) have been implicated in triggering seizures, especially in patients with renal dysfunction when the dosage was not reduced.  If seizures associated with drug therapy occur, cefuroxime should be discontinued.  Anticonvulsant therapy can be administered if clinically indicated.', '2', '"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38114, 20486, 'Cefuroxime', 'Epilepsy', 'Several cephalosporins (including cefuroxime) have been implicated in triggering seizures, especially in patients with renal dysfunction when the dosage was not reduced.  If seizures associated with drug therapy occur, cefuroxime should be discontinued.  Anticonvulsant therapy can be administered if clinically indicated.', '2', '"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38115, 24493, 'Cefuroxime', 'Epilepsy', 'Several cephalosporins (including cefuroxime) have been implicated in triggering seizures, especially in patients with renal dysfunction when the dosage was not reduced.  If seizures associated with drug therapy occur, cefuroxime should be discontinued.  Anticonvulsant therapy can be administered if clinically indicated.', '2', '"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38116, 24494, 'Cefuroxime', 'Epilepsy', 'Several cephalosporins (including cefuroxime) have been implicated in triggering seizures, especially in patients with renal dysfunction when the dosage was not reduced.  If seizures associated with drug therapy occur, cefuroxime should be discontinued.  Anticonvulsant therapy can be administered if clinically indicated.', '2', '"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38117, 29872, 'Cefuroxime', 'Epilepsy', 'Several cephalosporins (including cefuroxime) have been implicated in triggering seizures, especially in patients with renal dysfunction when the dosage was not reduced.  If seizures associated with drug therapy occur, cefuroxime should be discontinued.  Anticonvulsant therapy can be administered if clinically indicated.', '2', '"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38118, 29873, 'Cefuroxime', 'Epilepsy', 'Several cephalosporins (including cefuroxime) have been implicated in triggering seizures, especially in patients with renal dysfunction when the dosage was not reduced.  If seizures associated with drug therapy occur, cefuroxime should be discontinued.  Anticonvulsant therapy can be administered if clinically indicated.', '2', '"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38119, 29874, 'Cefuroxime', 'Epilepsy', 'Several cephalosporins (including cefuroxime) have been implicated in triggering seizures, especially in patients with renal dysfunction when the dosage was not reduced.  If seizures associated with drug therapy occur, cefuroxime should be discontinued.  Anticonvulsant therapy can be administered if clinically indicated.', '2', '"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38120, 29918, 'Cefuroxime', 'Epilepsy', 'Several cephalosporins (including cefuroxime) have been implicated in triggering seizures, especially in patients with renal dysfunction when the dosage was not reduced.  If seizures associated with drug therapy occur, cefuroxime should be discontinued.  Anticonvulsant therapy can be administered if clinically indicated.', '2', '"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38121, 29919, 'Cefuroxime', 'Epilepsy', 'Several cephalosporins (including cefuroxime) have been implicated in triggering seizures, especially in patients with renal dysfunction when the dosage was not reduced.  If seizures associated with drug therapy occur, cefuroxime should be discontinued.  Anticonvulsant therapy can be administered if clinically indicated.', '2', '"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38122, 29920, 'Cefuroxime', 'Epilepsy', 'Several cephalosporins (including cefuroxime) have been implicated in triggering seizures, especially in patients with renal dysfunction when the dosage was not reduced.  If seizures associated with drug therapy occur, cefuroxime should be discontinued.  Anticonvulsant therapy can be administered if clinically indicated.', '2', '"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38123, 29921, 'Cefuroxime', 'Epilepsy', 'Several cephalosporins (including cefuroxime) have been implicated in triggering seizures, especially in patients with renal dysfunction when the dosage was not reduced.  If seizures associated with drug therapy occur, cefuroxime should be discontinued.  Anticonvulsant therapy can be administered if clinically indicated.', '2', '"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38124, 29927, 'Cefuroxime', 'Epilepsy', 'Several cephalosporins (including cefuroxime) have been implicated in triggering seizures, especially in patients with renal dysfunction when the dosage was not reduced.  If seizures associated with drug therapy occur, cefuroxime should be discontinued.  Anticonvulsant therapy can be administered if clinically indicated.', '2', '"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38125, 29984, 'Cefuroxime', 'Epilepsy', 'Several cephalosporins (including cefuroxime) have been implicated in triggering seizures, especially in patients with renal dysfunction when the dosage was not reduced.  If seizures associated with drug therapy occur, cefuroxime should be discontinued.  Anticonvulsant therapy can be administered if clinically indicated.', '2', '"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38126, 2292, 'Cefuroxime', 'Heart Failure', 'Parenteral cefuroxime sodium contains approximately 54.2 mg (2.4 mEq) of sodium per gram of cefuroxime activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38127, 2293, 'Cefuroxime', 'Heart Failure', 'Parenteral cefuroxime sodium contains approximately 54.2 mg (2.4 mEq) of sodium per gram of cefuroxime activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38128, 2414, 'Cefuroxime', 'Heart Failure', 'Parenteral cefuroxime sodium contains approximately 54.2 mg (2.4 mEq) of sodium per gram of cefuroxime activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38129, 2417, 'Cefuroxime', 'Heart Failure', 'Parenteral cefuroxime sodium contains approximately 54.2 mg (2.4 mEq) of sodium per gram of cefuroxime activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38130, 6146, 'Cefuroxime', 'Heart Failure', 'Parenteral cefuroxime sodium contains approximately 54.2 mg (2.4 mEq) of sodium per gram of cefuroxime activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38131, 12874, 'Cefuroxime', 'Heart Failure', 'Parenteral cefuroxime sodium contains approximately 54.2 mg (2.4 mEq) of sodium per gram of cefuroxime activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38132, 16071, 'Cefuroxime', 'Heart Failure', 'Parenteral cefuroxime sodium contains approximately 54.2 mg (2.4 mEq) of sodium per gram of cefuroxime activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38133, 20292, 'Cefuroxime', 'Heart Failure', 'Parenteral cefuroxime sodium contains approximately 54.2 mg (2.4 mEq) of sodium per gram of cefuroxime activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38134, 20293, 'Cefuroxime', 'Heart Failure', 'Parenteral cefuroxime sodium contains approximately 54.2 mg (2.4 mEq) of sodium per gram of cefuroxime activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38135, 20294, 'Cefuroxime', 'Heart Failure', 'Parenteral cefuroxime sodium contains approximately 54.2 mg (2.4 mEq) of sodium per gram of cefuroxime activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38136, 20486, 'Cefuroxime', 'Heart Failure', 'Parenteral cefuroxime sodium contains approximately 54.2 mg (2.4 mEq) of sodium per gram of cefuroxime activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38137, 24493, 'Cefuroxime', 'Heart Failure', 'Parenteral cefuroxime sodium contains approximately 54.2 mg (2.4 mEq) of sodium per gram of cefuroxime activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38138, 24494, 'Cefuroxime', 'Heart Failure', 'Parenteral cefuroxime sodium contains approximately 54.2 mg (2.4 mEq) of sodium per gram of cefuroxime activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38139, 29872, 'Cefuroxime', 'Heart Failure', 'Parenteral cefuroxime sodium contains approximately 54.2 mg (2.4 mEq) of sodium per gram of cefuroxime activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38140, 29873, 'Cefuroxime', 'Heart Failure', 'Parenteral cefuroxime sodium contains approximately 54.2 mg (2.4 mEq) of sodium per gram of cefuroxime activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38141, 29874, 'Cefuroxime', 'Heart Failure', 'Parenteral cefuroxime sodium contains approximately 54.2 mg (2.4 mEq) of sodium per gram of cefuroxime activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38142, 29918, 'Cefuroxime', 'Heart Failure', 'Parenteral cefuroxime sodium contains approximately 54.2 mg (2.4 mEq) of sodium per gram of cefuroxime activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38143, 29919, 'Cefuroxime', 'Heart Failure', 'Parenteral cefuroxime sodium contains approximately 54.2 mg (2.4 mEq) of sodium per gram of cefuroxime activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38144, 29920, 'Cefuroxime', 'Heart Failure', 'Parenteral cefuroxime sodium contains approximately 54.2 mg (2.4 mEq) of sodium per gram of cefuroxime activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38145, 29921, 'Cefuroxime', 'Heart Failure', 'Parenteral cefuroxime sodium contains approximately 54.2 mg (2.4 mEq) of sodium per gram of cefuroxime activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38146, 29927, 'Cefuroxime', 'Heart Failure', 'Parenteral cefuroxime sodium contains approximately 54.2 mg (2.4 mEq) of sodium per gram of cefuroxime activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38147, 29984, 'Cefuroxime', 'Heart Failure', 'Parenteral cefuroxime sodium contains approximately 54.2 mg (2.4 mEq) of sodium per gram of cefuroxime activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38148, 2292, 'Cefuroxime', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38149, 2293, 'Cefuroxime', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38150, 2414, 'Cefuroxime', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38151, 2417, 'Cefuroxime', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38152, 6146, 'Cefuroxime', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38153, 12874, 'Cefuroxime', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38154, 16071, 'Cefuroxime', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38155, 20292, 'Cefuroxime', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38156, 20293, 'Cefuroxime', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38157, 20294, 'Cefuroxime', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38158, 20486, 'Cefuroxime', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38159, 24493, 'Cefuroxime', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38160, 24494, 'Cefuroxime', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38161, 29872, 'Cefuroxime', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38162, 29873, 'Cefuroxime', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38163, 29874, 'Cefuroxime', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38164, 29918, 'Cefuroxime', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38165, 29919, 'Cefuroxime', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38166, 29920, 'Cefuroxime', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38167, 29921, 'Cefuroxime', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38168, 29927, 'Cefuroxime', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38169, 29984, 'Cefuroxime', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38170, 2292, 'Cefuroxime', 'Vitamin K Deficiency', 'Cephalosporins may be associated with reduced prothrombin activity/prolonged prothrombin time.  Risk factors include renal or liver dysfunction, poor nutritional state, prolonged antimicrobial therapy, and previously stabilized on/receiving anticoagulant therapy.  Prothrombin time should be monitored in at-risk patients and managed as indicated (e.g., exogenous vitamin K administered).', '2', '"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38171, 2293, 'Cefuroxime', 'Vitamin K Deficiency', 'Cephalosporins may be associated with reduced prothrombin activity/prolonged prothrombin time.  Risk factors include renal or liver dysfunction, poor nutritional state, prolonged antimicrobial therapy, and previously stabilized on/receiving anticoagulant therapy.  Prothrombin time should be monitored in at-risk patients and managed as indicated (e.g., exogenous vitamin K administered).', '2', '"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38172, 2414, 'Cefuroxime', 'Vitamin K Deficiency', 'Cephalosporins may be associated with reduced prothrombin activity/prolonged prothrombin time.  Risk factors include renal or liver dysfunction, poor nutritional state, prolonged antimicrobial therapy, and previously stabilized on/receiving anticoagulant therapy.  Prothrombin time should be monitored in at-risk patients and managed as indicated (e.g., exogenous vitamin K administered).', '2', '"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38173, 2417, 'Cefuroxime', 'Vitamin K Deficiency', 'Cephalosporins may be associated with reduced prothrombin activity/prolonged prothrombin time.  Risk factors include renal or liver dysfunction, poor nutritional state, prolonged antimicrobial therapy, and previously stabilized on/receiving anticoagulant therapy.  Prothrombin time should be monitored in at-risk patients and managed as indicated (e.g., exogenous vitamin K administered).', '2', '"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38174, 6146, 'Cefuroxime', 'Vitamin K Deficiency', 'Cephalosporins may be associated with reduced prothrombin activity/prolonged prothrombin time.  Risk factors include renal or liver dysfunction, poor nutritional state, prolonged antimicrobial therapy, and previously stabilized on/receiving anticoagulant therapy.  Prothrombin time should be monitored in at-risk patients and managed as indicated (e.g., exogenous vitamin K administered).', '2', '"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38175, 12874, 'Cefuroxime', 'Vitamin K Deficiency', 'Cephalosporins may be associated with reduced prothrombin activity/prolonged prothrombin time.  Risk factors include renal or liver dysfunction, poor nutritional state, prolonged antimicrobial therapy, and previously stabilized on/receiving anticoagulant therapy.  Prothrombin time should be monitored in at-risk patients and managed as indicated (e.g., exogenous vitamin K administered).', '2', '"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38176, 16071, 'Cefuroxime', 'Vitamin K Deficiency', 'Cephalosporins may be associated with reduced prothrombin activity/prolonged prothrombin time.  Risk factors include renal or liver dysfunction, poor nutritional state, prolonged antimicrobial therapy, and previously stabilized on/receiving anticoagulant therapy.  Prothrombin time should be monitored in at-risk patients and managed as indicated (e.g., exogenous vitamin K administered).', '2', '"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38177, 20292, 'Cefuroxime', 'Vitamin K Deficiency', 'Cephalosporins may be associated with reduced prothrombin activity/prolonged prothrombin time.  Risk factors include renal or liver dysfunction, poor nutritional state, prolonged antimicrobial therapy, and previously stabilized on/receiving anticoagulant therapy.  Prothrombin time should be monitored in at-risk patients and managed as indicated (e.g., exogenous vitamin K administered).', '2', '"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38178, 20293, 'Cefuroxime', 'Vitamin K Deficiency', 'Cephalosporins may be associated with reduced prothrombin activity/prolonged prothrombin time.  Risk factors include renal or liver dysfunction, poor nutritional state, prolonged antimicrobial therapy, and previously stabilized on/receiving anticoagulant therapy.  Prothrombin time should be monitored in at-risk patients and managed as indicated (e.g., exogenous vitamin K administered).', '2', '"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38179, 20294, 'Cefuroxime', 'Vitamin K Deficiency', 'Cephalosporins may be associated with reduced prothrombin activity/prolonged prothrombin time.  Risk factors include renal or liver dysfunction, poor nutritional state, prolonged antimicrobial therapy, and previously stabilized on/receiving anticoagulant therapy.  Prothrombin time should be monitored in at-risk patients and managed as indicated (e.g., exogenous vitamin K administered).', '2', '"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38180, 20486, 'Cefuroxime', 'Vitamin K Deficiency', 'Cephalosporins may be associated with reduced prothrombin activity/prolonged prothrombin time.  Risk factors include renal or liver dysfunction, poor nutritional state, prolonged antimicrobial therapy, and previously stabilized on/receiving anticoagulant therapy.  Prothrombin time should be monitored in at-risk patients and managed as indicated (e.g., exogenous vitamin K administered).', '2', '"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38181, 24493, 'Cefuroxime', 'Vitamin K Deficiency', 'Cephalosporins may be associated with reduced prothrombin activity/prolonged prothrombin time.  Risk factors include renal or liver dysfunction, poor nutritional state, prolonged antimicrobial therapy, and previously stabilized on/receiving anticoagulant therapy.  Prothrombin time should be monitored in at-risk patients and managed as indicated (e.g., exogenous vitamin K administered).', '2', '"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38182, 24494, 'Cefuroxime', 'Vitamin K Deficiency', 'Cephalosporins may be associated with reduced prothrombin activity/prolonged prothrombin time.  Risk factors include renal or liver dysfunction, poor nutritional state, prolonged antimicrobial therapy, and previously stabilized on/receiving anticoagulant therapy.  Prothrombin time should be monitored in at-risk patients and managed as indicated (e.g., exogenous vitamin K administered).', '2', '"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38183, 29872, 'Cefuroxime', 'Vitamin K Deficiency', 'Cephalosporins may be associated with reduced prothrombin activity/prolonged prothrombin time.  Risk factors include renal or liver dysfunction, poor nutritional state, prolonged antimicrobial therapy, and previously stabilized on/receiving anticoagulant therapy.  Prothrombin time should be monitored in at-risk patients and managed as indicated (e.g., exogenous vitamin K administered).', '2', '"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38184, 29873, 'Cefuroxime', 'Vitamin K Deficiency', 'Cephalosporins may be associated with reduced prothrombin activity/prolonged prothrombin time.  Risk factors include renal or liver dysfunction, poor nutritional state, prolonged antimicrobial therapy, and previously stabilized on/receiving anticoagulant therapy.  Prothrombin time should be monitored in at-risk patients and managed as indicated (e.g., exogenous vitamin K administered).', '2', '"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38185, 29874, 'Cefuroxime', 'Vitamin K Deficiency', 'Cephalosporins may be associated with reduced prothrombin activity/prolonged prothrombin time.  Risk factors include renal or liver dysfunction, poor nutritional state, prolonged antimicrobial therapy, and previously stabilized on/receiving anticoagulant therapy.  Prothrombin time should be monitored in at-risk patients and managed as indicated (e.g., exogenous vitamin K administered).', '2', '"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38186, 29918, 'Cefuroxime', 'Vitamin K Deficiency', 'Cephalosporins may be associated with reduced prothrombin activity/prolonged prothrombin time.  Risk factors include renal or liver dysfunction, poor nutritional state, prolonged antimicrobial therapy, and previously stabilized on/receiving anticoagulant therapy.  Prothrombin time should be monitored in at-risk patients and managed as indicated (e.g., exogenous vitamin K administered).', '2', '"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38187, 29919, 'Cefuroxime', 'Vitamin K Deficiency', 'Cephalosporins may be associated with reduced prothrombin activity/prolonged prothrombin time.  Risk factors include renal or liver dysfunction, poor nutritional state, prolonged antimicrobial therapy, and previously stabilized on/receiving anticoagulant therapy.  Prothrombin time should be monitored in at-risk patients and managed as indicated (e.g., exogenous vitamin K administered).', '2', '"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38188, 29920, 'Cefuroxime', 'Vitamin K Deficiency', 'Cephalosporins may be associated with reduced prothrombin activity/prolonged prothrombin time.  Risk factors include renal or liver dysfunction, poor nutritional state, prolonged antimicrobial therapy, and previously stabilized on/receiving anticoagulant therapy.  Prothrombin time should be monitored in at-risk patients and managed as indicated (e.g., exogenous vitamin K administered).', '2', '"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38189, 29921, 'Cefuroxime', 'Vitamin K Deficiency', 'Cephalosporins may be associated with reduced prothrombin activity/prolonged prothrombin time.  Risk factors include renal or liver dysfunction, poor nutritional state, prolonged antimicrobial therapy, and previously stabilized on/receiving anticoagulant therapy.  Prothrombin time should be monitored in at-risk patients and managed as indicated (e.g., exogenous vitamin K administered).', '2', '"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38190, 29927, 'Cefuroxime', 'Vitamin K Deficiency', 'Cephalosporins may be associated with reduced prothrombin activity/prolonged prothrombin time.  Risk factors include renal or liver dysfunction, poor nutritional state, prolonged antimicrobial therapy, and previously stabilized on/receiving anticoagulant therapy.  Prothrombin time should be monitored in at-risk patients and managed as indicated (e.g., exogenous vitamin K administered).', '2', '"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38191, 29984, 'Cefuroxime', 'Vitamin K Deficiency', 'Cephalosporins may be associated with reduced prothrombin activity/prolonged prothrombin time.  Risk factors include renal or liver dysfunction, poor nutritional state, prolonged antimicrobial therapy, and previously stabilized on/receiving anticoagulant therapy.  Prothrombin time should be monitored in at-risk patients and managed as indicated (e.g., exogenous vitamin K administered).', '2', '"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38192, 0, 'Cephalexin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38193, 0, 'Cephalexin', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased and the half-lives prolonged in patients with impaired renal function.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy, since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', 'Bergan T "Pharmacokinetic comparison of oral bacampicillin and parenteral ampicillin." Antimicrob Agents Chemother 13 (1978):  971-4|Ehrnebo M, Nilsson SO, Boreus LO "Pharmacokinetics of ampicillin and its prodrugs bacampicillin and pivampicillin in man." J Pharmacokinet Biopharm 7 (1979):  429-51|Humbert G, Spyker DA, Fillastre JP, Leroy A "Pharmacokinetics of amoxicillin: dosage nomogram for patients with impaired renal function." Antimicrob Agents Chemother 15 (1979):  28-33|Bloch R, Szwed JJ, Sloan RS, Luft FC "Pharmacokinetics of cefaclor in normal subjects and patients with chronic renal failure." Antimicrob Agents Chemother 12 (1977):  730-2|Santoro J, Agarwal BN, Martinelli R, et al. "Pharmacology of cefaclor in normal volunteers and patients with renal failure." Antimicrob Agents Chemother 13 (1978):  951-4|Spyker DA, Thomas BL, Sande MA, Bolton WK "Pharmacokinetics of cefaclor and caphalexin: dosage nomograms for impaired renal function." Antimicrob Agents Chemother 14 (1978):  172-7|Gartenberg G, Meyers BR, Hirschman SZ, Srulevitch E "Pharmacokinetics of cefaclor in patients with stable renal impairment, and patients undergoing haemodialysis." J Antimicrob Chemother 5 (1979):  465-70|Fillastre JP, Leroy A, Humbert G, Godin M "Cefaclor pharmacokinetics and renal impairment." J Antimicrob Chemother 6 (1980):  155-6|Berman SJ, Boughton WH, Sugihara JG, et al. "Pharmacokinetics of cefaclor in patients with end stage renal disease and during hemodialysis." Antimicrob Agents Chemother 14 (1978):  281-3|Spyker DA, Gober LL, Scheld WM, et al. "Pharmacokinetics of cefaclor in renal failure: effects of multiple doses and hemodialysis." Antimicrob Agents Chemother 21 (1982):  278-81|Pommer W, Krause PH, Berg PA, et al. "Acute interstitial nephritis and non-oliguric renal failure after cefaclor treatment." Klin Wochenschr 64 (1986):  290-3|Guay DR, Meatherall RC, Harding GK, Brown GR "Pharmacokinetics of cefixime (CL 284,635; FK 027) in healthy subjects and patients with renal insufficiency." Antimicrob Agents Chemother 30 (1986):  485-90|Dhib M, Moulin B, Leroy A, et al. "Relationship between renal function and disposition of oral cefixime." Eur J Clin Pharmacol 41 (1991):  579-83|Shyu WC, Pittman KA, Wilber RB, et al. "Pharmacokinetics of cefprozil in healthy subjects and patients with renal impairment." J Clin Pharmacol 31 (1991):  362-71|Humbert G, Leroy A, Fillastre JP, Godin M "Pharmacokinetics of cefadroxil in normal subjects and in patients with renal insufficiency." Chemotherapy 25 (1979):  189-95|Leroy A, Humbert G, Godin M, Fillastre JP "Pharmacokinetics of cefadroxil in patients with impaired renal function." J Antimicrob Chemother 10 (1982):  39-46|Kabins SA, Kelner B, Walton E, Goldstein E "Cephalexin therapy as related to renal function." Am J Med Sci 259 (1970):  133-42|Kunin CM, Finkelberg Z "Oral cephalexin and ampicillin: antimicrobial activity, recovery in urine, and persistence in blood of uremic patients." Ann Intern Med 72 (1970):  349-56|Yamasaku F, Tsuchida R, Usuda Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Bailey RR, Gower PE, Dash CH "The effect of impairment of renal function and haemodialysis on serum and urine levels of cephalexin." Postgrad Med J 46 (1970):  60-4|Regamey C, Humair L "Pharmacokinetics of cephalexin in renal insufficiency." Postgrad Med J 47 Supp) (1971):  69-77|Reisberg BE, Mandelbaum JM "Cephalexin: absorption and excretion as related to renal function and hemodialysis." Infect Immun 3 (1971):  540-3|Kirby WM, de Maine JB, Serrill WS "Pharmacokinetics of the cephalosporins in healthy volunteers and uremic patients." Postgrad Med J 47 Suppl (1971):  41-6|Brogard JM, Pinget M, Dorner M, Lavillaureix J "Determination of cefalexin pharmacokinetics and dosage adjustments in relation to renal function." J Clin Pharmacol 15 (1975):  666-73|Chow M, Quintiliani R, Cunha BA, et al. "Pharmacokinetics of high-dose oral cephalosporins." J Clin Pharmacol 19 (1979):  185-94|Finkelstein ER, Quintiliani R, Nightingale CH "Pharmacokinetics of oral cephalosporins." J Pediatr 93 (1978):  902|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-99|Hori R, Okumura K, Nihira H, et al. "A new dosing regimen in renal insufficiency: application to cephalexin." Clin Pharmacol Ther 38 (1985):  290-5|St Peter JV, Borin MT, Hughes GS, et al. "Disposition of cefpodoxime proxetil in healthy volunteers and patients with impaired renal function." Antimicrob Agents Chemother 36 (1992):  126-31|Gibaldi M, Perrier D "Drug distribution and renal failure." J Clin Pharmacol 12 (1972):  201-4|Hoffman TA, Cestero R, Bullock WE "Pharmacodynamics of carbenicillin in hepatic and renal failure." Ann Intern Med 73 (1970):  173-8|Latos DL, Bryan CS, Stone WJ "Carbenicillin therapy in patients with normal and impaired renal function." Clin Pharmacol Ther 17 (1975):  692-700|Arancibia A, Droguett MT, Fuentes G, et al. "Pharmacokinetics of amoxicillin in subjects with normal and impaired renal function." Int J Clin Pharmacol Ther Toxicol 20 (1982):  447-53|Sjovall J, Westerlund D, Alvan G "Renal excretion of intravenously infused amoxycillin and ampicillin." Br J Clin Pharmacol 19 (1985):  191-201|Jackson EA, McLeod DC "Pharmacokinetics and dosing of antimicrobial agents in renal impairment, part I." Am J Hosp Pharm 31 (1974):  36-52|Bailey RR, Eastwood JB, Vaughan RB "The pharmacokinetics of an oral form of carbenicillin in patients with renal failure." Postgrad Med J 48 (1972):  422-5|Nelson JD, Reimold EW "Carbenicillin pharmacokinetics in an anephric patient." Lancet 1 (1973):  486-7|Nakano H, Sasaki K, Mizoguchi M, Ishibe T, Nihira H "Absorption and excretion of carbenicillin indanyl sodium in patients with reduced kidney function." Chemotherapy 23 (1977):  299-308|Hoffler D, Koeppe P, Corcilius M, Przyklink A "Cefpodoxime proxetil in patients with endstage renal failure on hemodialysis." Infection 18 (1990):  157-62|Yamasaku F, Tsuchida R, Usada Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Standiford HC, Jordan MC, Kirby WM "Clinical pharmacology of carbenicillin compared with other penicillins." J Infect Dis 122 (1970):  s9-13|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-97|Schwinghammer TL, Norden CW, Gill E "Pharmacokinetics of cephradine administered intravenously and orally to young and elderly subjects." J Clin Pharmacol 30 (1990):  893-9|Solomon AE, Briggs JD "The administration of cephradine to patients in renal failure." Br J Clin Pharmacol 2 (1975):  443-8|Neu HC "The pharmacokinetics of bacampicillin." Rev Infect Dis 3 (1981):  110-6|Braga PC, Fraschini F, Ceccarelli G, Scaglione F, Scarpazza G "Clinical pharmacokinetic evaluation of bacampicillin." Clin Ther 4 (1981):  32-42|DeSante KA, Zeckel ML "Pharmacokinetic profile of loracarbef." Am J Med 92 (1992):  s16-9|"Product Information. Polymox (amoxicillin)." Bristol-Myers Squibb, Princeton, NJ.|"Product Information. Spectrobid (bacampicillin)." Roerig Division  (2002):|"Product Information. Geocillin (carbenicillin)." Roerig Division  (2002):|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|Therasse DG, Farlow DS, Davidson RL, et al. "Effect of renal dysfunction on the pharmacokinetics of loracarbef." Clin Pharmacol Ther 54 (1993):  311-6|Granero L, Gimeno MJ, Torresmolina F, Chesajimenez J, Peris JE "Studies on the renal excretion mechanisms of cefadroxil." Drug Metab Dispos 22 (1994):  447-50|Hyslop DL "Cefaclor safety profile: a ten-year review." Clin Ther 11 Suppl A (1988):  83-94|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|Nix DE, Symonds WT, Hyatt JM, et al. "Comparative pharmacokinetics of oral ceftibuten, cefixime, cefaclor, and cefuroxime axetil in healthy volunteers." Pharmacotherapy 17 (1997):  121-5|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|Guay DRP "Ceftibuten: A new expanded-spectrum oral cephalosporin." Ann Pharmacother 31 (1997):  1022-33|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38194, 0, 'Cephalexin', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38195, 0, 'Cephalexin', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38196, 0, 'Cephalexin', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38197, 2224, 'Cefoperazone', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38198, 2270, 'Cefoperazone', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38199, 2274, 'Cefoperazone', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38200, 2278, 'Cefoperazone', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38201, 2279, 'Cefoperazone', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38202, 6385, 'Cefoperazone', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38203, 16001, 'Cefoperazone', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38204, 16002, 'Cefoperazone', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38205, 16022, 'Cefoperazone', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38206, 16023, 'Cefoperazone', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38207, 16024, 'Cefoperazone', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38208, 16028, 'Cefoperazone', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38209, 16051, 'Cefoperazone', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38210, 16052, 'Cefoperazone', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38211, 16057, 'Cefoperazone', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38212, 16060, 'Cefoperazone', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38213, 16296, 'Cefoperazone', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38214, 22387, 'Cefoperazone', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38215, 24726, 'Cefoperazone', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38216, 24727, 'Cefoperazone', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38217, 2224, 'Cefoperazone', 'Hypoprothrombinemias', 'Hypoprothrombinemia, with or without bleeding, has been reported rarely with various cephalosporins, particularly those containing an N-methylthiotetrazole (NMTT) side chain (cefamandole, cefmetazole, cefoperazone, cefotetan).  The sulfhydryl group of this side chain is suspected of interfering with the hepatic synthesis of prothrombin.  Risk factors include advanced age, debility, vitamin K deficiency, malnutrition, malabsorption, and severe renal or hepatobiliary impairment.  Therapy with cephalosporins containing the NMTT side chain should be administered cautiously in patients with any of these risk factors and/or significant active bleeding or a hemorrhagic diathesis.  Prophylactic administration of vitamin K may be indicated in some patients, especially when intestinal sterilization and surgical procedures are performed.', '3', 'Lerner PI, Lubin A "Coagulopathy with cefazolin in uremia." N Engl J Med 290 (1974):  1324|Fujita Y, Inoue S, Yorifuji R, et al. "Effects of cefotaxime on blood coagulation in patients with renal insufficiency." Drugs 35 (1988):  196-8|Kline SS, Mauro VF, Forney RB Jr, et al. "Cefotetan-induced disulfiram-type reactions and hypoprothrombinemia." Antimicrob Agents Chemother 31 (1987):  1328-31|Holt J "Hypoprothrombinemia and bleeding diathesis associated with cefotetan therapy in surgical patients." Arch Surg 123 (1988):  523|Conjura A, Bell W, Lipsky JJ "Cefotetan and hypoprothrombinemia." Ann Intern Med 108 (1988):  643|Kaiser CW, McAuliffe JD, Barth RJ, Lynch JA "Hypoprothrombinemia and hemorrhage in a surgical patient treated with cefotetan." Arch Surg 126 (1991):  524-5|Wurtz RM, Sande MA "Cefotetan and coagulopathy." J Infect Dis 160 (1989):  555-6|Shimada K, Matsuda T, Inamatsu T, Urayama K "Bleeding secondary to vitamin K deficiency in patients receiving parenteral cephem antibiotics." J Antimicrob Chemother 14 (1984):  325-30|Fass RJ, Copelan EA, Brandt JT, Moeschberger ML, Ashton JJ "Platelet-mediated bleeding caused by broad-spectrum penicillins." J Infect Dis 155 (1987):  1242-8|Sanburg AL, Hughes JD, Nichols C "Antibiotic-induced hypoprothrombinaemia." Med J Aust 143 (1985):  387-8|Alitalo R, Ruutu M, Valtonen V, et al. "Hypoprothrombinaemia and bleeding during administration of cefamandole and cefoperazone." Ann Clin Res 17 (1985):  116-9|Bertino JS, Kozak AJ, Reese RE, Chiarello LA "Hypoprothrombinemia associated with cefamandole use in a rural teaching hospital." Arch Intern Med 146 (1986):  1125-8|Yangco BG, Palumbo JA, Nolen T, et al. "Comparative multicentre evaluation of the safety and efficacy of ceftazidime versus cefamandole for pneumonia." J Antimicrob Chemother 18 (1986):  521-9|O''Donnell D "Hypoprothrombinaemia associated with use of cephamandole." Aust N Z J Surg 61 (1991):  471-2|Tibbitts JS, Lipsky JJ "Effect of biliary diversion on the ability of cefamandole to inhibit vitamin K metabolism." Drug Metabol Drug Interact 7 (1989):  149-60|Cristiano P "Hypoprothrombinemia associated with cefoperazone treatment." Drug Intell Clin Pharm 18 (1984):  314-6|Meisel S "Hypoprothrombinemia due to cefoperazone." Drug Intell Clin Pharm 18 (1984):  316|Parker SW, Baxter J, Beam TR "Cefoperazone-induced coagulopathy." Lancet 1 (1984):  1016|Andrassy K, Koderisch J, Fritz S, et al. "Alteration of hemostasis associated with cefoperazone treatment." Infection 14 (1986):  27-31|Mueller RJ, Green D, Phair JP "Hypoprothrombinemia associated with cefoperazone therapy." South Med J 80 (1987):  1360-2|Brown RB, Klar J, Lemeshow S, Teres D, Pastides H, Sands M "Enhanced bleeding with cefoxitin or moxalactam." Arch Intern Med 146 (1986):  2159-64|Shenkenberg TD, Mackowiak PA, Smith JW "Coagulopathy and hemorrhage associated with cefoperazone therapy in a patient with renal failure." South Med J 78 (1985):  488-9|D''Elia JA, Kaldany A, Miller DG, et al. "Moxalactam bleeding and renal insufficiency." JAMA 249 (1983):  1565|Clark J, Hochman R, Rolla A, et al. "Coagulopathy associated with the use of cephalosporin or moxalactam antibiotics in acute and chronic renal failure." Clin Exp Dial Apheresis 7 (1983):  177-90|Shimanda K, Matsuda T, Inamatsu T, Urayama K "Bleeding secondary to vitamin K deficiency in patients receiving parenteral cephem antibiotics." J Antimicrob Chemother 14 (1984):  325-30|Sanburg AL, Hughes JD, Nichols C "Antibiotic-induced hypoprothrombinaemia." Med J Aust 143 (1985):  387-8|Natelson EA, Brown CH, 3d  Bradshaw MW, Alfrey CP, Jr  Williams TW, Jr "Influence of cephalosporin antibiotics on blood coagulation and platelet function." Antimicrob Agents Chemother 9 (1976):  91-3|Freedy HR, Cetnarowski AB, Lumish RM, Schafer FJ "Cefoperazone-induced coagulopathy." Drug Intell Clin Pharm 20 (1986):  281-3|Osborne JC "Hypoprothrombinemia and bleeding due to cefoperazone." Ann Intern Med 102 (1985):  721-2|Haubenstock A, Schmidt P, Zazgornik J, Balcke P, Kopsa H "Hypoprothrombinaemic bleeding associated with ceftriaxone." Lancet 1 (1983):  1215-6|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jahnchen E, Ritz E "Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status." J Clin Pharmacol 28 (1988):  88-95|Riancho JA, Olmos JM, Sedano C "Life-threatening bleeding in a patient treated with cefonicid." Ann Intern Med 123 (1995):  472-3|Breen GA, Stpeter WL "Hypoprothrombinemia associated with cefmetazole." Ann Pharmacother 31 (1997):  180-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38218, 2270, 'Cefoperazone', 'Hypoprothrombinemias', 'Hypoprothrombinemia, with or without bleeding, has been reported rarely with various cephalosporins, particularly those containing an N-methylthiotetrazole (NMTT) side chain (cefamandole, cefmetazole, cefoperazone, cefotetan).  The sulfhydryl group of this side chain is suspected of interfering with the hepatic synthesis of prothrombin.  Risk factors include advanced age, debility, vitamin K deficiency, malnutrition, malabsorption, and severe renal or hepatobiliary impairment.  Therapy with cephalosporins containing the NMTT side chain should be administered cautiously in patients with any of these risk factors and/or significant active bleeding or a hemorrhagic diathesis.  Prophylactic administration of vitamin K may be indicated in some patients, especially when intestinal sterilization and surgical procedures are performed.', '3', 'Lerner PI, Lubin A "Coagulopathy with cefazolin in uremia." N Engl J Med 290 (1974):  1324|Fujita Y, Inoue S, Yorifuji R, et al. "Effects of cefotaxime on blood coagulation in patients with renal insufficiency." Drugs 35 (1988):  196-8|Kline SS, Mauro VF, Forney RB Jr, et al. "Cefotetan-induced disulfiram-type reactions and hypoprothrombinemia." Antimicrob Agents Chemother 31 (1987):  1328-31|Holt J "Hypoprothrombinemia and bleeding diathesis associated with cefotetan therapy in surgical patients." Arch Surg 123 (1988):  523|Conjura A, Bell W, Lipsky JJ "Cefotetan and hypoprothrombinemia." Ann Intern Med 108 (1988):  643|Kaiser CW, McAuliffe JD, Barth RJ, Lynch JA "Hypoprothrombinemia and hemorrhage in a surgical patient treated with cefotetan." Arch Surg 126 (1991):  524-5|Wurtz RM, Sande MA "Cefotetan and coagulopathy." J Infect Dis 160 (1989):  555-6|Shimada K, Matsuda T, Inamatsu T, Urayama K "Bleeding secondary to vitamin K deficiency in patients receiving parenteral cephem antibiotics." J Antimicrob Chemother 14 (1984):  325-30|Fass RJ, Copelan EA, Brandt JT, Moeschberger ML, Ashton JJ "Platelet-mediated bleeding caused by broad-spectrum penicillins." J Infect Dis 155 (1987):  1242-8|Sanburg AL, Hughes JD, Nichols C "Antibiotic-induced hypoprothrombinaemia." Med J Aust 143 (1985):  387-8|Alitalo R, Ruutu M, Valtonen V, et al. "Hypoprothrombinaemia and bleeding during administration of cefamandole and cefoperazone." Ann Clin Res 17 (1985):  116-9|Bertino JS, Kozak AJ, Reese RE, Chiarello LA "Hypoprothrombinemia associated with cefamandole use in a rural teaching hospital." Arch Intern Med 146 (1986):  1125-8|Yangco BG, Palumbo JA, Nolen T, et al. "Comparative multicentre evaluation of the safety and efficacy of ceftazidime versus cefamandole for pneumonia." J Antimicrob Chemother 18 (1986):  521-9|O''Donnell D "Hypoprothrombinaemia associated with use of cephamandole." Aust N Z J Surg 61 (1991):  471-2|Tibbitts JS, Lipsky JJ "Effect of biliary diversion on the ability of cefamandole to inhibit vitamin K metabolism." Drug Metabol Drug Interact 7 (1989):  149-60|Cristiano P "Hypoprothrombinemia associated with cefoperazone treatment." Drug Intell Clin Pharm 18 (1984):  314-6|Meisel S "Hypoprothrombinemia due to cefoperazone." Drug Intell Clin Pharm 18 (1984):  316|Parker SW, Baxter J, Beam TR "Cefoperazone-induced coagulopathy." Lancet 1 (1984):  1016|Andrassy K, Koderisch J, Fritz S, et al. "Alteration of hemostasis associated with cefoperazone treatment." Infection 14 (1986):  27-31|Mueller RJ, Green D, Phair JP "Hypoprothrombinemia associated with cefoperazone therapy." South Med J 80 (1987):  1360-2|Brown RB, Klar J, Lemeshow S, Teres D, Pastides H, Sands M "Enhanced bleeding with cefoxitin or moxalactam." Arch Intern Med 146 (1986):  2159-64|Shenkenberg TD, Mackowiak PA, Smith JW "Coagulopathy and hemorrhage associated with cefoperazone therapy in a patient with renal failure." South Med J 78 (1985):  488-9|D''Elia JA, Kaldany A, Miller DG, et al. "Moxalactam bleeding and renal insufficiency." JAMA 249 (1983):  1565|Clark J, Hochman R, Rolla A, et al. "Coagulopathy associated with the use of cephalosporin or moxalactam antibiotics in acute and chronic renal failure." Clin Exp Dial Apheresis 7 (1983):  177-90|Shimanda K, Matsuda T, Inamatsu T, Urayama K "Bleeding secondary to vitamin K deficiency in patients receiving parenteral cephem antibiotics." J Antimicrob Chemother 14 (1984):  325-30|Sanburg AL, Hughes JD, Nichols C "Antibiotic-induced hypoprothrombinaemia." Med J Aust 143 (1985):  387-8|Natelson EA, Brown CH, 3d  Bradshaw MW, Alfrey CP, Jr  Williams TW, Jr "Influence of cephalosporin antibiotics on blood coagulation and platelet function." Antimicrob Agents Chemother 9 (1976):  91-3|Freedy HR, Cetnarowski AB, Lumish RM, Schafer FJ "Cefoperazone-induced coagulopathy." Drug Intell Clin Pharm 20 (1986):  281-3|Osborne JC "Hypoprothrombinemia and bleeding due to cefoperazone." Ann Intern Med 102 (1985):  721-2|Haubenstock A, Schmidt P, Zazgornik J, Balcke P, Kopsa H "Hypoprothrombinaemic bleeding associated with ceftriaxone." Lancet 1 (1983):  1215-6|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jahnchen E, Ritz E "Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status." J Clin Pharmacol 28 (1988):  88-95|Riancho JA, Olmos JM, Sedano C "Life-threatening bleeding in a patient treated with cefonicid." Ann Intern Med 123 (1995):  472-3|Breen GA, Stpeter WL "Hypoprothrombinemia associated with cefmetazole." Ann Pharmacother 31 (1997):  180-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38219, 2274, 'Cefoperazone', 'Hypoprothrombinemias', 'Hypoprothrombinemia, with or without bleeding, has been reported rarely with various cephalosporins, particularly those containing an N-methylthiotetrazole (NMTT) side chain (cefamandole, cefmetazole, cefoperazone, cefotetan).  The sulfhydryl group of this side chain is suspected of interfering with the hepatic synthesis of prothrombin.  Risk factors include advanced age, debility, vitamin K deficiency, malnutrition, malabsorption, and severe renal or hepatobiliary impairment.  Therapy with cephalosporins containing the NMTT side chain should be administered cautiously in patients with any of these risk factors and/or significant active bleeding or a hemorrhagic diathesis.  Prophylactic administration of vitamin K may be indicated in some patients, especially when intestinal sterilization and surgical procedures are performed.', '3', 'Lerner PI, Lubin A "Coagulopathy with cefazolin in uremia." N Engl J Med 290 (1974):  1324|Fujita Y, Inoue S, Yorifuji R, et al. "Effects of cefotaxime on blood coagulation in patients with renal insufficiency." Drugs 35 (1988):  196-8|Kline SS, Mauro VF, Forney RB Jr, et al. "Cefotetan-induced disulfiram-type reactions and hypoprothrombinemia." Antimicrob Agents Chemother 31 (1987):  1328-31|Holt J "Hypoprothrombinemia and bleeding diathesis associated with cefotetan therapy in surgical patients." Arch Surg 123 (1988):  523|Conjura A, Bell W, Lipsky JJ "Cefotetan and hypoprothrombinemia." Ann Intern Med 108 (1988):  643|Kaiser CW, McAuliffe JD, Barth RJ, Lynch JA "Hypoprothrombinemia and hemorrhage in a surgical patient treated with cefotetan." Arch Surg 126 (1991):  524-5|Wurtz RM, Sande MA "Cefotetan and coagulopathy." J Infect Dis 160 (1989):  555-6|Shimada K, Matsuda T, Inamatsu T, Urayama K "Bleeding secondary to vitamin K deficiency in patients receiving parenteral cephem antibiotics." J Antimicrob Chemother 14 (1984):  325-30|Fass RJ, Copelan EA, Brandt JT, Moeschberger ML, Ashton JJ "Platelet-mediated bleeding caused by broad-spectrum penicillins." J Infect Dis 155 (1987):  1242-8|Sanburg AL, Hughes JD, Nichols C "Antibiotic-induced hypoprothrombinaemia." Med J Aust 143 (1985):  387-8|Alitalo R, Ruutu M, Valtonen V, et al. "Hypoprothrombinaemia and bleeding during administration of cefamandole and cefoperazone." Ann Clin Res 17 (1985):  116-9|Bertino JS, Kozak AJ, Reese RE, Chiarello LA "Hypoprothrombinemia associated with cefamandole use in a rural teaching hospital." Arch Intern Med 146 (1986):  1125-8|Yangco BG, Palumbo JA, Nolen T, et al. "Comparative multicentre evaluation of the safety and efficacy of ceftazidime versus cefamandole for pneumonia." J Antimicrob Chemother 18 (1986):  521-9|O''Donnell D "Hypoprothrombinaemia associated with use of cephamandole." Aust N Z J Surg 61 (1991):  471-2|Tibbitts JS, Lipsky JJ "Effect of biliary diversion on the ability of cefamandole to inhibit vitamin K metabolism." Drug Metabol Drug Interact 7 (1989):  149-60|Cristiano P "Hypoprothrombinemia associated with cefoperazone treatment." Drug Intell Clin Pharm 18 (1984):  314-6|Meisel S "Hypoprothrombinemia due to cefoperazone." Drug Intell Clin Pharm 18 (1984):  316|Parker SW, Baxter J, Beam TR "Cefoperazone-induced coagulopathy." Lancet 1 (1984):  1016|Andrassy K, Koderisch J, Fritz S, et al. "Alteration of hemostasis associated with cefoperazone treatment." Infection 14 (1986):  27-31|Mueller RJ, Green D, Phair JP "Hypoprothrombinemia associated with cefoperazone therapy." South Med J 80 (1987):  1360-2|Brown RB, Klar J, Lemeshow S, Teres D, Pastides H, Sands M "Enhanced bleeding with cefoxitin or moxalactam." Arch Intern Med 146 (1986):  2159-64|Shenkenberg TD, Mackowiak PA, Smith JW "Coagulopathy and hemorrhage associated with cefoperazone therapy in a patient with renal failure." South Med J 78 (1985):  488-9|D''Elia JA, Kaldany A, Miller DG, et al. "Moxalactam bleeding and renal insufficiency." JAMA 249 (1983):  1565|Clark J, Hochman R, Rolla A, et al. "Coagulopathy associated with the use of cephalosporin or moxalactam antibiotics in acute and chronic renal failure." Clin Exp Dial Apheresis 7 (1983):  177-90|Shimanda K, Matsuda T, Inamatsu T, Urayama K "Bleeding secondary to vitamin K deficiency in patients receiving parenteral cephem antibiotics." J Antimicrob Chemother 14 (1984):  325-30|Sanburg AL, Hughes JD, Nichols C "Antibiotic-induced hypoprothrombinaemia." Med J Aust 143 (1985):  387-8|Natelson EA, Brown CH, 3d  Bradshaw MW, Alfrey CP, Jr  Williams TW, Jr "Influence of cephalosporin antibiotics on blood coagulation and platelet function." Antimicrob Agents Chemother 9 (1976):  91-3|Freedy HR, Cetnarowski AB, Lumish RM, Schafer FJ "Cefoperazone-induced coagulopathy." Drug Intell Clin Pharm 20 (1986):  281-3|Osborne JC "Hypoprothrombinemia and bleeding due to cefoperazone." Ann Intern Med 102 (1985):  721-2|Haubenstock A, Schmidt P, Zazgornik J, Balcke P, Kopsa H "Hypoprothrombinaemic bleeding associated with ceftriaxone." Lancet 1 (1983):  1215-6|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jahnchen E, Ritz E "Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status." J Clin Pharmacol 28 (1988):  88-95|Riancho JA, Olmos JM, Sedano C "Life-threatening bleeding in a patient treated with cefonicid." Ann Intern Med 123 (1995):  472-3|Breen GA, Stpeter WL "Hypoprothrombinemia associated with cefmetazole." Ann Pharmacother 31 (1997):  180-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38220, 2278, 'Cefoperazone', 'Hypoprothrombinemias', 'Hypoprothrombinemia, with or without bleeding, has been reported rarely with various cephalosporins, particularly those containing an N-methylthiotetrazole (NMTT) side chain (cefamandole, cefmetazole, cefoperazone, cefotetan).  The sulfhydryl group of this side chain is suspected of interfering with the hepatic synthesis of prothrombin.  Risk factors include advanced age, debility, vitamin K deficiency, malnutrition, malabsorption, and severe renal or hepatobiliary impairment.  Therapy with cephalosporins containing the NMTT side chain should be administered cautiously in patients with any of these risk factors and/or significant active bleeding or a hemorrhagic diathesis.  Prophylactic administration of vitamin K may be indicated in some patients, especially when intestinal sterilization and surgical procedures are performed.', '3', 'Lerner PI, Lubin A "Coagulopathy with cefazolin in uremia." N Engl J Med 290 (1974):  1324|Fujita Y, Inoue S, Yorifuji R, et al. "Effects of cefotaxime on blood coagulation in patients with renal insufficiency." Drugs 35 (1988):  196-8|Kline SS, Mauro VF, Forney RB Jr, et al. "Cefotetan-induced disulfiram-type reactions and hypoprothrombinemia." Antimicrob Agents Chemother 31 (1987):  1328-31|Holt J "Hypoprothrombinemia and bleeding diathesis associated with cefotetan therapy in surgical patients." Arch Surg 123 (1988):  523|Conjura A, Bell W, Lipsky JJ "Cefotetan and hypoprothrombinemia." Ann Intern Med 108 (1988):  643|Kaiser CW, McAuliffe JD, Barth RJ, Lynch JA "Hypoprothrombinemia and hemorrhage in a surgical patient treated with cefotetan." Arch Surg 126 (1991):  524-5|Wurtz RM, Sande MA "Cefotetan and coagulopathy." J Infect Dis 160 (1989):  555-6|Shimada K, Matsuda T, Inamatsu T, Urayama K "Bleeding secondary to vitamin K deficiency in patients receiving parenteral cephem antibiotics." J Antimicrob Chemother 14 (1984):  325-30|Fass RJ, Copelan EA, Brandt JT, Moeschberger ML, Ashton JJ "Platelet-mediated bleeding caused by broad-spectrum penicillins." J Infect Dis 155 (1987):  1242-8|Sanburg AL, Hughes JD, Nichols C "Antibiotic-induced hypoprothrombinaemia." Med J Aust 143 (1985):  387-8|Alitalo R, Ruutu M, Valtonen V, et al. "Hypoprothrombinaemia and bleeding during administration of cefamandole and cefoperazone." Ann Clin Res 17 (1985):  116-9|Bertino JS, Kozak AJ, Reese RE, Chiarello LA "Hypoprothrombinemia associated with cefamandole use in a rural teaching hospital." Arch Intern Med 146 (1986):  1125-8|Yangco BG, Palumbo JA, Nolen T, et al. "Comparative multicentre evaluation of the safety and efficacy of ceftazidime versus cefamandole for pneumonia." J Antimicrob Chemother 18 (1986):  521-9|O''Donnell D "Hypoprothrombinaemia associated with use of cephamandole." Aust N Z J Surg 61 (1991):  471-2|Tibbitts JS, Lipsky JJ "Effect of biliary diversion on the ability of cefamandole to inhibit vitamin K metabolism." Drug Metabol Drug Interact 7 (1989):  149-60|Cristiano P "Hypoprothrombinemia associated with cefoperazone treatment." Drug Intell Clin Pharm 18 (1984):  314-6|Meisel S "Hypoprothrombinemia due to cefoperazone." Drug Intell Clin Pharm 18 (1984):  316|Parker SW, Baxter J, Beam TR "Cefoperazone-induced coagulopathy." Lancet 1 (1984):  1016|Andrassy K, Koderisch J, Fritz S, et al. "Alteration of hemostasis associated with cefoperazone treatment." Infection 14 (1986):  27-31|Mueller RJ, Green D, Phair JP "Hypoprothrombinemia associated with cefoperazone therapy." South Med J 80 (1987):  1360-2|Brown RB, Klar J, Lemeshow S, Teres D, Pastides H, Sands M "Enhanced bleeding with cefoxitin or moxalactam." Arch Intern Med 146 (1986):  2159-64|Shenkenberg TD, Mackowiak PA, Smith JW "Coagulopathy and hemorrhage associated with cefoperazone therapy in a patient with renal failure." South Med J 78 (1985):  488-9|D''Elia JA, Kaldany A, Miller DG, et al. "Moxalactam bleeding and renal insufficiency." JAMA 249 (1983):  1565|Clark J, Hochman R, Rolla A, et al. "Coagulopathy associated with the use of cephalosporin or moxalactam antibiotics in acute and chronic renal failure." Clin Exp Dial Apheresis 7 (1983):  177-90|Shimanda K, Matsuda T, Inamatsu T, Urayama K "Bleeding secondary to vitamin K deficiency in patients receiving parenteral cephem antibiotics." J Antimicrob Chemother 14 (1984):  325-30|Sanburg AL, Hughes JD, Nichols C "Antibiotic-induced hypoprothrombinaemia." Med J Aust 143 (1985):  387-8|Natelson EA, Brown CH, 3d  Bradshaw MW, Alfrey CP, Jr  Williams TW, Jr "Influence of cephalosporin antibiotics on blood coagulation and platelet function." Antimicrob Agents Chemother 9 (1976):  91-3|Freedy HR, Cetnarowski AB, Lumish RM, Schafer FJ "Cefoperazone-induced coagulopathy." Drug Intell Clin Pharm 20 (1986):  281-3|Osborne JC "Hypoprothrombinemia and bleeding due to cefoperazone." Ann Intern Med 102 (1985):  721-2|Haubenstock A, Schmidt P, Zazgornik J, Balcke P, Kopsa H "Hypoprothrombinaemic bleeding associated with ceftriaxone." Lancet 1 (1983):  1215-6|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jahnchen E, Ritz E "Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status." J Clin Pharmacol 28 (1988):  88-95|Riancho JA, Olmos JM, Sedano C "Life-threatening bleeding in a patient treated with cefonicid." Ann Intern Med 123 (1995):  472-3|Breen GA, Stpeter WL "Hypoprothrombinemia associated with cefmetazole." Ann Pharmacother 31 (1997):  180-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38221, 2279, 'Cefoperazone', 'Hypoprothrombinemias', 'Hypoprothrombinemia, with or without bleeding, has been reported rarely with various cephalosporins, particularly those containing an N-methylthiotetrazole (NMTT) side chain (cefamandole, cefmetazole, cefoperazone, cefotetan).  The sulfhydryl group of this side chain is suspected of interfering with the hepatic synthesis of prothrombin.  Risk factors include advanced age, debility, vitamin K deficiency, malnutrition, malabsorption, and severe renal or hepatobiliary impairment.  Therapy with cephalosporins containing the NMTT side chain should be administered cautiously in patients with any of these risk factors and/or significant active bleeding or a hemorrhagic diathesis.  Prophylactic administration of vitamin K may be indicated in some patients, especially when intestinal sterilization and surgical procedures are performed.', '3', 'Lerner PI, Lubin A "Coagulopathy with cefazolin in uremia." N Engl J Med 290 (1974):  1324|Fujita Y, Inoue S, Yorifuji R, et al. "Effects of cefotaxime on blood coagulation in patients with renal insufficiency." Drugs 35 (1988):  196-8|Kline SS, Mauro VF, Forney RB Jr, et al. "Cefotetan-induced disulfiram-type reactions and hypoprothrombinemia." Antimicrob Agents Chemother 31 (1987):  1328-31|Holt J "Hypoprothrombinemia and bleeding diathesis associated with cefotetan therapy in surgical patients." Arch Surg 123 (1988):  523|Conjura A, Bell W, Lipsky JJ "Cefotetan and hypoprothrombinemia." Ann Intern Med 108 (1988):  643|Kaiser CW, McAuliffe JD, Barth RJ, Lynch JA "Hypoprothrombinemia and hemorrhage in a surgical patient treated with cefotetan." Arch Surg 126 (1991):  524-5|Wurtz RM, Sande MA "Cefotetan and coagulopathy." J Infect Dis 160 (1989):  555-6|Shimada K, Matsuda T, Inamatsu T, Urayama K "Bleeding secondary to vitamin K deficiency in patients receiving parenteral cephem antibiotics." J Antimicrob Chemother 14 (1984):  325-30|Fass RJ, Copelan EA, Brandt JT, Moeschberger ML, Ashton JJ "Platelet-mediated bleeding caused by broad-spectrum penicillins." J Infect Dis 155 (1987):  1242-8|Sanburg AL, Hughes JD, Nichols C "Antibiotic-induced hypoprothrombinaemia." Med J Aust 143 (1985):  387-8|Alitalo R, Ruutu M, Valtonen V, et al. "Hypoprothrombinaemia and bleeding during administration of cefamandole and cefoperazone." Ann Clin Res 17 (1985):  116-9|Bertino JS, Kozak AJ, Reese RE, Chiarello LA "Hypoprothrombinemia associated with cefamandole use in a rural teaching hospital." Arch Intern Med 146 (1986):  1125-8|Yangco BG, Palumbo JA, Nolen T, et al. "Comparative multicentre evaluation of the safety and efficacy of ceftazidime versus cefamandole for pneumonia." J Antimicrob Chemother 18 (1986):  521-9|O''Donnell D "Hypoprothrombinaemia associated with use of cephamandole." Aust N Z J Surg 61 (1991):  471-2|Tibbitts JS, Lipsky JJ "Effect of biliary diversion on the ability of cefamandole to inhibit vitamin K metabolism." Drug Metabol Drug Interact 7 (1989):  149-60|Cristiano P "Hypoprothrombinemia associated with cefoperazone treatment." Drug Intell Clin Pharm 18 (1984):  314-6|Meisel S "Hypoprothrombinemia due to cefoperazone." Drug Intell Clin Pharm 18 (1984):  316|Parker SW, Baxter J, Beam TR "Cefoperazone-induced coagulopathy." Lancet 1 (1984):  1016|Andrassy K, Koderisch J, Fritz S, et al. "Alteration of hemostasis associated with cefoperazone treatment." Infection 14 (1986):  27-31|Mueller RJ, Green D, Phair JP "Hypoprothrombinemia associated with cefoperazone therapy." South Med J 80 (1987):  1360-2|Brown RB, Klar J, Lemeshow S, Teres D, Pastides H, Sands M "Enhanced bleeding with cefoxitin or moxalactam." Arch Intern Med 146 (1986):  2159-64|Shenkenberg TD, Mackowiak PA, Smith JW "Coagulopathy and hemorrhage associated with cefoperazone therapy in a patient with renal failure." South Med J 78 (1985):  488-9|D''Elia JA, Kaldany A, Miller DG, et al. "Moxalactam bleeding and renal insufficiency." JAMA 249 (1983):  1565|Clark J, Hochman R, Rolla A, et al. "Coagulopathy associated with the use of cephalosporin or moxalactam antibiotics in acute and chronic renal failure." Clin Exp Dial Apheresis 7 (1983):  177-90|Shimanda K, Matsuda T, Inamatsu T, Urayama K "Bleeding secondary to vitamin K deficiency in patients receiving parenteral cephem antibiotics." J Antimicrob Chemother 14 (1984):  325-30|Sanburg AL, Hughes JD, Nichols C "Antibiotic-induced hypoprothrombinaemia." Med J Aust 143 (1985):  387-8|Natelson EA, Brown CH, 3d  Bradshaw MW, Alfrey CP, Jr  Williams TW, Jr "Influence of cephalosporin antibiotics on blood coagulation and platelet function." Antimicrob Agents Chemother 9 (1976):  91-3|Freedy HR, Cetnarowski AB, Lumish RM, Schafer FJ "Cefoperazone-induced coagulopathy." Drug Intell Clin Pharm 20 (1986):  281-3|Osborne JC "Hypoprothrombinemia and bleeding due to cefoperazone." Ann Intern Med 102 (1985):  721-2|Haubenstock A, Schmidt P, Zazgornik J, Balcke P, Kopsa H "Hypoprothrombinaemic bleeding associated with ceftriaxone." Lancet 1 (1983):  1215-6|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jahnchen E, Ritz E "Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status." J Clin Pharmacol 28 (1988):  88-95|Riancho JA, Olmos JM, Sedano C "Life-threatening bleeding in a patient treated with cefonicid." Ann Intern Med 123 (1995):  472-3|Breen GA, Stpeter WL "Hypoprothrombinemia associated with cefmetazole." Ann Pharmacother 31 (1997):  180-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38222, 6385, 'Cefoperazone', 'Hypoprothrombinemias', 'Hypoprothrombinemia, with or without bleeding, has been reported rarely with various cephalosporins, particularly those containing an N-methylthiotetrazole (NMTT) side chain (cefamandole, cefmetazole, cefoperazone, cefotetan).  The sulfhydryl group of this side chain is suspected of interfering with the hepatic synthesis of prothrombin.  Risk factors include advanced age, debility, vitamin K deficiency, malnutrition, malabsorption, and severe renal or hepatobiliary impairment.  Therapy with cephalosporins containing the NMTT side chain should be administered cautiously in patients with any of these risk factors and/or significant active bleeding or a hemorrhagic diathesis.  Prophylactic administration of vitamin K may be indicated in some patients, especially when intestinal sterilization and surgical procedures are performed.', '3', 'Lerner PI, Lubin A "Coagulopathy with cefazolin in uremia." N Engl J Med 290 (1974):  1324|Fujita Y, Inoue S, Yorifuji R, et al. "Effects of cefotaxime on blood coagulation in patients with renal insufficiency." Drugs 35 (1988):  196-8|Kline SS, Mauro VF, Forney RB Jr, et al. "Cefotetan-induced disulfiram-type reactions and hypoprothrombinemia." Antimicrob Agents Chemother 31 (1987):  1328-31|Holt J "Hypoprothrombinemia and bleeding diathesis associated with cefotetan therapy in surgical patients." Arch Surg 123 (1988):  523|Conjura A, Bell W, Lipsky JJ "Cefotetan and hypoprothrombinemia." Ann Intern Med 108 (1988):  643|Kaiser CW, McAuliffe JD, Barth RJ, Lynch JA "Hypoprothrombinemia and hemorrhage in a surgical patient treated with cefotetan." Arch Surg 126 (1991):  524-5|Wurtz RM, Sande MA "Cefotetan and coagulopathy." J Infect Dis 160 (1989):  555-6|Shimada K, Matsuda T, Inamatsu T, Urayama K "Bleeding secondary to vitamin K deficiency in patients receiving parenteral cephem antibiotics." J Antimicrob Chemother 14 (1984):  325-30|Fass RJ, Copelan EA, Brandt JT, Moeschberger ML, Ashton JJ "Platelet-mediated bleeding caused by broad-spectrum penicillins." J Infect Dis 155 (1987):  1242-8|Sanburg AL, Hughes JD, Nichols C "Antibiotic-induced hypoprothrombinaemia." Med J Aust 143 (1985):  387-8|Alitalo R, Ruutu M, Valtonen V, et al. "Hypoprothrombinaemia and bleeding during administration of cefamandole and cefoperazone." Ann Clin Res 17 (1985):  116-9|Bertino JS, Kozak AJ, Reese RE, Chiarello LA "Hypoprothrombinemia associated with cefamandole use in a rural teaching hospital." Arch Intern Med 146 (1986):  1125-8|Yangco BG, Palumbo JA, Nolen T, et al. "Comparative multicentre evaluation of the safety and efficacy of ceftazidime versus cefamandole for pneumonia." J Antimicrob Chemother 18 (1986):  521-9|O''Donnell D "Hypoprothrombinaemia associated with use of cephamandole." Aust N Z J Surg 61 (1991):  471-2|Tibbitts JS, Lipsky JJ "Effect of biliary diversion on the ability of cefamandole to inhibit vitamin K metabolism." Drug Metabol Drug Interact 7 (1989):  149-60|Cristiano P "Hypoprothrombinemia associated with cefoperazone treatment." Drug Intell Clin Pharm 18 (1984):  314-6|Meisel S "Hypoprothrombinemia due to cefoperazone." Drug Intell Clin Pharm 18 (1984):  316|Parker SW, Baxter J, Beam TR "Cefoperazone-induced coagulopathy." Lancet 1 (1984):  1016|Andrassy K, Koderisch J, Fritz S, et al. "Alteration of hemostasis associated with cefoperazone treatment." Infection 14 (1986):  27-31|Mueller RJ, Green D, Phair JP "Hypoprothrombinemia associated with cefoperazone therapy." South Med J 80 (1987):  1360-2|Brown RB, Klar J, Lemeshow S, Teres D, Pastides H, Sands M "Enhanced bleeding with cefoxitin or moxalactam." Arch Intern Med 146 (1986):  2159-64|Shenkenberg TD, Mackowiak PA, Smith JW "Coagulopathy and hemorrhage associated with cefoperazone therapy in a patient with renal failure." South Med J 78 (1985):  488-9|D''Elia JA, Kaldany A, Miller DG, et al. "Moxalactam bleeding and renal insufficiency." JAMA 249 (1983):  1565|Clark J, Hochman R, Rolla A, et al. "Coagulopathy associated with the use of cephalosporin or moxalactam antibiotics in acute and chronic renal failure." Clin Exp Dial Apheresis 7 (1983):  177-90|Shimanda K, Matsuda T, Inamatsu T, Urayama K "Bleeding secondary to vitamin K deficiency in patients receiving parenteral cephem antibiotics." J Antimicrob Chemother 14 (1984):  325-30|Sanburg AL, Hughes JD, Nichols C "Antibiotic-induced hypoprothrombinaemia." Med J Aust 143 (1985):  387-8|Natelson EA, Brown CH, 3d  Bradshaw MW, Alfrey CP, Jr  Williams TW, Jr "Influence of cephalosporin antibiotics on blood coagulation and platelet function." Antimicrob Agents Chemother 9 (1976):  91-3|Freedy HR, Cetnarowski AB, Lumish RM, Schafer FJ "Cefoperazone-induced coagulopathy." Drug Intell Clin Pharm 20 (1986):  281-3|Osborne JC "Hypoprothrombinemia and bleeding due to cefoperazone." Ann Intern Med 102 (1985):  721-2|Haubenstock A, Schmidt P, Zazgornik J, Balcke P, Kopsa H "Hypoprothrombinaemic bleeding associated with ceftriaxone." Lancet 1 (1983):  1215-6|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jahnchen E, Ritz E "Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status." J Clin Pharmacol 28 (1988):  88-95|Riancho JA, Olmos JM, Sedano C "Life-threatening bleeding in a patient treated with cefonicid." Ann Intern Med 123 (1995):  472-3|Breen GA, Stpeter WL "Hypoprothrombinemia associated with cefmetazole." Ann Pharmacother 31 (1997):  180-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38223, 16001, 'Cefoperazone', 'Hypoprothrombinemias', 'Hypoprothrombinemia, with or without bleeding, has been reported rarely with various cephalosporins, particularly those containing an N-methylthiotetrazole (NMTT) side chain (cefamandole, cefmetazole, cefoperazone, cefotetan).  The sulfhydryl group of this side chain is suspected of interfering with the hepatic synthesis of prothrombin.  Risk factors include advanced age, debility, vitamin K deficiency, malnutrition, malabsorption, and severe renal or hepatobiliary impairment.  Therapy with cephalosporins containing the NMTT side chain should be administered cautiously in patients with any of these risk factors and/or significant active bleeding or a hemorrhagic diathesis.  Prophylactic administration of vitamin K may be indicated in some patients, especially when intestinal sterilization and surgical procedures are performed.', '3', 'Lerner PI, Lubin A "Coagulopathy with cefazolin in uremia." N Engl J Med 290 (1974):  1324|Fujita Y, Inoue S, Yorifuji R, et al. "Effects of cefotaxime on blood coagulation in patients with renal insufficiency." Drugs 35 (1988):  196-8|Kline SS, Mauro VF, Forney RB Jr, et al. "Cefotetan-induced disulfiram-type reactions and hypoprothrombinemia." Antimicrob Agents Chemother 31 (1987):  1328-31|Holt J "Hypoprothrombinemia and bleeding diathesis associated with cefotetan therapy in surgical patients." Arch Surg 123 (1988):  523|Conjura A, Bell W, Lipsky JJ "Cefotetan and hypoprothrombinemia." Ann Intern Med 108 (1988):  643|Kaiser CW, McAuliffe JD, Barth RJ, Lynch JA "Hypoprothrombinemia and hemorrhage in a surgical patient treated with cefotetan." Arch Surg 126 (1991):  524-5|Wurtz RM, Sande MA "Cefotetan and coagulopathy." J Infect Dis 160 (1989):  555-6|Shimada K, Matsuda T, Inamatsu T, Urayama K "Bleeding secondary to vitamin K deficiency in patients receiving parenteral cephem antibiotics." J Antimicrob Chemother 14 (1984):  325-30|Fass RJ, Copelan EA, Brandt JT, Moeschberger ML, Ashton JJ "Platelet-mediated bleeding caused by broad-spectrum penicillins." J Infect Dis 155 (1987):  1242-8|Sanburg AL, Hughes JD, Nichols C "Antibiotic-induced hypoprothrombinaemia." Med J Aust 143 (1985):  387-8|Alitalo R, Ruutu M, Valtonen V, et al. "Hypoprothrombinaemia and bleeding during administration of cefamandole and cefoperazone." Ann Clin Res 17 (1985):  116-9|Bertino JS, Kozak AJ, Reese RE, Chiarello LA "Hypoprothrombinemia associated with cefamandole use in a rural teaching hospital." Arch Intern Med 146 (1986):  1125-8|Yangco BG, Palumbo JA, Nolen T, et al. "Comparative multicentre evaluation of the safety and efficacy of ceftazidime versus cefamandole for pneumonia." J Antimicrob Chemother 18 (1986):  521-9|O''Donnell D "Hypoprothrombinaemia associated with use of cephamandole." Aust N Z J Surg 61 (1991):  471-2|Tibbitts JS, Lipsky JJ "Effect of biliary diversion on the ability of cefamandole to inhibit vitamin K metabolism." Drug Metabol Drug Interact 7 (1989):  149-60|Cristiano P "Hypoprothrombinemia associated with cefoperazone treatment." Drug Intell Clin Pharm 18 (1984):  314-6|Meisel S "Hypoprothrombinemia due to cefoperazone." Drug Intell Clin Pharm 18 (1984):  316|Parker SW, Baxter J, Beam TR "Cefoperazone-induced coagulopathy." Lancet 1 (1984):  1016|Andrassy K, Koderisch J, Fritz S, et al. "Alteration of hemostasis associated with cefoperazone treatment." Infection 14 (1986):  27-31|Mueller RJ, Green D, Phair JP "Hypoprothrombinemia associated with cefoperazone therapy." South Med J 80 (1987):  1360-2|Brown RB, Klar J, Lemeshow S, Teres D, Pastides H, Sands M "Enhanced bleeding with cefoxitin or moxalactam." Arch Intern Med 146 (1986):  2159-64|Shenkenberg TD, Mackowiak PA, Smith JW "Coagulopathy and hemorrhage associated with cefoperazone therapy in a patient with renal failure." South Med J 78 (1985):  488-9|D''Elia JA, Kaldany A, Miller DG, et al. "Moxalactam bleeding and renal insufficiency." JAMA 249 (1983):  1565|Clark J, Hochman R, Rolla A, et al. "Coagulopathy associated with the use of cephalosporin or moxalactam antibiotics in acute and chronic renal failure." Clin Exp Dial Apheresis 7 (1983):  177-90|Shimanda K, Matsuda T, Inamatsu T, Urayama K "Bleeding secondary to vitamin K deficiency in patients receiving parenteral cephem antibiotics." J Antimicrob Chemother 14 (1984):  325-30|Sanburg AL, Hughes JD, Nichols C "Antibiotic-induced hypoprothrombinaemia." Med J Aust 143 (1985):  387-8|Natelson EA, Brown CH, 3d  Bradshaw MW, Alfrey CP, Jr  Williams TW, Jr "Influence of cephalosporin antibiotics on blood coagulation and platelet function." Antimicrob Agents Chemother 9 (1976):  91-3|Freedy HR, Cetnarowski AB, Lumish RM, Schafer FJ "Cefoperazone-induced coagulopathy." Drug Intell Clin Pharm 20 (1986):  281-3|Osborne JC "Hypoprothrombinemia and bleeding due to cefoperazone." Ann Intern Med 102 (1985):  721-2|Haubenstock A, Schmidt P, Zazgornik J, Balcke P, Kopsa H "Hypoprothrombinaemic bleeding associated with ceftriaxone." Lancet 1 (1983):  1215-6|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jahnchen E, Ritz E "Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status." J Clin Pharmacol 28 (1988):  88-95|Riancho JA, Olmos JM, Sedano C "Life-threatening bleeding in a patient treated with cefonicid." Ann Intern Med 123 (1995):  472-3|Breen GA, Stpeter WL "Hypoprothrombinemia associated with cefmetazole." Ann Pharmacother 31 (1997):  180-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38224, 16002, 'Cefoperazone', 'Hypoprothrombinemias', 'Hypoprothrombinemia, with or without bleeding, has been reported rarely with various cephalosporins, particularly those containing an N-methylthiotetrazole (NMTT) side chain (cefamandole, cefmetazole, cefoperazone, cefotetan).  The sulfhydryl group of this side chain is suspected of interfering with the hepatic synthesis of prothrombin.  Risk factors include advanced age, debility, vitamin K deficiency, malnutrition, malabsorption, and severe renal or hepatobiliary impairment.  Therapy with cephalosporins containing the NMTT side chain should be administered cautiously in patients with any of these risk factors and/or significant active bleeding or a hemorrhagic diathesis.  Prophylactic administration of vitamin K may be indicated in some patients, especially when intestinal sterilization and surgical procedures are performed.', '3', 'Lerner PI, Lubin A "Coagulopathy with cefazolin in uremia." N Engl J Med 290 (1974):  1324|Fujita Y, Inoue S, Yorifuji R, et al. "Effects of cefotaxime on blood coagulation in patients with renal insufficiency." Drugs 35 (1988):  196-8|Kline SS, Mauro VF, Forney RB Jr, et al. "Cefotetan-induced disulfiram-type reactions and hypoprothrombinemia." Antimicrob Agents Chemother 31 (1987):  1328-31|Holt J "Hypoprothrombinemia and bleeding diathesis associated with cefotetan therapy in surgical patients." Arch Surg 123 (1988):  523|Conjura A, Bell W, Lipsky JJ "Cefotetan and hypoprothrombinemia." Ann Intern Med 108 (1988):  643|Kaiser CW, McAuliffe JD, Barth RJ, Lynch JA "Hypoprothrombinemia and hemorrhage in a surgical patient treated with cefotetan." Arch Surg 126 (1991):  524-5|Wurtz RM, Sande MA "Cefotetan and coagulopathy." J Infect Dis 160 (1989):  555-6|Shimada K, Matsuda T, Inamatsu T, Urayama K "Bleeding secondary to vitamin K deficiency in patients receiving parenteral cephem antibiotics." J Antimicrob Chemother 14 (1984):  325-30|Fass RJ, Copelan EA, Brandt JT, Moeschberger ML, Ashton JJ "Platelet-mediated bleeding caused by broad-spectrum penicillins." J Infect Dis 155 (1987):  1242-8|Sanburg AL, Hughes JD, Nichols C "Antibiotic-induced hypoprothrombinaemia." Med J Aust 143 (1985):  387-8|Alitalo R, Ruutu M, Valtonen V, et al. "Hypoprothrombinaemia and bleeding during administration of cefamandole and cefoperazone." Ann Clin Res 17 (1985):  116-9|Bertino JS, Kozak AJ, Reese RE, Chiarello LA "Hypoprothrombinemia associated with cefamandole use in a rural teaching hospital." Arch Intern Med 146 (1986):  1125-8|Yangco BG, Palumbo JA, Nolen T, et al. "Comparative multicentre evaluation of the safety and efficacy of ceftazidime versus cefamandole for pneumonia." J Antimicrob Chemother 18 (1986):  521-9|O''Donnell D "Hypoprothrombinaemia associated with use of cephamandole." Aust N Z J Surg 61 (1991):  471-2|Tibbitts JS, Lipsky JJ "Effect of biliary diversion on the ability of cefamandole to inhibit vitamin K metabolism." Drug Metabol Drug Interact 7 (1989):  149-60|Cristiano P "Hypoprothrombinemia associated with cefoperazone treatment." Drug Intell Clin Pharm 18 (1984):  314-6|Meisel S "Hypoprothrombinemia due to cefoperazone." Drug Intell Clin Pharm 18 (1984):  316|Parker SW, Baxter J, Beam TR "Cefoperazone-induced coagulopathy." Lancet 1 (1984):  1016|Andrassy K, Koderisch J, Fritz S, et al. "Alteration of hemostasis associated with cefoperazone treatment." Infection 14 (1986):  27-31|Mueller RJ, Green D, Phair JP "Hypoprothrombinemia associated with cefoperazone therapy." South Med J 80 (1987):  1360-2|Brown RB, Klar J, Lemeshow S, Teres D, Pastides H, Sands M "Enhanced bleeding with cefoxitin or moxalactam." Arch Intern Med 146 (1986):  2159-64|Shenkenberg TD, Mackowiak PA, Smith JW "Coagulopathy and hemorrhage associated with cefoperazone therapy in a patient with renal failure." South Med J 78 (1985):  488-9|D''Elia JA, Kaldany A, Miller DG, et al. "Moxalactam bleeding and renal insufficiency." JAMA 249 (1983):  1565|Clark J, Hochman R, Rolla A, et al. "Coagulopathy associated with the use of cephalosporin or moxalactam antibiotics in acute and chronic renal failure." Clin Exp Dial Apheresis 7 (1983):  177-90|Shimanda K, Matsuda T, Inamatsu T, Urayama K "Bleeding secondary to vitamin K deficiency in patients receiving parenteral cephem antibiotics." J Antimicrob Chemother 14 (1984):  325-30|Sanburg AL, Hughes JD, Nichols C "Antibiotic-induced hypoprothrombinaemia." Med J Aust 143 (1985):  387-8|Natelson EA, Brown CH, 3d  Bradshaw MW, Alfrey CP, Jr  Williams TW, Jr "Influence of cephalosporin antibiotics on blood coagulation and platelet function." Antimicrob Agents Chemother 9 (1976):  91-3|Freedy HR, Cetnarowski AB, Lumish RM, Schafer FJ "Cefoperazone-induced coagulopathy." Drug Intell Clin Pharm 20 (1986):  281-3|Osborne JC "Hypoprothrombinemia and bleeding due to cefoperazone." Ann Intern Med 102 (1985):  721-2|Haubenstock A, Schmidt P, Zazgornik J, Balcke P, Kopsa H "Hypoprothrombinaemic bleeding associated with ceftriaxone." Lancet 1 (1983):  1215-6|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jahnchen E, Ritz E "Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status." J Clin Pharmacol 28 (1988):  88-95|Riancho JA, Olmos JM, Sedano C "Life-threatening bleeding in a patient treated with cefonicid." Ann Intern Med 123 (1995):  472-3|Breen GA, Stpeter WL "Hypoprothrombinemia associated with cefmetazole." Ann Pharmacother 31 (1997):  180-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38225, 16022, 'Cefoperazone', 'Hypoprothrombinemias', 'Hypoprothrombinemia, with or without bleeding, has been reported rarely with various cephalosporins, particularly those containing an N-methylthiotetrazole (NMTT) side chain (cefamandole, cefmetazole, cefoperazone, cefotetan).  The sulfhydryl group of this side chain is suspected of interfering with the hepatic synthesis of prothrombin.  Risk factors include advanced age, debility, vitamin K deficiency, malnutrition, malabsorption, and severe renal or hepatobiliary impairment.  Therapy with cephalosporins containing the NMTT side chain should be administered cautiously in patients with any of these risk factors and/or significant active bleeding or a hemorrhagic diathesis.  Prophylactic administration of vitamin K may be indicated in some patients, especially when intestinal sterilization and surgical procedures are performed.', '3', 'Lerner PI, Lubin A "Coagulopathy with cefazolin in uremia." N Engl J Med 290 (1974):  1324|Fujita Y, Inoue S, Yorifuji R, et al. "Effects of cefotaxime on blood coagulation in patients with renal insufficiency." Drugs 35 (1988):  196-8|Kline SS, Mauro VF, Forney RB Jr, et al. "Cefotetan-induced disulfiram-type reactions and hypoprothrombinemia." Antimicrob Agents Chemother 31 (1987):  1328-31|Holt J "Hypoprothrombinemia and bleeding diathesis associated with cefotetan therapy in surgical patients." Arch Surg 123 (1988):  523|Conjura A, Bell W, Lipsky JJ "Cefotetan and hypoprothrombinemia." Ann Intern Med 108 (1988):  643|Kaiser CW, McAuliffe JD, Barth RJ, Lynch JA "Hypoprothrombinemia and hemorrhage in a surgical patient treated with cefotetan." Arch Surg 126 (1991):  524-5|Wurtz RM, Sande MA "Cefotetan and coagulopathy." J Infect Dis 160 (1989):  555-6|Shimada K, Matsuda T, Inamatsu T, Urayama K "Bleeding secondary to vitamin K deficiency in patients receiving parenteral cephem antibiotics." J Antimicrob Chemother 14 (1984):  325-30|Fass RJ, Copelan EA, Brandt JT, Moeschberger ML, Ashton JJ "Platelet-mediated bleeding caused by broad-spectrum penicillins." J Infect Dis 155 (1987):  1242-8|Sanburg AL, Hughes JD, Nichols C "Antibiotic-induced hypoprothrombinaemia." Med J Aust 143 (1985):  387-8|Alitalo R, Ruutu M, Valtonen V, et al. "Hypoprothrombinaemia and bleeding during administration of cefamandole and cefoperazone." Ann Clin Res 17 (1985):  116-9|Bertino JS, Kozak AJ, Reese RE, Chiarello LA "Hypoprothrombinemia associated with cefamandole use in a rural teaching hospital." Arch Intern Med 146 (1986):  1125-8|Yangco BG, Palumbo JA, Nolen T, et al. "Comparative multicentre evaluation of the safety and efficacy of ceftazidime versus cefamandole for pneumonia." J Antimicrob Chemother 18 (1986):  521-9|O''Donnell D "Hypoprothrombinaemia associated with use of cephamandole." Aust N Z J Surg 61 (1991):  471-2|Tibbitts JS, Lipsky JJ "Effect of biliary diversion on the ability of cefamandole to inhibit vitamin K metabolism." Drug Metabol Drug Interact 7 (1989):  149-60|Cristiano P "Hypoprothrombinemia associated with cefoperazone treatment." Drug Intell Clin Pharm 18 (1984):  314-6|Meisel S "Hypoprothrombinemia due to cefoperazone." Drug Intell Clin Pharm 18 (1984):  316|Parker SW, Baxter J, Beam TR "Cefoperazone-induced coagulopathy." Lancet 1 (1984):  1016|Andrassy K, Koderisch J, Fritz S, et al. "Alteration of hemostasis associated with cefoperazone treatment." Infection 14 (1986):  27-31|Mueller RJ, Green D, Phair JP "Hypoprothrombinemia associated with cefoperazone therapy." South Med J 80 (1987):  1360-2|Brown RB, Klar J, Lemeshow S, Teres D, Pastides H, Sands M "Enhanced bleeding with cefoxitin or moxalactam." Arch Intern Med 146 (1986):  2159-64|Shenkenberg TD, Mackowiak PA, Smith JW "Coagulopathy and hemorrhage associated with cefoperazone therapy in a patient with renal failure." South Med J 78 (1985):  488-9|D''Elia JA, Kaldany A, Miller DG, et al. "Moxalactam bleeding and renal insufficiency." JAMA 249 (1983):  1565|Clark J, Hochman R, Rolla A, et al. "Coagulopathy associated with the use of cephalosporin or moxalactam antibiotics in acute and chronic renal failure." Clin Exp Dial Apheresis 7 (1983):  177-90|Shimanda K, Matsuda T, Inamatsu T, Urayama K "Bleeding secondary to vitamin K deficiency in patients receiving parenteral cephem antibiotics." J Antimicrob Chemother 14 (1984):  325-30|Sanburg AL, Hughes JD, Nichols C "Antibiotic-induced hypoprothrombinaemia." Med J Aust 143 (1985):  387-8|Natelson EA, Brown CH, 3d  Bradshaw MW, Alfrey CP, Jr  Williams TW, Jr "Influence of cephalosporin antibiotics on blood coagulation and platelet function." Antimicrob Agents Chemother 9 (1976):  91-3|Freedy HR, Cetnarowski AB, Lumish RM, Schafer FJ "Cefoperazone-induced coagulopathy." Drug Intell Clin Pharm 20 (1986):  281-3|Osborne JC "Hypoprothrombinemia and bleeding due to cefoperazone." Ann Intern Med 102 (1985):  721-2|Haubenstock A, Schmidt P, Zazgornik J, Balcke P, Kopsa H "Hypoprothrombinaemic bleeding associated with ceftriaxone." Lancet 1 (1983):  1215-6|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jahnchen E, Ritz E "Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status." J Clin Pharmacol 28 (1988):  88-95|Riancho JA, Olmos JM, Sedano C "Life-threatening bleeding in a patient treated with cefonicid." Ann Intern Med 123 (1995):  472-3|Breen GA, Stpeter WL "Hypoprothrombinemia associated with cefmetazole." Ann Pharmacother 31 (1997):  180-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38226, 16023, 'Cefoperazone', 'Hypoprothrombinemias', 'Hypoprothrombinemia, with or without bleeding, has been reported rarely with various cephalosporins, particularly those containing an N-methylthiotetrazole (NMTT) side chain (cefamandole, cefmetazole, cefoperazone, cefotetan).  The sulfhydryl group of this side chain is suspected of interfering with the hepatic synthesis of prothrombin.  Risk factors include advanced age, debility, vitamin K deficiency, malnutrition, malabsorption, and severe renal or hepatobiliary impairment.  Therapy with cephalosporins containing the NMTT side chain should be administered cautiously in patients with any of these risk factors and/or significant active bleeding or a hemorrhagic diathesis.  Prophylactic administration of vitamin K may be indicated in some patients, especially when intestinal sterilization and surgical procedures are performed.', '3', 'Lerner PI, Lubin A "Coagulopathy with cefazolin in uremia." N Engl J Med 290 (1974):  1324|Fujita Y, Inoue S, Yorifuji R, et al. "Effects of cefotaxime on blood coagulation in patients with renal insufficiency." Drugs 35 (1988):  196-8|Kline SS, Mauro VF, Forney RB Jr, et al. "Cefotetan-induced disulfiram-type reactions and hypoprothrombinemia." Antimicrob Agents Chemother 31 (1987):  1328-31|Holt J "Hypoprothrombinemia and bleeding diathesis associated with cefotetan therapy in surgical patients." Arch Surg 123 (1988):  523|Conjura A, Bell W, Lipsky JJ "Cefotetan and hypoprothrombinemia." Ann Intern Med 108 (1988):  643|Kaiser CW, McAuliffe JD, Barth RJ, Lynch JA "Hypoprothrombinemia and hemorrhage in a surgical patient treated with cefotetan." Arch Surg 126 (1991):  524-5|Wurtz RM, Sande MA "Cefotetan and coagulopathy." J Infect Dis 160 (1989):  555-6|Shimada K, Matsuda T, Inamatsu T, Urayama K "Bleeding secondary to vitamin K deficiency in patients receiving parenteral cephem antibiotics." J Antimicrob Chemother 14 (1984):  325-30|Fass RJ, Copelan EA, Brandt JT, Moeschberger ML, Ashton JJ "Platelet-mediated bleeding caused by broad-spectrum penicillins." J Infect Dis 155 (1987):  1242-8|Sanburg AL, Hughes JD, Nichols C "Antibiotic-induced hypoprothrombinaemia." Med J Aust 143 (1985):  387-8|Alitalo R, Ruutu M, Valtonen V, et al. "Hypoprothrombinaemia and bleeding during administration of cefamandole and cefoperazone." Ann Clin Res 17 (1985):  116-9|Bertino JS, Kozak AJ, Reese RE, Chiarello LA "Hypoprothrombinemia associated with cefamandole use in a rural teaching hospital." Arch Intern Med 146 (1986):  1125-8|Yangco BG, Palumbo JA, Nolen T, et al. "Comparative multicentre evaluation of the safety and efficacy of ceftazidime versus cefamandole for pneumonia." J Antimicrob Chemother 18 (1986):  521-9|O''Donnell D "Hypoprothrombinaemia associated with use of cephamandole." Aust N Z J Surg 61 (1991):  471-2|Tibbitts JS, Lipsky JJ "Effect of biliary diversion on the ability of cefamandole to inhibit vitamin K metabolism." Drug Metabol Drug Interact 7 (1989):  149-60|Cristiano P "Hypoprothrombinemia associated with cefoperazone treatment." Drug Intell Clin Pharm 18 (1984):  314-6|Meisel S "Hypoprothrombinemia due to cefoperazone." Drug Intell Clin Pharm 18 (1984):  316|Parker SW, Baxter J, Beam TR "Cefoperazone-induced coagulopathy." Lancet 1 (1984):  1016|Andrassy K, Koderisch J, Fritz S, et al. "Alteration of hemostasis associated with cefoperazone treatment." Infection 14 (1986):  27-31|Mueller RJ, Green D, Phair JP "Hypoprothrombinemia associated with cefoperazone therapy." South Med J 80 (1987):  1360-2|Brown RB, Klar J, Lemeshow S, Teres D, Pastides H, Sands M "Enhanced bleeding with cefoxitin or moxalactam." Arch Intern Med 146 (1986):  2159-64|Shenkenberg TD, Mackowiak PA, Smith JW "Coagulopathy and hemorrhage associated with cefoperazone therapy in a patient with renal failure." South Med J 78 (1985):  488-9|D''Elia JA, Kaldany A, Miller DG, et al. "Moxalactam bleeding and renal insufficiency." JAMA 249 (1983):  1565|Clark J, Hochman R, Rolla A, et al. "Coagulopathy associated with the use of cephalosporin or moxalactam antibiotics in acute and chronic renal failure." Clin Exp Dial Apheresis 7 (1983):  177-90|Shimanda K, Matsuda T, Inamatsu T, Urayama K "Bleeding secondary to vitamin K deficiency in patients receiving parenteral cephem antibiotics." J Antimicrob Chemother 14 (1984):  325-30|Sanburg AL, Hughes JD, Nichols C "Antibiotic-induced hypoprothrombinaemia." Med J Aust 143 (1985):  387-8|Natelson EA, Brown CH, 3d  Bradshaw MW, Alfrey CP, Jr  Williams TW, Jr "Influence of cephalosporin antibiotics on blood coagulation and platelet function." Antimicrob Agents Chemother 9 (1976):  91-3|Freedy HR, Cetnarowski AB, Lumish RM, Schafer FJ "Cefoperazone-induced coagulopathy." Drug Intell Clin Pharm 20 (1986):  281-3|Osborne JC "Hypoprothrombinemia and bleeding due to cefoperazone." Ann Intern Med 102 (1985):  721-2|Haubenstock A, Schmidt P, Zazgornik J, Balcke P, Kopsa H "Hypoprothrombinaemic bleeding associated with ceftriaxone." Lancet 1 (1983):  1215-6|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jahnchen E, Ritz E "Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status." J Clin Pharmacol 28 (1988):  88-95|Riancho JA, Olmos JM, Sedano C "Life-threatening bleeding in a patient treated with cefonicid." Ann Intern Med 123 (1995):  472-3|Breen GA, Stpeter WL "Hypoprothrombinemia associated with cefmetazole." Ann Pharmacother 31 (1997):  180-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38227, 16024, 'Cefoperazone', 'Hypoprothrombinemias', 'Hypoprothrombinemia, with or without bleeding, has been reported rarely with various cephalosporins, particularly those containing an N-methylthiotetrazole (NMTT) side chain (cefamandole, cefmetazole, cefoperazone, cefotetan).  The sulfhydryl group of this side chain is suspected of interfering with the hepatic synthesis of prothrombin.  Risk factors include advanced age, debility, vitamin K deficiency, malnutrition, malabsorption, and severe renal or hepatobiliary impairment.  Therapy with cephalosporins containing the NMTT side chain should be administered cautiously in patients with any of these risk factors and/or significant active bleeding or a hemorrhagic diathesis.  Prophylactic administration of vitamin K may be indicated in some patients, especially when intestinal sterilization and surgical procedures are performed.', '3', 'Lerner PI, Lubin A "Coagulopathy with cefazolin in uremia." N Engl J Med 290 (1974):  1324|Fujita Y, Inoue S, Yorifuji R, et al. "Effects of cefotaxime on blood coagulation in patients with renal insufficiency." Drugs 35 (1988):  196-8|Kline SS, Mauro VF, Forney RB Jr, et al. "Cefotetan-induced disulfiram-type reactions and hypoprothrombinemia." Antimicrob Agents Chemother 31 (1987):  1328-31|Holt J "Hypoprothrombinemia and bleeding diathesis associated with cefotetan therapy in surgical patients." Arch Surg 123 (1988):  523|Conjura A, Bell W, Lipsky JJ "Cefotetan and hypoprothrombinemia." Ann Intern Med 108 (1988):  643|Kaiser CW, McAuliffe JD, Barth RJ, Lynch JA "Hypoprothrombinemia and hemorrhage in a surgical patient treated with cefotetan." Arch Surg 126 (1991):  524-5|Wurtz RM, Sande MA "Cefotetan and coagulopathy." J Infect Dis 160 (1989):  555-6|Shimada K, Matsuda T, Inamatsu T, Urayama K "Bleeding secondary to vitamin K deficiency in patients receiving parenteral cephem antibiotics." J Antimicrob Chemother 14 (1984):  325-30|Fass RJ, Copelan EA, Brandt JT, Moeschberger ML, Ashton JJ "Platelet-mediated bleeding caused by broad-spectrum penicillins." J Infect Dis 155 (1987):  1242-8|Sanburg AL, Hughes JD, Nichols C "Antibiotic-induced hypoprothrombinaemia." Med J Aust 143 (1985):  387-8|Alitalo R, Ruutu M, Valtonen V, et al. "Hypoprothrombinaemia and bleeding during administration of cefamandole and cefoperazone." Ann Clin Res 17 (1985):  116-9|Bertino JS, Kozak AJ, Reese RE, Chiarello LA "Hypoprothrombinemia associated with cefamandole use in a rural teaching hospital." Arch Intern Med 146 (1986):  1125-8|Yangco BG, Palumbo JA, Nolen T, et al. "Comparative multicentre evaluation of the safety and efficacy of ceftazidime versus cefamandole for pneumonia." J Antimicrob Chemother 18 (1986):  521-9|O''Donnell D "Hypoprothrombinaemia associated with use of cephamandole." Aust N Z J Surg 61 (1991):  471-2|Tibbitts JS, Lipsky JJ "Effect of biliary diversion on the ability of cefamandole to inhibit vitamin K metabolism." Drug Metabol Drug Interact 7 (1989):  149-60|Cristiano P "Hypoprothrombinemia associated with cefoperazone treatment." Drug Intell Clin Pharm 18 (1984):  314-6|Meisel S "Hypoprothrombinemia due to cefoperazone." Drug Intell Clin Pharm 18 (1984):  316|Parker SW, Baxter J, Beam TR "Cefoperazone-induced coagulopathy." Lancet 1 (1984):  1016|Andrassy K, Koderisch J, Fritz S, et al. "Alteration of hemostasis associated with cefoperazone treatment." Infection 14 (1986):  27-31|Mueller RJ, Green D, Phair JP "Hypoprothrombinemia associated with cefoperazone therapy." South Med J 80 (1987):  1360-2|Brown RB, Klar J, Lemeshow S, Teres D, Pastides H, Sands M "Enhanced bleeding with cefoxitin or moxalactam." Arch Intern Med 146 (1986):  2159-64|Shenkenberg TD, Mackowiak PA, Smith JW "Coagulopathy and hemorrhage associated with cefoperazone therapy in a patient with renal failure." South Med J 78 (1985):  488-9|D''Elia JA, Kaldany A, Miller DG, et al. "Moxalactam bleeding and renal insufficiency." JAMA 249 (1983):  1565|Clark J, Hochman R, Rolla A, et al. "Coagulopathy associated with the use of cephalosporin or moxalactam antibiotics in acute and chronic renal failure." Clin Exp Dial Apheresis 7 (1983):  177-90|Shimanda K, Matsuda T, Inamatsu T, Urayama K "Bleeding secondary to vitamin K deficiency in patients receiving parenteral cephem antibiotics." J Antimicrob Chemother 14 (1984):  325-30|Sanburg AL, Hughes JD, Nichols C "Antibiotic-induced hypoprothrombinaemia." Med J Aust 143 (1985):  387-8|Natelson EA, Brown CH, 3d  Bradshaw MW, Alfrey CP, Jr  Williams TW, Jr "Influence of cephalosporin antibiotics on blood coagulation and platelet function." Antimicrob Agents Chemother 9 (1976):  91-3|Freedy HR, Cetnarowski AB, Lumish RM, Schafer FJ "Cefoperazone-induced coagulopathy." Drug Intell Clin Pharm 20 (1986):  281-3|Osborne JC "Hypoprothrombinemia and bleeding due to cefoperazone." Ann Intern Med 102 (1985):  721-2|Haubenstock A, Schmidt P, Zazgornik J, Balcke P, Kopsa H "Hypoprothrombinaemic bleeding associated with ceftriaxone." Lancet 1 (1983):  1215-6|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jahnchen E, Ritz E "Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status." J Clin Pharmacol 28 (1988):  88-95|Riancho JA, Olmos JM, Sedano C "Life-threatening bleeding in a patient treated with cefonicid." Ann Intern Med 123 (1995):  472-3|Breen GA, Stpeter WL "Hypoprothrombinemia associated with cefmetazole." Ann Pharmacother 31 (1997):  180-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38228, 16028, 'Cefoperazone', 'Hypoprothrombinemias', 'Hypoprothrombinemia, with or without bleeding, has been reported rarely with various cephalosporins, particularly those containing an N-methylthiotetrazole (NMTT) side chain (cefamandole, cefmetazole, cefoperazone, cefotetan).  The sulfhydryl group of this side chain is suspected of interfering with the hepatic synthesis of prothrombin.  Risk factors include advanced age, debility, vitamin K deficiency, malnutrition, malabsorption, and severe renal or hepatobiliary impairment.  Therapy with cephalosporins containing the NMTT side chain should be administered cautiously in patients with any of these risk factors and/or significant active bleeding or a hemorrhagic diathesis.  Prophylactic administration of vitamin K may be indicated in some patients, especially when intestinal sterilization and surgical procedures are performed.', '3', 'Lerner PI, Lubin A "Coagulopathy with cefazolin in uremia." N Engl J Med 290 (1974):  1324|Fujita Y, Inoue S, Yorifuji R, et al. "Effects of cefotaxime on blood coagulation in patients with renal insufficiency." Drugs 35 (1988):  196-8|Kline SS, Mauro VF, Forney RB Jr, et al. "Cefotetan-induced disulfiram-type reactions and hypoprothrombinemia." Antimicrob Agents Chemother 31 (1987):  1328-31|Holt J "Hypoprothrombinemia and bleeding diathesis associated with cefotetan therapy in surgical patients." Arch Surg 123 (1988):  523|Conjura A, Bell W, Lipsky JJ "Cefotetan and hypoprothrombinemia." Ann Intern Med 108 (1988):  643|Kaiser CW, McAuliffe JD, Barth RJ, Lynch JA "Hypoprothrombinemia and hemorrhage in a surgical patient treated with cefotetan." Arch Surg 126 (1991):  524-5|Wurtz RM, Sande MA "Cefotetan and coagulopathy." J Infect Dis 160 (1989):  555-6|Shimada K, Matsuda T, Inamatsu T, Urayama K "Bleeding secondary to vitamin K deficiency in patients receiving parenteral cephem antibiotics." J Antimicrob Chemother 14 (1984):  325-30|Fass RJ, Copelan EA, Brandt JT, Moeschberger ML, Ashton JJ "Platelet-mediated bleeding caused by broad-spectrum penicillins." J Infect Dis 155 (1987):  1242-8|Sanburg AL, Hughes JD, Nichols C "Antibiotic-induced hypoprothrombinaemia." Med J Aust 143 (1985):  387-8|Alitalo R, Ruutu M, Valtonen V, et al. "Hypoprothrombinaemia and bleeding during administration of cefamandole and cefoperazone." Ann Clin Res 17 (1985):  116-9|Bertino JS, Kozak AJ, Reese RE, Chiarello LA "Hypoprothrombinemia associated with cefamandole use in a rural teaching hospital." Arch Intern Med 146 (1986):  1125-8|Yangco BG, Palumbo JA, Nolen T, et al. "Comparative multicentre evaluation of the safety and efficacy of ceftazidime versus cefamandole for pneumonia." J Antimicrob Chemother 18 (1986):  521-9|O''Donnell D "Hypoprothrombinaemia associated with use of cephamandole." Aust N Z J Surg 61 (1991):  471-2|Tibbitts JS, Lipsky JJ "Effect of biliary diversion on the ability of cefamandole to inhibit vitamin K metabolism." Drug Metabol Drug Interact 7 (1989):  149-60|Cristiano P "Hypoprothrombinemia associated with cefoperazone treatment." Drug Intell Clin Pharm 18 (1984):  314-6|Meisel S "Hypoprothrombinemia due to cefoperazone." Drug Intell Clin Pharm 18 (1984):  316|Parker SW, Baxter J, Beam TR "Cefoperazone-induced coagulopathy." Lancet 1 (1984):  1016|Andrassy K, Koderisch J, Fritz S, et al. "Alteration of hemostasis associated with cefoperazone treatment." Infection 14 (1986):  27-31|Mueller RJ, Green D, Phair JP "Hypoprothrombinemia associated with cefoperazone therapy." South Med J 80 (1987):  1360-2|Brown RB, Klar J, Lemeshow S, Teres D, Pastides H, Sands M "Enhanced bleeding with cefoxitin or moxalactam." Arch Intern Med 146 (1986):  2159-64|Shenkenberg TD, Mackowiak PA, Smith JW "Coagulopathy and hemorrhage associated with cefoperazone therapy in a patient with renal failure." South Med J 78 (1985):  488-9|D''Elia JA, Kaldany A, Miller DG, et al. "Moxalactam bleeding and renal insufficiency." JAMA 249 (1983):  1565|Clark J, Hochman R, Rolla A, et al. "Coagulopathy associated with the use of cephalosporin or moxalactam antibiotics in acute and chronic renal failure." Clin Exp Dial Apheresis 7 (1983):  177-90|Shimanda K, Matsuda T, Inamatsu T, Urayama K "Bleeding secondary to vitamin K deficiency in patients receiving parenteral cephem antibiotics." J Antimicrob Chemother 14 (1984):  325-30|Sanburg AL, Hughes JD, Nichols C "Antibiotic-induced hypoprothrombinaemia." Med J Aust 143 (1985):  387-8|Natelson EA, Brown CH, 3d  Bradshaw MW, Alfrey CP, Jr  Williams TW, Jr "Influence of cephalosporin antibiotics on blood coagulation and platelet function." Antimicrob Agents Chemother 9 (1976):  91-3|Freedy HR, Cetnarowski AB, Lumish RM, Schafer FJ "Cefoperazone-induced coagulopathy." Drug Intell Clin Pharm 20 (1986):  281-3|Osborne JC "Hypoprothrombinemia and bleeding due to cefoperazone." Ann Intern Med 102 (1985):  721-2|Haubenstock A, Schmidt P, Zazgornik J, Balcke P, Kopsa H "Hypoprothrombinaemic bleeding associated with ceftriaxone." Lancet 1 (1983):  1215-6|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jahnchen E, Ritz E "Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status." J Clin Pharmacol 28 (1988):  88-95|Riancho JA, Olmos JM, Sedano C "Life-threatening bleeding in a patient treated with cefonicid." Ann Intern Med 123 (1995):  472-3|Breen GA, Stpeter WL "Hypoprothrombinemia associated with cefmetazole." Ann Pharmacother 31 (1997):  180-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38229, 16051, 'Cefoperazone', 'Hypoprothrombinemias', 'Hypoprothrombinemia, with or without bleeding, has been reported rarely with various cephalosporins, particularly those containing an N-methylthiotetrazole (NMTT) side chain (cefamandole, cefmetazole, cefoperazone, cefotetan).  The sulfhydryl group of this side chain is suspected of interfering with the hepatic synthesis of prothrombin.  Risk factors include advanced age, debility, vitamin K deficiency, malnutrition, malabsorption, and severe renal or hepatobiliary impairment.  Therapy with cephalosporins containing the NMTT side chain should be administered cautiously in patients with any of these risk factors and/or significant active bleeding or a hemorrhagic diathesis.  Prophylactic administration of vitamin K may be indicated in some patients, especially when intestinal sterilization and surgical procedures are performed.', '3', 'Lerner PI, Lubin A "Coagulopathy with cefazolin in uremia." N Engl J Med 290 (1974):  1324|Fujita Y, Inoue S, Yorifuji R, et al. "Effects of cefotaxime on blood coagulation in patients with renal insufficiency." Drugs 35 (1988):  196-8|Kline SS, Mauro VF, Forney RB Jr, et al. "Cefotetan-induced disulfiram-type reactions and hypoprothrombinemia." Antimicrob Agents Chemother 31 (1987):  1328-31|Holt J "Hypoprothrombinemia and bleeding diathesis associated with cefotetan therapy in surgical patients." Arch Surg 123 (1988):  523|Conjura A, Bell W, Lipsky JJ "Cefotetan and hypoprothrombinemia." Ann Intern Med 108 (1988):  643|Kaiser CW, McAuliffe JD, Barth RJ, Lynch JA "Hypoprothrombinemia and hemorrhage in a surgical patient treated with cefotetan." Arch Surg 126 (1991):  524-5|Wurtz RM, Sande MA "Cefotetan and coagulopathy." J Infect Dis 160 (1989):  555-6|Shimada K, Matsuda T, Inamatsu T, Urayama K "Bleeding secondary to vitamin K deficiency in patients receiving parenteral cephem antibiotics." J Antimicrob Chemother 14 (1984):  325-30|Fass RJ, Copelan EA, Brandt JT, Moeschberger ML, Ashton JJ "Platelet-mediated bleeding caused by broad-spectrum penicillins." J Infect Dis 155 (1987):  1242-8|Sanburg AL, Hughes JD, Nichols C "Antibiotic-induced hypoprothrombinaemia." Med J Aust 143 (1985):  387-8|Alitalo R, Ruutu M, Valtonen V, et al. "Hypoprothrombinaemia and bleeding during administration of cefamandole and cefoperazone." Ann Clin Res 17 (1985):  116-9|Bertino JS, Kozak AJ, Reese RE, Chiarello LA "Hypoprothrombinemia associated with cefamandole use in a rural teaching hospital." Arch Intern Med 146 (1986):  1125-8|Yangco BG, Palumbo JA, Nolen T, et al. "Comparative multicentre evaluation of the safety and efficacy of ceftazidime versus cefamandole for pneumonia." J Antimicrob Chemother 18 (1986):  521-9|O''Donnell D "Hypoprothrombinaemia associated with use of cephamandole." Aust N Z J Surg 61 (1991):  471-2|Tibbitts JS, Lipsky JJ "Effect of biliary diversion on the ability of cefamandole to inhibit vitamin K metabolism." Drug Metabol Drug Interact 7 (1989):  149-60|Cristiano P "Hypoprothrombinemia associated with cefoperazone treatment." Drug Intell Clin Pharm 18 (1984):  314-6|Meisel S "Hypoprothrombinemia due to cefoperazone." Drug Intell Clin Pharm 18 (1984):  316|Parker SW, Baxter J, Beam TR "Cefoperazone-induced coagulopathy." Lancet 1 (1984):  1016|Andrassy K, Koderisch J, Fritz S, et al. "Alteration of hemostasis associated with cefoperazone treatment." Infection 14 (1986):  27-31|Mueller RJ, Green D, Phair JP "Hypoprothrombinemia associated with cefoperazone therapy." South Med J 80 (1987):  1360-2|Brown RB, Klar J, Lemeshow S, Teres D, Pastides H, Sands M "Enhanced bleeding with cefoxitin or moxalactam." Arch Intern Med 146 (1986):  2159-64|Shenkenberg TD, Mackowiak PA, Smith JW "Coagulopathy and hemorrhage associated with cefoperazone therapy in a patient with renal failure." South Med J 78 (1985):  488-9|D''Elia JA, Kaldany A, Miller DG, et al. "Moxalactam bleeding and renal insufficiency." JAMA 249 (1983):  1565|Clark J, Hochman R, Rolla A, et al. "Coagulopathy associated with the use of cephalosporin or moxalactam antibiotics in acute and chronic renal failure." Clin Exp Dial Apheresis 7 (1983):  177-90|Shimanda K, Matsuda T, Inamatsu T, Urayama K "Bleeding secondary to vitamin K deficiency in patients receiving parenteral cephem antibiotics." J Antimicrob Chemother 14 (1984):  325-30|Sanburg AL, Hughes JD, Nichols C "Antibiotic-induced hypoprothrombinaemia." Med J Aust 143 (1985):  387-8|Natelson EA, Brown CH, 3d  Bradshaw MW, Alfrey CP, Jr  Williams TW, Jr "Influence of cephalosporin antibiotics on blood coagulation and platelet function." Antimicrob Agents Chemother 9 (1976):  91-3|Freedy HR, Cetnarowski AB, Lumish RM, Schafer FJ "Cefoperazone-induced coagulopathy." Drug Intell Clin Pharm 20 (1986):  281-3|Osborne JC "Hypoprothrombinemia and bleeding due to cefoperazone." Ann Intern Med 102 (1985):  721-2|Haubenstock A, Schmidt P, Zazgornik J, Balcke P, Kopsa H "Hypoprothrombinaemic bleeding associated with ceftriaxone." Lancet 1 (1983):  1215-6|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jahnchen E, Ritz E "Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status." J Clin Pharmacol 28 (1988):  88-95|Riancho JA, Olmos JM, Sedano C "Life-threatening bleeding in a patient treated with cefonicid." Ann Intern Med 123 (1995):  472-3|Breen GA, Stpeter WL "Hypoprothrombinemia associated with cefmetazole." Ann Pharmacother 31 (1997):  180-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38230, 16052, 'Cefoperazone', 'Hypoprothrombinemias', 'Hypoprothrombinemia, with or without bleeding, has been reported rarely with various cephalosporins, particularly those containing an N-methylthiotetrazole (NMTT) side chain (cefamandole, cefmetazole, cefoperazone, cefotetan).  The sulfhydryl group of this side chain is suspected of interfering with the hepatic synthesis of prothrombin.  Risk factors include advanced age, debility, vitamin K deficiency, malnutrition, malabsorption, and severe renal or hepatobiliary impairment.  Therapy with cephalosporins containing the NMTT side chain should be administered cautiously in patients with any of these risk factors and/or significant active bleeding or a hemorrhagic diathesis.  Prophylactic administration of vitamin K may be indicated in some patients, especially when intestinal sterilization and surgical procedures are performed.', '3', 'Lerner PI, Lubin A "Coagulopathy with cefazolin in uremia." N Engl J Med 290 (1974):  1324|Fujita Y, Inoue S, Yorifuji R, et al. "Effects of cefotaxime on blood coagulation in patients with renal insufficiency." Drugs 35 (1988):  196-8|Kline SS, Mauro VF, Forney RB Jr, et al. "Cefotetan-induced disulfiram-type reactions and hypoprothrombinemia." Antimicrob Agents Chemother 31 (1987):  1328-31|Holt J "Hypoprothrombinemia and bleeding diathesis associated with cefotetan therapy in surgical patients." Arch Surg 123 (1988):  523|Conjura A, Bell W, Lipsky JJ "Cefotetan and hypoprothrombinemia." Ann Intern Med 108 (1988):  643|Kaiser CW, McAuliffe JD, Barth RJ, Lynch JA "Hypoprothrombinemia and hemorrhage in a surgical patient treated with cefotetan." Arch Surg 126 (1991):  524-5|Wurtz RM, Sande MA "Cefotetan and coagulopathy." J Infect Dis 160 (1989):  555-6|Shimada K, Matsuda T, Inamatsu T, Urayama K "Bleeding secondary to vitamin K deficiency in patients receiving parenteral cephem antibiotics." J Antimicrob Chemother 14 (1984):  325-30|Fass RJ, Copelan EA, Brandt JT, Moeschberger ML, Ashton JJ "Platelet-mediated bleeding caused by broad-spectrum penicillins." J Infect Dis 155 (1987):  1242-8|Sanburg AL, Hughes JD, Nichols C "Antibiotic-induced hypoprothrombinaemia." Med J Aust 143 (1985):  387-8|Alitalo R, Ruutu M, Valtonen V, et al. "Hypoprothrombinaemia and bleeding during administration of cefamandole and cefoperazone." Ann Clin Res 17 (1985):  116-9|Bertino JS, Kozak AJ, Reese RE, Chiarello LA "Hypoprothrombinemia associated with cefamandole use in a rural teaching hospital." Arch Intern Med 146 (1986):  1125-8|Yangco BG, Palumbo JA, Nolen T, et al. "Comparative multicentre evaluation of the safety and efficacy of ceftazidime versus cefamandole for pneumonia." J Antimicrob Chemother 18 (1986):  521-9|O''Donnell D "Hypoprothrombinaemia associated with use of cephamandole." Aust N Z J Surg 61 (1991):  471-2|Tibbitts JS, Lipsky JJ "Effect of biliary diversion on the ability of cefamandole to inhibit vitamin K metabolism." Drug Metabol Drug Interact 7 (1989):  149-60|Cristiano P "Hypoprothrombinemia associated with cefoperazone treatment." Drug Intell Clin Pharm 18 (1984):  314-6|Meisel S "Hypoprothrombinemia due to cefoperazone." Drug Intell Clin Pharm 18 (1984):  316|Parker SW, Baxter J, Beam TR "Cefoperazone-induced coagulopathy." Lancet 1 (1984):  1016|Andrassy K, Koderisch J, Fritz S, et al. "Alteration of hemostasis associated with cefoperazone treatment." Infection 14 (1986):  27-31|Mueller RJ, Green D, Phair JP "Hypoprothrombinemia associated with cefoperazone therapy." South Med J 80 (1987):  1360-2|Brown RB, Klar J, Lemeshow S, Teres D, Pastides H, Sands M "Enhanced bleeding with cefoxitin or moxalactam." Arch Intern Med 146 (1986):  2159-64|Shenkenberg TD, Mackowiak PA, Smith JW "Coagulopathy and hemorrhage associated with cefoperazone therapy in a patient with renal failure." South Med J 78 (1985):  488-9|D''Elia JA, Kaldany A, Miller DG, et al. "Moxalactam bleeding and renal insufficiency." JAMA 249 (1983):  1565|Clark J, Hochman R, Rolla A, et al. "Coagulopathy associated with the use of cephalosporin or moxalactam antibiotics in acute and chronic renal failure." Clin Exp Dial Apheresis 7 (1983):  177-90|Shimanda K, Matsuda T, Inamatsu T, Urayama K "Bleeding secondary to vitamin K deficiency in patients receiving parenteral cephem antibiotics." J Antimicrob Chemother 14 (1984):  325-30|Sanburg AL, Hughes JD, Nichols C "Antibiotic-induced hypoprothrombinaemia." Med J Aust 143 (1985):  387-8|Natelson EA, Brown CH, 3d  Bradshaw MW, Alfrey CP, Jr  Williams TW, Jr "Influence of cephalosporin antibiotics on blood coagulation and platelet function." Antimicrob Agents Chemother 9 (1976):  91-3|Freedy HR, Cetnarowski AB, Lumish RM, Schafer FJ "Cefoperazone-induced coagulopathy." Drug Intell Clin Pharm 20 (1986):  281-3|Osborne JC "Hypoprothrombinemia and bleeding due to cefoperazone." Ann Intern Med 102 (1985):  721-2|Haubenstock A, Schmidt P, Zazgornik J, Balcke P, Kopsa H "Hypoprothrombinaemic bleeding associated with ceftriaxone." Lancet 1 (1983):  1215-6|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jahnchen E, Ritz E "Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status." J Clin Pharmacol 28 (1988):  88-95|Riancho JA, Olmos JM, Sedano C "Life-threatening bleeding in a patient treated with cefonicid." Ann Intern Med 123 (1995):  472-3|Breen GA, Stpeter WL "Hypoprothrombinemia associated with cefmetazole." Ann Pharmacother 31 (1997):  180-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38231, 16057, 'Cefoperazone', 'Hypoprothrombinemias', 'Hypoprothrombinemia, with or without bleeding, has been reported rarely with various cephalosporins, particularly those containing an N-methylthiotetrazole (NMTT) side chain (cefamandole, cefmetazole, cefoperazone, cefotetan).  The sulfhydryl group of this side chain is suspected of interfering with the hepatic synthesis of prothrombin.  Risk factors include advanced age, debility, vitamin K deficiency, malnutrition, malabsorption, and severe renal or hepatobiliary impairment.  Therapy with cephalosporins containing the NMTT side chain should be administered cautiously in patients with any of these risk factors and/or significant active bleeding or a hemorrhagic diathesis.  Prophylactic administration of vitamin K may be indicated in some patients, especially when intestinal sterilization and surgical procedures are performed.', '3', 'Lerner PI, Lubin A "Coagulopathy with cefazolin in uremia." N Engl J Med 290 (1974):  1324|Fujita Y, Inoue S, Yorifuji R, et al. "Effects of cefotaxime on blood coagulation in patients with renal insufficiency." Drugs 35 (1988):  196-8|Kline SS, Mauro VF, Forney RB Jr, et al. "Cefotetan-induced disulfiram-type reactions and hypoprothrombinemia." Antimicrob Agents Chemother 31 (1987):  1328-31|Holt J "Hypoprothrombinemia and bleeding diathesis associated with cefotetan therapy in surgical patients." Arch Surg 123 (1988):  523|Conjura A, Bell W, Lipsky JJ "Cefotetan and hypoprothrombinemia." Ann Intern Med 108 (1988):  643|Kaiser CW, McAuliffe JD, Barth RJ, Lynch JA "Hypoprothrombinemia and hemorrhage in a surgical patient treated with cefotetan." Arch Surg 126 (1991):  524-5|Wurtz RM, Sande MA "Cefotetan and coagulopathy." J Infect Dis 160 (1989):  555-6|Shimada K, Matsuda T, Inamatsu T, Urayama K "Bleeding secondary to vitamin K deficiency in patients receiving parenteral cephem antibiotics." J Antimicrob Chemother 14 (1984):  325-30|Fass RJ, Copelan EA, Brandt JT, Moeschberger ML, Ashton JJ "Platelet-mediated bleeding caused by broad-spectrum penicillins." J Infect Dis 155 (1987):  1242-8|Sanburg AL, Hughes JD, Nichols C "Antibiotic-induced hypoprothrombinaemia." Med J Aust 143 (1985):  387-8|Alitalo R, Ruutu M, Valtonen V, et al. "Hypoprothrombinaemia and bleeding during administration of cefamandole and cefoperazone." Ann Clin Res 17 (1985):  116-9|Bertino JS, Kozak AJ, Reese RE, Chiarello LA "Hypoprothrombinemia associated with cefamandole use in a rural teaching hospital." Arch Intern Med 146 (1986):  1125-8|Yangco BG, Palumbo JA, Nolen T, et al. "Comparative multicentre evaluation of the safety and efficacy of ceftazidime versus cefamandole for pneumonia." J Antimicrob Chemother 18 (1986):  521-9|O''Donnell D "Hypoprothrombinaemia associated with use of cephamandole." Aust N Z J Surg 61 (1991):  471-2|Tibbitts JS, Lipsky JJ "Effect of biliary diversion on the ability of cefamandole to inhibit vitamin K metabolism." Drug Metabol Drug Interact 7 (1989):  149-60|Cristiano P "Hypoprothrombinemia associated with cefoperazone treatment." Drug Intell Clin Pharm 18 (1984):  314-6|Meisel S "Hypoprothrombinemia due to cefoperazone." Drug Intell Clin Pharm 18 (1984):  316|Parker SW, Baxter J, Beam TR "Cefoperazone-induced coagulopathy." Lancet 1 (1984):  1016|Andrassy K, Koderisch J, Fritz S, et al. "Alteration of hemostasis associated with cefoperazone treatment." Infection 14 (1986):  27-31|Mueller RJ, Green D, Phair JP "Hypoprothrombinemia associated with cefoperazone therapy." South Med J 80 (1987):  1360-2|Brown RB, Klar J, Lemeshow S, Teres D, Pastides H, Sands M "Enhanced bleeding with cefoxitin or moxalactam." Arch Intern Med 146 (1986):  2159-64|Shenkenberg TD, Mackowiak PA, Smith JW "Coagulopathy and hemorrhage associated with cefoperazone therapy in a patient with renal failure." South Med J 78 (1985):  488-9|D''Elia JA, Kaldany A, Miller DG, et al. "Moxalactam bleeding and renal insufficiency." JAMA 249 (1983):  1565|Clark J, Hochman R, Rolla A, et al. "Coagulopathy associated with the use of cephalosporin or moxalactam antibiotics in acute and chronic renal failure." Clin Exp Dial Apheresis 7 (1983):  177-90|Shimanda K, Matsuda T, Inamatsu T, Urayama K "Bleeding secondary to vitamin K deficiency in patients receiving parenteral cephem antibiotics." J Antimicrob Chemother 14 (1984):  325-30|Sanburg AL, Hughes JD, Nichols C "Antibiotic-induced hypoprothrombinaemia." Med J Aust 143 (1985):  387-8|Natelson EA, Brown CH, 3d  Bradshaw MW, Alfrey CP, Jr  Williams TW, Jr "Influence of cephalosporin antibiotics on blood coagulation and platelet function." Antimicrob Agents Chemother 9 (1976):  91-3|Freedy HR, Cetnarowski AB, Lumish RM, Schafer FJ "Cefoperazone-induced coagulopathy." Drug Intell Clin Pharm 20 (1986):  281-3|Osborne JC "Hypoprothrombinemia and bleeding due to cefoperazone." Ann Intern Med 102 (1985):  721-2|Haubenstock A, Schmidt P, Zazgornik J, Balcke P, Kopsa H "Hypoprothrombinaemic bleeding associated with ceftriaxone." Lancet 1 (1983):  1215-6|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jahnchen E, Ritz E "Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status." J Clin Pharmacol 28 (1988):  88-95|Riancho JA, Olmos JM, Sedano C "Life-threatening bleeding in a patient treated with cefonicid." Ann Intern Med 123 (1995):  472-3|Breen GA, Stpeter WL "Hypoprothrombinemia associated with cefmetazole." Ann Pharmacother 31 (1997):  180-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38232, 16060, 'Cefoperazone', 'Hypoprothrombinemias', 'Hypoprothrombinemia, with or without bleeding, has been reported rarely with various cephalosporins, particularly those containing an N-methylthiotetrazole (NMTT) side chain (cefamandole, cefmetazole, cefoperazone, cefotetan).  The sulfhydryl group of this side chain is suspected of interfering with the hepatic synthesis of prothrombin.  Risk factors include advanced age, debility, vitamin K deficiency, malnutrition, malabsorption, and severe renal or hepatobiliary impairment.  Therapy with cephalosporins containing the NMTT side chain should be administered cautiously in patients with any of these risk factors and/or significant active bleeding or a hemorrhagic diathesis.  Prophylactic administration of vitamin K may be indicated in some patients, especially when intestinal sterilization and surgical procedures are performed.', '3', 'Lerner PI, Lubin A "Coagulopathy with cefazolin in uremia." N Engl J Med 290 (1974):  1324|Fujita Y, Inoue S, Yorifuji R, et al. "Effects of cefotaxime on blood coagulation in patients with renal insufficiency." Drugs 35 (1988):  196-8|Kline SS, Mauro VF, Forney RB Jr, et al. "Cefotetan-induced disulfiram-type reactions and hypoprothrombinemia." Antimicrob Agents Chemother 31 (1987):  1328-31|Holt J "Hypoprothrombinemia and bleeding diathesis associated with cefotetan therapy in surgical patients." Arch Surg 123 (1988):  523|Conjura A, Bell W, Lipsky JJ "Cefotetan and hypoprothrombinemia." Ann Intern Med 108 (1988):  643|Kaiser CW, McAuliffe JD, Barth RJ, Lynch JA "Hypoprothrombinemia and hemorrhage in a surgical patient treated with cefotetan." Arch Surg 126 (1991):  524-5|Wurtz RM, Sande MA "Cefotetan and coagulopathy." J Infect Dis 160 (1989):  555-6|Shimada K, Matsuda T, Inamatsu T, Urayama K "Bleeding secondary to vitamin K deficiency in patients receiving parenteral cephem antibiotics." J Antimicrob Chemother 14 (1984):  325-30|Fass RJ, Copelan EA, Brandt JT, Moeschberger ML, Ashton JJ "Platelet-mediated bleeding caused by broad-spectrum penicillins." J Infect Dis 155 (1987):  1242-8|Sanburg AL, Hughes JD, Nichols C "Antibiotic-induced hypoprothrombinaemia." Med J Aust 143 (1985):  387-8|Alitalo R, Ruutu M, Valtonen V, et al. "Hypoprothrombinaemia and bleeding during administration of cefamandole and cefoperazone." Ann Clin Res 17 (1985):  116-9|Bertino JS, Kozak AJ, Reese RE, Chiarello LA "Hypoprothrombinemia associated with cefamandole use in a rural teaching hospital." Arch Intern Med 146 (1986):  1125-8|Yangco BG, Palumbo JA, Nolen T, et al. "Comparative multicentre evaluation of the safety and efficacy of ceftazidime versus cefamandole for pneumonia." J Antimicrob Chemother 18 (1986):  521-9|O''Donnell D "Hypoprothrombinaemia associated with use of cephamandole." Aust N Z J Surg 61 (1991):  471-2|Tibbitts JS, Lipsky JJ "Effect of biliary diversion on the ability of cefamandole to inhibit vitamin K metabolism." Drug Metabol Drug Interact 7 (1989):  149-60|Cristiano P "Hypoprothrombinemia associated with cefoperazone treatment." Drug Intell Clin Pharm 18 (1984):  314-6|Meisel S "Hypoprothrombinemia due to cefoperazone." Drug Intell Clin Pharm 18 (1984):  316|Parker SW, Baxter J, Beam TR "Cefoperazone-induced coagulopathy." Lancet 1 (1984):  1016|Andrassy K, Koderisch J, Fritz S, et al. "Alteration of hemostasis associated with cefoperazone treatment." Infection 14 (1986):  27-31|Mueller RJ, Green D, Phair JP "Hypoprothrombinemia associated with cefoperazone therapy." South Med J 80 (1987):  1360-2|Brown RB, Klar J, Lemeshow S, Teres D, Pastides H, Sands M "Enhanced bleeding with cefoxitin or moxalactam." Arch Intern Med 146 (1986):  2159-64|Shenkenberg TD, Mackowiak PA, Smith JW "Coagulopathy and hemorrhage associated with cefoperazone therapy in a patient with renal failure." South Med J 78 (1985):  488-9|D''Elia JA, Kaldany A, Miller DG, et al. "Moxalactam bleeding and renal insufficiency." JAMA 249 (1983):  1565|Clark J, Hochman R, Rolla A, et al. "Coagulopathy associated with the use of cephalosporin or moxalactam antibiotics in acute and chronic renal failure." Clin Exp Dial Apheresis 7 (1983):  177-90|Shimanda K, Matsuda T, Inamatsu T, Urayama K "Bleeding secondary to vitamin K deficiency in patients receiving parenteral cephem antibiotics." J Antimicrob Chemother 14 (1984):  325-30|Sanburg AL, Hughes JD, Nichols C "Antibiotic-induced hypoprothrombinaemia." Med J Aust 143 (1985):  387-8|Natelson EA, Brown CH, 3d  Bradshaw MW, Alfrey CP, Jr  Williams TW, Jr "Influence of cephalosporin antibiotics on blood coagulation and platelet function." Antimicrob Agents Chemother 9 (1976):  91-3|Freedy HR, Cetnarowski AB, Lumish RM, Schafer FJ "Cefoperazone-induced coagulopathy." Drug Intell Clin Pharm 20 (1986):  281-3|Osborne JC "Hypoprothrombinemia and bleeding due to cefoperazone." Ann Intern Med 102 (1985):  721-2|Haubenstock A, Schmidt P, Zazgornik J, Balcke P, Kopsa H "Hypoprothrombinaemic bleeding associated with ceftriaxone." Lancet 1 (1983):  1215-6|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jahnchen E, Ritz E "Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status." J Clin Pharmacol 28 (1988):  88-95|Riancho JA, Olmos JM, Sedano C "Life-threatening bleeding in a patient treated with cefonicid." Ann Intern Med 123 (1995):  472-3|Breen GA, Stpeter WL "Hypoprothrombinemia associated with cefmetazole." Ann Pharmacother 31 (1997):  180-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38233, 16296, 'Cefoperazone', 'Hypoprothrombinemias', 'Hypoprothrombinemia, with or without bleeding, has been reported rarely with various cephalosporins, particularly those containing an N-methylthiotetrazole (NMTT) side chain (cefamandole, cefmetazole, cefoperazone, cefotetan).  The sulfhydryl group of this side chain is suspected of interfering with the hepatic synthesis of prothrombin.  Risk factors include advanced age, debility, vitamin K deficiency, malnutrition, malabsorption, and severe renal or hepatobiliary impairment.  Therapy with cephalosporins containing the NMTT side chain should be administered cautiously in patients with any of these risk factors and/or significant active bleeding or a hemorrhagic diathesis.  Prophylactic administration of vitamin K may be indicated in some patients, especially when intestinal sterilization and surgical procedures are performed.', '3', 'Lerner PI, Lubin A "Coagulopathy with cefazolin in uremia." N Engl J Med 290 (1974):  1324|Fujita Y, Inoue S, Yorifuji R, et al. "Effects of cefotaxime on blood coagulation in patients with renal insufficiency." Drugs 35 (1988):  196-8|Kline SS, Mauro VF, Forney RB Jr, et al. "Cefotetan-induced disulfiram-type reactions and hypoprothrombinemia." Antimicrob Agents Chemother 31 (1987):  1328-31|Holt J "Hypoprothrombinemia and bleeding diathesis associated with cefotetan therapy in surgical patients." Arch Surg 123 (1988):  523|Conjura A, Bell W, Lipsky JJ "Cefotetan and hypoprothrombinemia." Ann Intern Med 108 (1988):  643|Kaiser CW, McAuliffe JD, Barth RJ, Lynch JA "Hypoprothrombinemia and hemorrhage in a surgical patient treated with cefotetan." Arch Surg 126 (1991):  524-5|Wurtz RM, Sande MA "Cefotetan and coagulopathy." J Infect Dis 160 (1989):  555-6|Shimada K, Matsuda T, Inamatsu T, Urayama K "Bleeding secondary to vitamin K deficiency in patients receiving parenteral cephem antibiotics." J Antimicrob Chemother 14 (1984):  325-30|Fass RJ, Copelan EA, Brandt JT, Moeschberger ML, Ashton JJ "Platelet-mediated bleeding caused by broad-spectrum penicillins." J Infect Dis 155 (1987):  1242-8|Sanburg AL, Hughes JD, Nichols C "Antibiotic-induced hypoprothrombinaemia." Med J Aust 143 (1985):  387-8|Alitalo R, Ruutu M, Valtonen V, et al. "Hypoprothrombinaemia and bleeding during administration of cefamandole and cefoperazone." Ann Clin Res 17 (1985):  116-9|Bertino JS, Kozak AJ, Reese RE, Chiarello LA "Hypoprothrombinemia associated with cefamandole use in a rural teaching hospital." Arch Intern Med 146 (1986):  1125-8|Yangco BG, Palumbo JA, Nolen T, et al. "Comparative multicentre evaluation of the safety and efficacy of ceftazidime versus cefamandole for pneumonia." J Antimicrob Chemother 18 (1986):  521-9|O''Donnell D "Hypoprothrombinaemia associated with use of cephamandole." Aust N Z J Surg 61 (1991):  471-2|Tibbitts JS, Lipsky JJ "Effect of biliary diversion on the ability of cefamandole to inhibit vitamin K metabolism." Drug Metabol Drug Interact 7 (1989):  149-60|Cristiano P "Hypoprothrombinemia associated with cefoperazone treatment." Drug Intell Clin Pharm 18 (1984):  314-6|Meisel S "Hypoprothrombinemia due to cefoperazone." Drug Intell Clin Pharm 18 (1984):  316|Parker SW, Baxter J, Beam TR "Cefoperazone-induced coagulopathy." Lancet 1 (1984):  1016|Andrassy K, Koderisch J, Fritz S, et al. "Alteration of hemostasis associated with cefoperazone treatment." Infection 14 (1986):  27-31|Mueller RJ, Green D, Phair JP "Hypoprothrombinemia associated with cefoperazone therapy." South Med J 80 (1987):  1360-2|Brown RB, Klar J, Lemeshow S, Teres D, Pastides H, Sands M "Enhanced bleeding with cefoxitin or moxalactam." Arch Intern Med 146 (1986):  2159-64|Shenkenberg TD, Mackowiak PA, Smith JW "Coagulopathy and hemorrhage associated with cefoperazone therapy in a patient with renal failure." South Med J 78 (1985):  488-9|D''Elia JA, Kaldany A, Miller DG, et al. "Moxalactam bleeding and renal insufficiency." JAMA 249 (1983):  1565|Clark J, Hochman R, Rolla A, et al. "Coagulopathy associated with the use of cephalosporin or moxalactam antibiotics in acute and chronic renal failure." Clin Exp Dial Apheresis 7 (1983):  177-90|Shimanda K, Matsuda T, Inamatsu T, Urayama K "Bleeding secondary to vitamin K deficiency in patients receiving parenteral cephem antibiotics." J Antimicrob Chemother 14 (1984):  325-30|Sanburg AL, Hughes JD, Nichols C "Antibiotic-induced hypoprothrombinaemia." Med J Aust 143 (1985):  387-8|Natelson EA, Brown CH, 3d  Bradshaw MW, Alfrey CP, Jr  Williams TW, Jr "Influence of cephalosporin antibiotics on blood coagulation and platelet function." Antimicrob Agents Chemother 9 (1976):  91-3|Freedy HR, Cetnarowski AB, Lumish RM, Schafer FJ "Cefoperazone-induced coagulopathy." Drug Intell Clin Pharm 20 (1986):  281-3|Osborne JC "Hypoprothrombinemia and bleeding due to cefoperazone." Ann Intern Med 102 (1985):  721-2|Haubenstock A, Schmidt P, Zazgornik J, Balcke P, Kopsa H "Hypoprothrombinaemic bleeding associated with ceftriaxone." Lancet 1 (1983):  1215-6|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jahnchen E, Ritz E "Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status." J Clin Pharmacol 28 (1988):  88-95|Riancho JA, Olmos JM, Sedano C "Life-threatening bleeding in a patient treated with cefonicid." Ann Intern Med 123 (1995):  472-3|Breen GA, Stpeter WL "Hypoprothrombinemia associated with cefmetazole." Ann Pharmacother 31 (1997):  180-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38234, 22387, 'Cefoperazone', 'Hypoprothrombinemias', 'Hypoprothrombinemia, with or without bleeding, has been reported rarely with various cephalosporins, particularly those containing an N-methylthiotetrazole (NMTT) side chain (cefamandole, cefmetazole, cefoperazone, cefotetan).  The sulfhydryl group of this side chain is suspected of interfering with the hepatic synthesis of prothrombin.  Risk factors include advanced age, debility, vitamin K deficiency, malnutrition, malabsorption, and severe renal or hepatobiliary impairment.  Therapy with cephalosporins containing the NMTT side chain should be administered cautiously in patients with any of these risk factors and/or significant active bleeding or a hemorrhagic diathesis.  Prophylactic administration of vitamin K may be indicated in some patients, especially when intestinal sterilization and surgical procedures are performed.', '3', 'Lerner PI, Lubin A "Coagulopathy with cefazolin in uremia." N Engl J Med 290 (1974):  1324|Fujita Y, Inoue S, Yorifuji R, et al. "Effects of cefotaxime on blood coagulation in patients with renal insufficiency." Drugs 35 (1988):  196-8|Kline SS, Mauro VF, Forney RB Jr, et al. "Cefotetan-induced disulfiram-type reactions and hypoprothrombinemia." Antimicrob Agents Chemother 31 (1987):  1328-31|Holt J "Hypoprothrombinemia and bleeding diathesis associated with cefotetan therapy in surgical patients." Arch Surg 123 (1988):  523|Conjura A, Bell W, Lipsky JJ "Cefotetan and hypoprothrombinemia." Ann Intern Med 108 (1988):  643|Kaiser CW, McAuliffe JD, Barth RJ, Lynch JA "Hypoprothrombinemia and hemorrhage in a surgical patient treated with cefotetan." Arch Surg 126 (1991):  524-5|Wurtz RM, Sande MA "Cefotetan and coagulopathy." J Infect Dis 160 (1989):  555-6|Shimada K, Matsuda T, Inamatsu T, Urayama K "Bleeding secondary to vitamin K deficiency in patients receiving parenteral cephem antibiotics." J Antimicrob Chemother 14 (1984):  325-30|Fass RJ, Copelan EA, Brandt JT, Moeschberger ML, Ashton JJ "Platelet-mediated bleeding caused by broad-spectrum penicillins." J Infect Dis 155 (1987):  1242-8|Sanburg AL, Hughes JD, Nichols C "Antibiotic-induced hypoprothrombinaemia." Med J Aust 143 (1985):  387-8|Alitalo R, Ruutu M, Valtonen V, et al. "Hypoprothrombinaemia and bleeding during administration of cefamandole and cefoperazone." Ann Clin Res 17 (1985):  116-9|Bertino JS, Kozak AJ, Reese RE, Chiarello LA "Hypoprothrombinemia associated with cefamandole use in a rural teaching hospital." Arch Intern Med 146 (1986):  1125-8|Yangco BG, Palumbo JA, Nolen T, et al. "Comparative multicentre evaluation of the safety and efficacy of ceftazidime versus cefamandole for pneumonia." J Antimicrob Chemother 18 (1986):  521-9|O''Donnell D "Hypoprothrombinaemia associated with use of cephamandole." Aust N Z J Surg 61 (1991):  471-2|Tibbitts JS, Lipsky JJ "Effect of biliary diversion on the ability of cefamandole to inhibit vitamin K metabolism." Drug Metabol Drug Interact 7 (1989):  149-60|Cristiano P "Hypoprothrombinemia associated with cefoperazone treatment." Drug Intell Clin Pharm 18 (1984):  314-6|Meisel S "Hypoprothrombinemia due to cefoperazone." Drug Intell Clin Pharm 18 (1984):  316|Parker SW, Baxter J, Beam TR "Cefoperazone-induced coagulopathy." Lancet 1 (1984):  1016|Andrassy K, Koderisch J, Fritz S, et al. "Alteration of hemostasis associated with cefoperazone treatment." Infection 14 (1986):  27-31|Mueller RJ, Green D, Phair JP "Hypoprothrombinemia associated with cefoperazone therapy." South Med J 80 (1987):  1360-2|Brown RB, Klar J, Lemeshow S, Teres D, Pastides H, Sands M "Enhanced bleeding with cefoxitin or moxalactam." Arch Intern Med 146 (1986):  2159-64|Shenkenberg TD, Mackowiak PA, Smith JW "Coagulopathy and hemorrhage associated with cefoperazone therapy in a patient with renal failure." South Med J 78 (1985):  488-9|D''Elia JA, Kaldany A, Miller DG, et al. "Moxalactam bleeding and renal insufficiency." JAMA 249 (1983):  1565|Clark J, Hochman R, Rolla A, et al. "Coagulopathy associated with the use of cephalosporin or moxalactam antibiotics in acute and chronic renal failure." Clin Exp Dial Apheresis 7 (1983):  177-90|Shimanda K, Matsuda T, Inamatsu T, Urayama K "Bleeding secondary to vitamin K deficiency in patients receiving parenteral cephem antibiotics." J Antimicrob Chemother 14 (1984):  325-30|Sanburg AL, Hughes JD, Nichols C "Antibiotic-induced hypoprothrombinaemia." Med J Aust 143 (1985):  387-8|Natelson EA, Brown CH, 3d  Bradshaw MW, Alfrey CP, Jr  Williams TW, Jr "Influence of cephalosporin antibiotics on blood coagulation and platelet function." Antimicrob Agents Chemother 9 (1976):  91-3|Freedy HR, Cetnarowski AB, Lumish RM, Schafer FJ "Cefoperazone-induced coagulopathy." Drug Intell Clin Pharm 20 (1986):  281-3|Osborne JC "Hypoprothrombinemia and bleeding due to cefoperazone." Ann Intern Med 102 (1985):  721-2|Haubenstock A, Schmidt P, Zazgornik J, Balcke P, Kopsa H "Hypoprothrombinaemic bleeding associated with ceftriaxone." Lancet 1 (1983):  1215-6|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jahnchen E, Ritz E "Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status." J Clin Pharmacol 28 (1988):  88-95|Riancho JA, Olmos JM, Sedano C "Life-threatening bleeding in a patient treated with cefonicid." Ann Intern Med 123 (1995):  472-3|Breen GA, Stpeter WL "Hypoprothrombinemia associated with cefmetazole." Ann Pharmacother 31 (1997):  180-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38235, 24726, 'Cefoperazone', 'Hypoprothrombinemias', 'Hypoprothrombinemia, with or without bleeding, has been reported rarely with various cephalosporins, particularly those containing an N-methylthiotetrazole (NMTT) side chain (cefamandole, cefmetazole, cefoperazone, cefotetan).  The sulfhydryl group of this side chain is suspected of interfering with the hepatic synthesis of prothrombin.  Risk factors include advanced age, debility, vitamin K deficiency, malnutrition, malabsorption, and severe renal or hepatobiliary impairment.  Therapy with cephalosporins containing the NMTT side chain should be administered cautiously in patients with any of these risk factors and/or significant active bleeding or a hemorrhagic diathesis.  Prophylactic administration of vitamin K may be indicated in some patients, especially when intestinal sterilization and surgical procedures are performed.', '3', 'Lerner PI, Lubin A "Coagulopathy with cefazolin in uremia." N Engl J Med 290 (1974):  1324|Fujita Y, Inoue S, Yorifuji R, et al. "Effects of cefotaxime on blood coagulation in patients with renal insufficiency." Drugs 35 (1988):  196-8|Kline SS, Mauro VF, Forney RB Jr, et al. "Cefotetan-induced disulfiram-type reactions and hypoprothrombinemia." Antimicrob Agents Chemother 31 (1987):  1328-31|Holt J "Hypoprothrombinemia and bleeding diathesis associated with cefotetan therapy in surgical patients." Arch Surg 123 (1988):  523|Conjura A, Bell W, Lipsky JJ "Cefotetan and hypoprothrombinemia." Ann Intern Med 108 (1988):  643|Kaiser CW, McAuliffe JD, Barth RJ, Lynch JA "Hypoprothrombinemia and hemorrhage in a surgical patient treated with cefotetan." Arch Surg 126 (1991):  524-5|Wurtz RM, Sande MA "Cefotetan and coagulopathy." J Infect Dis 160 (1989):  555-6|Shimada K, Matsuda T, Inamatsu T, Urayama K "Bleeding secondary to vitamin K deficiency in patients receiving parenteral cephem antibiotics." J Antimicrob Chemother 14 (1984):  325-30|Fass RJ, Copelan EA, Brandt JT, Moeschberger ML, Ashton JJ "Platelet-mediated bleeding caused by broad-spectrum penicillins." J Infect Dis 155 (1987):  1242-8|Sanburg AL, Hughes JD, Nichols C "Antibiotic-induced hypoprothrombinaemia." Med J Aust 143 (1985):  387-8|Alitalo R, Ruutu M, Valtonen V, et al. "Hypoprothrombinaemia and bleeding during administration of cefamandole and cefoperazone." Ann Clin Res 17 (1985):  116-9|Bertino JS, Kozak AJ, Reese RE, Chiarello LA "Hypoprothrombinemia associated with cefamandole use in a rural teaching hospital." Arch Intern Med 146 (1986):  1125-8|Yangco BG, Palumbo JA, Nolen T, et al. "Comparative multicentre evaluation of the safety and efficacy of ceftazidime versus cefamandole for pneumonia." J Antimicrob Chemother 18 (1986):  521-9|O''Donnell D "Hypoprothrombinaemia associated with use of cephamandole." Aust N Z J Surg 61 (1991):  471-2|Tibbitts JS, Lipsky JJ "Effect of biliary diversion on the ability of cefamandole to inhibit vitamin K metabolism." Drug Metabol Drug Interact 7 (1989):  149-60|Cristiano P "Hypoprothrombinemia associated with cefoperazone treatment." Drug Intell Clin Pharm 18 (1984):  314-6|Meisel S "Hypoprothrombinemia due to cefoperazone." Drug Intell Clin Pharm 18 (1984):  316|Parker SW, Baxter J, Beam TR "Cefoperazone-induced coagulopathy." Lancet 1 (1984):  1016|Andrassy K, Koderisch J, Fritz S, et al. "Alteration of hemostasis associated with cefoperazone treatment." Infection 14 (1986):  27-31|Mueller RJ, Green D, Phair JP "Hypoprothrombinemia associated with cefoperazone therapy." South Med J 80 (1987):  1360-2|Brown RB, Klar J, Lemeshow S, Teres D, Pastides H, Sands M "Enhanced bleeding with cefoxitin or moxalactam." Arch Intern Med 146 (1986):  2159-64|Shenkenberg TD, Mackowiak PA, Smith JW "Coagulopathy and hemorrhage associated with cefoperazone therapy in a patient with renal failure." South Med J 78 (1985):  488-9|D''Elia JA, Kaldany A, Miller DG, et al. "Moxalactam bleeding and renal insufficiency." JAMA 249 (1983):  1565|Clark J, Hochman R, Rolla A, et al. "Coagulopathy associated with the use of cephalosporin or moxalactam antibiotics in acute and chronic renal failure." Clin Exp Dial Apheresis 7 (1983):  177-90|Shimanda K, Matsuda T, Inamatsu T, Urayama K "Bleeding secondary to vitamin K deficiency in patients receiving parenteral cephem antibiotics." J Antimicrob Chemother 14 (1984):  325-30|Sanburg AL, Hughes JD, Nichols C "Antibiotic-induced hypoprothrombinaemia." Med J Aust 143 (1985):  387-8|Natelson EA, Brown CH, 3d  Bradshaw MW, Alfrey CP, Jr  Williams TW, Jr "Influence of cephalosporin antibiotics on blood coagulation and platelet function." Antimicrob Agents Chemother 9 (1976):  91-3|Freedy HR, Cetnarowski AB, Lumish RM, Schafer FJ "Cefoperazone-induced coagulopathy." Drug Intell Clin Pharm 20 (1986):  281-3|Osborne JC "Hypoprothrombinemia and bleeding due to cefoperazone." Ann Intern Med 102 (1985):  721-2|Haubenstock A, Schmidt P, Zazgornik J, Balcke P, Kopsa H "Hypoprothrombinaemic bleeding associated with ceftriaxone." Lancet 1 (1983):  1215-6|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jahnchen E, Ritz E "Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status." J Clin Pharmacol 28 (1988):  88-95|Riancho JA, Olmos JM, Sedano C "Life-threatening bleeding in a patient treated with cefonicid." Ann Intern Med 123 (1995):  472-3|Breen GA, Stpeter WL "Hypoprothrombinemia associated with cefmetazole." Ann Pharmacother 31 (1997):  180-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38236, 24727, 'Cefoperazone', 'Hypoprothrombinemias', 'Hypoprothrombinemia, with or without bleeding, has been reported rarely with various cephalosporins, particularly those containing an N-methylthiotetrazole (NMTT) side chain (cefamandole, cefmetazole, cefoperazone, cefotetan).  The sulfhydryl group of this side chain is suspected of interfering with the hepatic synthesis of prothrombin.  Risk factors include advanced age, debility, vitamin K deficiency, malnutrition, malabsorption, and severe renal or hepatobiliary impairment.  Therapy with cephalosporins containing the NMTT side chain should be administered cautiously in patients with any of these risk factors and/or significant active bleeding or a hemorrhagic diathesis.  Prophylactic administration of vitamin K may be indicated in some patients, especially when intestinal sterilization and surgical procedures are performed.', '3', 'Lerner PI, Lubin A "Coagulopathy with cefazolin in uremia." N Engl J Med 290 (1974):  1324|Fujita Y, Inoue S, Yorifuji R, et al. "Effects of cefotaxime on blood coagulation in patients with renal insufficiency." Drugs 35 (1988):  196-8|Kline SS, Mauro VF, Forney RB Jr, et al. "Cefotetan-induced disulfiram-type reactions and hypoprothrombinemia." Antimicrob Agents Chemother 31 (1987):  1328-31|Holt J "Hypoprothrombinemia and bleeding diathesis associated with cefotetan therapy in surgical patients." Arch Surg 123 (1988):  523|Conjura A, Bell W, Lipsky JJ "Cefotetan and hypoprothrombinemia." Ann Intern Med 108 (1988):  643|Kaiser CW, McAuliffe JD, Barth RJ, Lynch JA "Hypoprothrombinemia and hemorrhage in a surgical patient treated with cefotetan." Arch Surg 126 (1991):  524-5|Wurtz RM, Sande MA "Cefotetan and coagulopathy." J Infect Dis 160 (1989):  555-6|Shimada K, Matsuda T, Inamatsu T, Urayama K "Bleeding secondary to vitamin K deficiency in patients receiving parenteral cephem antibiotics." J Antimicrob Chemother 14 (1984):  325-30|Fass RJ, Copelan EA, Brandt JT, Moeschberger ML, Ashton JJ "Platelet-mediated bleeding caused by broad-spectrum penicillins." J Infect Dis 155 (1987):  1242-8|Sanburg AL, Hughes JD, Nichols C "Antibiotic-induced hypoprothrombinaemia." Med J Aust 143 (1985):  387-8|Alitalo R, Ruutu M, Valtonen V, et al. "Hypoprothrombinaemia and bleeding during administration of cefamandole and cefoperazone." Ann Clin Res 17 (1985):  116-9|Bertino JS, Kozak AJ, Reese RE, Chiarello LA "Hypoprothrombinemia associated with cefamandole use in a rural teaching hospital." Arch Intern Med 146 (1986):  1125-8|Yangco BG, Palumbo JA, Nolen T, et al. "Comparative multicentre evaluation of the safety and efficacy of ceftazidime versus cefamandole for pneumonia." J Antimicrob Chemother 18 (1986):  521-9|O''Donnell D "Hypoprothrombinaemia associated with use of cephamandole." Aust N Z J Surg 61 (1991):  471-2|Tibbitts JS, Lipsky JJ "Effect of biliary diversion on the ability of cefamandole to inhibit vitamin K metabolism." Drug Metabol Drug Interact 7 (1989):  149-60|Cristiano P "Hypoprothrombinemia associated with cefoperazone treatment." Drug Intell Clin Pharm 18 (1984):  314-6|Meisel S "Hypoprothrombinemia due to cefoperazone." Drug Intell Clin Pharm 18 (1984):  316|Parker SW, Baxter J, Beam TR "Cefoperazone-induced coagulopathy." Lancet 1 (1984):  1016|Andrassy K, Koderisch J, Fritz S, et al. "Alteration of hemostasis associated with cefoperazone treatment." Infection 14 (1986):  27-31|Mueller RJ, Green D, Phair JP "Hypoprothrombinemia associated with cefoperazone therapy." South Med J 80 (1987):  1360-2|Brown RB, Klar J, Lemeshow S, Teres D, Pastides H, Sands M "Enhanced bleeding with cefoxitin or moxalactam." Arch Intern Med 146 (1986):  2159-64|Shenkenberg TD, Mackowiak PA, Smith JW "Coagulopathy and hemorrhage associated with cefoperazone therapy in a patient with renal failure." South Med J 78 (1985):  488-9|D''Elia JA, Kaldany A, Miller DG, et al. "Moxalactam bleeding and renal insufficiency." JAMA 249 (1983):  1565|Clark J, Hochman R, Rolla A, et al. "Coagulopathy associated with the use of cephalosporin or moxalactam antibiotics in acute and chronic renal failure." Clin Exp Dial Apheresis 7 (1983):  177-90|Shimanda K, Matsuda T, Inamatsu T, Urayama K "Bleeding secondary to vitamin K deficiency in patients receiving parenteral cephem antibiotics." J Antimicrob Chemother 14 (1984):  325-30|Sanburg AL, Hughes JD, Nichols C "Antibiotic-induced hypoprothrombinaemia." Med J Aust 143 (1985):  387-8|Natelson EA, Brown CH, 3d  Bradshaw MW, Alfrey CP, Jr  Williams TW, Jr "Influence of cephalosporin antibiotics on blood coagulation and platelet function." Antimicrob Agents Chemother 9 (1976):  91-3|Freedy HR, Cetnarowski AB, Lumish RM, Schafer FJ "Cefoperazone-induced coagulopathy." Drug Intell Clin Pharm 20 (1986):  281-3|Osborne JC "Hypoprothrombinemia and bleeding due to cefoperazone." Ann Intern Med 102 (1985):  721-2|Haubenstock A, Schmidt P, Zazgornik J, Balcke P, Kopsa H "Hypoprothrombinaemic bleeding associated with ceftriaxone." Lancet 1 (1983):  1215-6|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jahnchen E, Ritz E "Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status." J Clin Pharmacol 28 (1988):  88-95|Riancho JA, Olmos JM, Sedano C "Life-threatening bleeding in a patient treated with cefonicid." Ann Intern Med 123 (1995):  472-3|Breen GA, Stpeter WL "Hypoprothrombinemia associated with cefmetazole." Ann Pharmacother 31 (1997):  180-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38237, 2224, 'Cefoperazone', 'Liver Diseases', 'Cefoperazone is primarily eliminated by hepatobiliary excretion.  In patients with impaired hepatic function and/or biliary obstruction, the half-life of cefoperazone is prolonged 2- to 4-fold but urinary excretion is increased.  At usual dosages, adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored if high dosages are used (i.e. > 4 g/day), and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, cefoperazone dosage should not exceed 1 to 2 grams per day without close monitoring of serum concentrations.', '2', 'Balant L, Dayer P, Rudhardt M, et al. "Cefoperazone: pharmacokinetics in humans with normal and impaired renal function and pharmacokinetics in rats." Clin Ther 3 (1980):  50-9|Neu HC "A review and summary of the pharmacokinetics of cefoperazone: a new, extended-spectrum B-lactam antibiotic." Ther Drug Monit 3 (1981):  121-8|Cochet B, Belaieff J, Allaz AF, et al. "Serum levels and urinary excretion of cefoperazone in patients with hepatic insufficiency." Infection 9 (1981):  s37-9|Bolton WK, Scheld WM, Spyker DA, Sande MA "Pharmacokinetics of cefoperazone in normal volunteers and subjects with renal insufficiency." Antimicrob Agents Chemother 19 (1981):  821-5|Boscia JA, Korzeniowski OM, Snepar R, et al. "Cefoperazone pharmacokinetics in normal subjects and patients with cirrhosis." Antimicrob Agents Chemother 23 (1983):  385-9|Greenfield RA, Gerber AU, Craig WA "Pharmacokinetics of cefoperazone in patients with normal and impaired hepataic and renal function." Rev Infect Dis 5 (1983):  s127-36|Saudek F, Moravek J, Modr Z "Cefoperazone pharmacokinetics in patients with liver cirrhosis: a predictive value of the ujoviridin test." Int J Clin Pharmacol Ther Toxicol 27 (1989):  82-7|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|Muder RR, Agarwala S, Mirani A, Gayowski T, Venkataramanan R "Pharmacokinetics of cefoperazone and sulbactam in liver transplant patients." J Clin Pharmacol 42 (2002):  644-50', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38238, 2270, 'Cefoperazone', 'Liver Diseases', 'Cefoperazone is primarily eliminated by hepatobiliary excretion.  In patients with impaired hepatic function and/or biliary obstruction, the half-life of cefoperazone is prolonged 2- to 4-fold but urinary excretion is increased.  At usual dosages, adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored if high dosages are used (i.e. > 4 g/day), and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, cefoperazone dosage should not exceed 1 to 2 grams per day without close monitoring of serum concentrations.', '2', 'Balant L, Dayer P, Rudhardt M, et al. "Cefoperazone: pharmacokinetics in humans with normal and impaired renal function and pharmacokinetics in rats." Clin Ther 3 (1980):  50-9|Neu HC "A review and summary of the pharmacokinetics of cefoperazone: a new, extended-spectrum B-lactam antibiotic." Ther Drug Monit 3 (1981):  121-8|Cochet B, Belaieff J, Allaz AF, et al. "Serum levels and urinary excretion of cefoperazone in patients with hepatic insufficiency." Infection 9 (1981):  s37-9|Bolton WK, Scheld WM, Spyker DA, Sande MA "Pharmacokinetics of cefoperazone in normal volunteers and subjects with renal insufficiency." Antimicrob Agents Chemother 19 (1981):  821-5|Boscia JA, Korzeniowski OM, Snepar R, et al. "Cefoperazone pharmacokinetics in normal subjects and patients with cirrhosis." Antimicrob Agents Chemother 23 (1983):  385-9|Greenfield RA, Gerber AU, Craig WA "Pharmacokinetics of cefoperazone in patients with normal and impaired hepataic and renal function." Rev Infect Dis 5 (1983):  s127-36|Saudek F, Moravek J, Modr Z "Cefoperazone pharmacokinetics in patients with liver cirrhosis: a predictive value of the ujoviridin test." Int J Clin Pharmacol Ther Toxicol 27 (1989):  82-7|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|Muder RR, Agarwala S, Mirani A, Gayowski T, Venkataramanan R "Pharmacokinetics of cefoperazone and sulbactam in liver transplant patients." J Clin Pharmacol 42 (2002):  644-50', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38239, 2274, 'Cefoperazone', 'Liver Diseases', 'Cefoperazone is primarily eliminated by hepatobiliary excretion.  In patients with impaired hepatic function and/or biliary obstruction, the half-life of cefoperazone is prolonged 2- to 4-fold but urinary excretion is increased.  At usual dosages, adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored if high dosages are used (i.e. > 4 g/day), and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, cefoperazone dosage should not exceed 1 to 2 grams per day without close monitoring of serum concentrations.', '2', 'Balant L, Dayer P, Rudhardt M, et al. "Cefoperazone: pharmacokinetics in humans with normal and impaired renal function and pharmacokinetics in rats." Clin Ther 3 (1980):  50-9|Neu HC "A review and summary of the pharmacokinetics of cefoperazone: a new, extended-spectrum B-lactam antibiotic." Ther Drug Monit 3 (1981):  121-8|Cochet B, Belaieff J, Allaz AF, et al. "Serum levels and urinary excretion of cefoperazone in patients with hepatic insufficiency." Infection 9 (1981):  s37-9|Bolton WK, Scheld WM, Spyker DA, Sande MA "Pharmacokinetics of cefoperazone in normal volunteers and subjects with renal insufficiency." Antimicrob Agents Chemother 19 (1981):  821-5|Boscia JA, Korzeniowski OM, Snepar R, et al. "Cefoperazone pharmacokinetics in normal subjects and patients with cirrhosis." Antimicrob Agents Chemother 23 (1983):  385-9|Greenfield RA, Gerber AU, Craig WA "Pharmacokinetics of cefoperazone in patients with normal and impaired hepataic and renal function." Rev Infect Dis 5 (1983):  s127-36|Saudek F, Moravek J, Modr Z "Cefoperazone pharmacokinetics in patients with liver cirrhosis: a predictive value of the ujoviridin test." Int J Clin Pharmacol Ther Toxicol 27 (1989):  82-7|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|Muder RR, Agarwala S, Mirani A, Gayowski T, Venkataramanan R "Pharmacokinetics of cefoperazone and sulbactam in liver transplant patients." J Clin Pharmacol 42 (2002):  644-50', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38240, 2278, 'Cefoperazone', 'Liver Diseases', 'Cefoperazone is primarily eliminated by hepatobiliary excretion.  In patients with impaired hepatic function and/or biliary obstruction, the half-life of cefoperazone is prolonged 2- to 4-fold but urinary excretion is increased.  At usual dosages, adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored if high dosages are used (i.e. > 4 g/day), and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, cefoperazone dosage should not exceed 1 to 2 grams per day without close monitoring of serum concentrations.', '2', 'Balant L, Dayer P, Rudhardt M, et al. "Cefoperazone: pharmacokinetics in humans with normal and impaired renal function and pharmacokinetics in rats." Clin Ther 3 (1980):  50-9|Neu HC "A review and summary of the pharmacokinetics of cefoperazone: a new, extended-spectrum B-lactam antibiotic." Ther Drug Monit 3 (1981):  121-8|Cochet B, Belaieff J, Allaz AF, et al. "Serum levels and urinary excretion of cefoperazone in patients with hepatic insufficiency." Infection 9 (1981):  s37-9|Bolton WK, Scheld WM, Spyker DA, Sande MA "Pharmacokinetics of cefoperazone in normal volunteers and subjects with renal insufficiency." Antimicrob Agents Chemother 19 (1981):  821-5|Boscia JA, Korzeniowski OM, Snepar R, et al. "Cefoperazone pharmacokinetics in normal subjects and patients with cirrhosis." Antimicrob Agents Chemother 23 (1983):  385-9|Greenfield RA, Gerber AU, Craig WA "Pharmacokinetics of cefoperazone in patients with normal and impaired hepataic and renal function." Rev Infect Dis 5 (1983):  s127-36|Saudek F, Moravek J, Modr Z "Cefoperazone pharmacokinetics in patients with liver cirrhosis: a predictive value of the ujoviridin test." Int J Clin Pharmacol Ther Toxicol 27 (1989):  82-7|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|Muder RR, Agarwala S, Mirani A, Gayowski T, Venkataramanan R "Pharmacokinetics of cefoperazone and sulbactam in liver transplant patients." J Clin Pharmacol 42 (2002):  644-50', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38241, 2279, 'Cefoperazone', 'Liver Diseases', 'Cefoperazone is primarily eliminated by hepatobiliary excretion.  In patients with impaired hepatic function and/or biliary obstruction, the half-life of cefoperazone is prolonged 2- to 4-fold but urinary excretion is increased.  At usual dosages, adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored if high dosages are used (i.e. > 4 g/day), and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, cefoperazone dosage should not exceed 1 to 2 grams per day without close monitoring of serum concentrations.', '2', 'Balant L, Dayer P, Rudhardt M, et al. "Cefoperazone: pharmacokinetics in humans with normal and impaired renal function and pharmacokinetics in rats." Clin Ther 3 (1980):  50-9|Neu HC "A review and summary of the pharmacokinetics of cefoperazone: a new, extended-spectrum B-lactam antibiotic." Ther Drug Monit 3 (1981):  121-8|Cochet B, Belaieff J, Allaz AF, et al. "Serum levels and urinary excretion of cefoperazone in patients with hepatic insufficiency." Infection 9 (1981):  s37-9|Bolton WK, Scheld WM, Spyker DA, Sande MA "Pharmacokinetics of cefoperazone in normal volunteers and subjects with renal insufficiency." Antimicrob Agents Chemother 19 (1981):  821-5|Boscia JA, Korzeniowski OM, Snepar R, et al. "Cefoperazone pharmacokinetics in normal subjects and patients with cirrhosis." Antimicrob Agents Chemother 23 (1983):  385-9|Greenfield RA, Gerber AU, Craig WA "Pharmacokinetics of cefoperazone in patients with normal and impaired hepataic and renal function." Rev Infect Dis 5 (1983):  s127-36|Saudek F, Moravek J, Modr Z "Cefoperazone pharmacokinetics in patients with liver cirrhosis: a predictive value of the ujoviridin test." Int J Clin Pharmacol Ther Toxicol 27 (1989):  82-7|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|Muder RR, Agarwala S, Mirani A, Gayowski T, Venkataramanan R "Pharmacokinetics of cefoperazone and sulbactam in liver transplant patients." J Clin Pharmacol 42 (2002):  644-50', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38242, 6385, 'Cefoperazone', 'Liver Diseases', 'Cefoperazone is primarily eliminated by hepatobiliary excretion.  In patients with impaired hepatic function and/or biliary obstruction, the half-life of cefoperazone is prolonged 2- to 4-fold but urinary excretion is increased.  At usual dosages, adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored if high dosages are used (i.e. > 4 g/day), and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, cefoperazone dosage should not exceed 1 to 2 grams per day without close monitoring of serum concentrations.', '2', 'Balant L, Dayer P, Rudhardt M, et al. "Cefoperazone: pharmacokinetics in humans with normal and impaired renal function and pharmacokinetics in rats." Clin Ther 3 (1980):  50-9|Neu HC "A review and summary of the pharmacokinetics of cefoperazone: a new, extended-spectrum B-lactam antibiotic." Ther Drug Monit 3 (1981):  121-8|Cochet B, Belaieff J, Allaz AF, et al. "Serum levels and urinary excretion of cefoperazone in patients with hepatic insufficiency." Infection 9 (1981):  s37-9|Bolton WK, Scheld WM, Spyker DA, Sande MA "Pharmacokinetics of cefoperazone in normal volunteers and subjects with renal insufficiency." Antimicrob Agents Chemother 19 (1981):  821-5|Boscia JA, Korzeniowski OM, Snepar R, et al. "Cefoperazone pharmacokinetics in normal subjects and patients with cirrhosis." Antimicrob Agents Chemother 23 (1983):  385-9|Greenfield RA, Gerber AU, Craig WA "Pharmacokinetics of cefoperazone in patients with normal and impaired hepataic and renal function." Rev Infect Dis 5 (1983):  s127-36|Saudek F, Moravek J, Modr Z "Cefoperazone pharmacokinetics in patients with liver cirrhosis: a predictive value of the ujoviridin test." Int J Clin Pharmacol Ther Toxicol 27 (1989):  82-7|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|Muder RR, Agarwala S, Mirani A, Gayowski T, Venkataramanan R "Pharmacokinetics of cefoperazone and sulbactam in liver transplant patients." J Clin Pharmacol 42 (2002):  644-50', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38243, 16001, 'Cefoperazone', 'Liver Diseases', 'Cefoperazone is primarily eliminated by hepatobiliary excretion.  In patients with impaired hepatic function and/or biliary obstruction, the half-life of cefoperazone is prolonged 2- to 4-fold but urinary excretion is increased.  At usual dosages, adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored if high dosages are used (i.e. > 4 g/day), and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, cefoperazone dosage should not exceed 1 to 2 grams per day without close monitoring of serum concentrations.', '2', 'Balant L, Dayer P, Rudhardt M, et al. "Cefoperazone: pharmacokinetics in humans with normal and impaired renal function and pharmacokinetics in rats." Clin Ther 3 (1980):  50-9|Neu HC "A review and summary of the pharmacokinetics of cefoperazone: a new, extended-spectrum B-lactam antibiotic." Ther Drug Monit 3 (1981):  121-8|Cochet B, Belaieff J, Allaz AF, et al. "Serum levels and urinary excretion of cefoperazone in patients with hepatic insufficiency." Infection 9 (1981):  s37-9|Bolton WK, Scheld WM, Spyker DA, Sande MA "Pharmacokinetics of cefoperazone in normal volunteers and subjects with renal insufficiency." Antimicrob Agents Chemother 19 (1981):  821-5|Boscia JA, Korzeniowski OM, Snepar R, et al. "Cefoperazone pharmacokinetics in normal subjects and patients with cirrhosis." Antimicrob Agents Chemother 23 (1983):  385-9|Greenfield RA, Gerber AU, Craig WA "Pharmacokinetics of cefoperazone in patients with normal and impaired hepataic and renal function." Rev Infect Dis 5 (1983):  s127-36|Saudek F, Moravek J, Modr Z "Cefoperazone pharmacokinetics in patients with liver cirrhosis: a predictive value of the ujoviridin test." Int J Clin Pharmacol Ther Toxicol 27 (1989):  82-7|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|Muder RR, Agarwala S, Mirani A, Gayowski T, Venkataramanan R "Pharmacokinetics of cefoperazone and sulbactam in liver transplant patients." J Clin Pharmacol 42 (2002):  644-50', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38244, 16002, 'Cefoperazone', 'Liver Diseases', 'Cefoperazone is primarily eliminated by hepatobiliary excretion.  In patients with impaired hepatic function and/or biliary obstruction, the half-life of cefoperazone is prolonged 2- to 4-fold but urinary excretion is increased.  At usual dosages, adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored if high dosages are used (i.e. > 4 g/day), and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, cefoperazone dosage should not exceed 1 to 2 grams per day without close monitoring of serum concentrations.', '2', 'Balant L, Dayer P, Rudhardt M, et al. "Cefoperazone: pharmacokinetics in humans with normal and impaired renal function and pharmacokinetics in rats." Clin Ther 3 (1980):  50-9|Neu HC "A review and summary of the pharmacokinetics of cefoperazone: a new, extended-spectrum B-lactam antibiotic." Ther Drug Monit 3 (1981):  121-8|Cochet B, Belaieff J, Allaz AF, et al. "Serum levels and urinary excretion of cefoperazone in patients with hepatic insufficiency." Infection 9 (1981):  s37-9|Bolton WK, Scheld WM, Spyker DA, Sande MA "Pharmacokinetics of cefoperazone in normal volunteers and subjects with renal insufficiency." Antimicrob Agents Chemother 19 (1981):  821-5|Boscia JA, Korzeniowski OM, Snepar R, et al. "Cefoperazone pharmacokinetics in normal subjects and patients with cirrhosis." Antimicrob Agents Chemother 23 (1983):  385-9|Greenfield RA, Gerber AU, Craig WA "Pharmacokinetics of cefoperazone in patients with normal and impaired hepataic and renal function." Rev Infect Dis 5 (1983):  s127-36|Saudek F, Moravek J, Modr Z "Cefoperazone pharmacokinetics in patients with liver cirrhosis: a predictive value of the ujoviridin test." Int J Clin Pharmacol Ther Toxicol 27 (1989):  82-7|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|Muder RR, Agarwala S, Mirani A, Gayowski T, Venkataramanan R "Pharmacokinetics of cefoperazone and sulbactam in liver transplant patients." J Clin Pharmacol 42 (2002):  644-50', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38245, 16022, 'Cefoperazone', 'Liver Diseases', 'Cefoperazone is primarily eliminated by hepatobiliary excretion.  In patients with impaired hepatic function and/or biliary obstruction, the half-life of cefoperazone is prolonged 2- to 4-fold but urinary excretion is increased.  At usual dosages, adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored if high dosages are used (i.e. > 4 g/day), and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, cefoperazone dosage should not exceed 1 to 2 grams per day without close monitoring of serum concentrations.', '2', 'Balant L, Dayer P, Rudhardt M, et al. "Cefoperazone: pharmacokinetics in humans with normal and impaired renal function and pharmacokinetics in rats." Clin Ther 3 (1980):  50-9|Neu HC "A review and summary of the pharmacokinetics of cefoperazone: a new, extended-spectrum B-lactam antibiotic." Ther Drug Monit 3 (1981):  121-8|Cochet B, Belaieff J, Allaz AF, et al. "Serum levels and urinary excretion of cefoperazone in patients with hepatic insufficiency." Infection 9 (1981):  s37-9|Bolton WK, Scheld WM, Spyker DA, Sande MA "Pharmacokinetics of cefoperazone in normal volunteers and subjects with renal insufficiency." Antimicrob Agents Chemother 19 (1981):  821-5|Boscia JA, Korzeniowski OM, Snepar R, et al. "Cefoperazone pharmacokinetics in normal subjects and patients with cirrhosis." Antimicrob Agents Chemother 23 (1983):  385-9|Greenfield RA, Gerber AU, Craig WA "Pharmacokinetics of cefoperazone in patients with normal and impaired hepataic and renal function." Rev Infect Dis 5 (1983):  s127-36|Saudek F, Moravek J, Modr Z "Cefoperazone pharmacokinetics in patients with liver cirrhosis: a predictive value of the ujoviridin test." Int J Clin Pharmacol Ther Toxicol 27 (1989):  82-7|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|Muder RR, Agarwala S, Mirani A, Gayowski T, Venkataramanan R "Pharmacokinetics of cefoperazone and sulbactam in liver transplant patients." J Clin Pharmacol 42 (2002):  644-50', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38246, 16023, 'Cefoperazone', 'Liver Diseases', 'Cefoperazone is primarily eliminated by hepatobiliary excretion.  In patients with impaired hepatic function and/or biliary obstruction, the half-life of cefoperazone is prolonged 2- to 4-fold but urinary excretion is increased.  At usual dosages, adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored if high dosages are used (i.e. > 4 g/day), and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, cefoperazone dosage should not exceed 1 to 2 grams per day without close monitoring of serum concentrations.', '2', 'Balant L, Dayer P, Rudhardt M, et al. "Cefoperazone: pharmacokinetics in humans with normal and impaired renal function and pharmacokinetics in rats." Clin Ther 3 (1980):  50-9|Neu HC "A review and summary of the pharmacokinetics of cefoperazone: a new, extended-spectrum B-lactam antibiotic." Ther Drug Monit 3 (1981):  121-8|Cochet B, Belaieff J, Allaz AF, et al. "Serum levels and urinary excretion of cefoperazone in patients with hepatic insufficiency." Infection 9 (1981):  s37-9|Bolton WK, Scheld WM, Spyker DA, Sande MA "Pharmacokinetics of cefoperazone in normal volunteers and subjects with renal insufficiency." Antimicrob Agents Chemother 19 (1981):  821-5|Boscia JA, Korzeniowski OM, Snepar R, et al. "Cefoperazone pharmacokinetics in normal subjects and patients with cirrhosis." Antimicrob Agents Chemother 23 (1983):  385-9|Greenfield RA, Gerber AU, Craig WA "Pharmacokinetics of cefoperazone in patients with normal and impaired hepataic and renal function." Rev Infect Dis 5 (1983):  s127-36|Saudek F, Moravek J, Modr Z "Cefoperazone pharmacokinetics in patients with liver cirrhosis: a predictive value of the ujoviridin test." Int J Clin Pharmacol Ther Toxicol 27 (1989):  82-7|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|Muder RR, Agarwala S, Mirani A, Gayowski T, Venkataramanan R "Pharmacokinetics of cefoperazone and sulbactam in liver transplant patients." J Clin Pharmacol 42 (2002):  644-50', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38247, 16024, 'Cefoperazone', 'Liver Diseases', 'Cefoperazone is primarily eliminated by hepatobiliary excretion.  In patients with impaired hepatic function and/or biliary obstruction, the half-life of cefoperazone is prolonged 2- to 4-fold but urinary excretion is increased.  At usual dosages, adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored if high dosages are used (i.e. > 4 g/day), and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, cefoperazone dosage should not exceed 1 to 2 grams per day without close monitoring of serum concentrations.', '2', 'Balant L, Dayer P, Rudhardt M, et al. "Cefoperazone: pharmacokinetics in humans with normal and impaired renal function and pharmacokinetics in rats." Clin Ther 3 (1980):  50-9|Neu HC "A review and summary of the pharmacokinetics of cefoperazone: a new, extended-spectrum B-lactam antibiotic." Ther Drug Monit 3 (1981):  121-8|Cochet B, Belaieff J, Allaz AF, et al. "Serum levels and urinary excretion of cefoperazone in patients with hepatic insufficiency." Infection 9 (1981):  s37-9|Bolton WK, Scheld WM, Spyker DA, Sande MA "Pharmacokinetics of cefoperazone in normal volunteers and subjects with renal insufficiency." Antimicrob Agents Chemother 19 (1981):  821-5|Boscia JA, Korzeniowski OM, Snepar R, et al. "Cefoperazone pharmacokinetics in normal subjects and patients with cirrhosis." Antimicrob Agents Chemother 23 (1983):  385-9|Greenfield RA, Gerber AU, Craig WA "Pharmacokinetics of cefoperazone in patients with normal and impaired hepataic and renal function." Rev Infect Dis 5 (1983):  s127-36|Saudek F, Moravek J, Modr Z "Cefoperazone pharmacokinetics in patients with liver cirrhosis: a predictive value of the ujoviridin test." Int J Clin Pharmacol Ther Toxicol 27 (1989):  82-7|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|Muder RR, Agarwala S, Mirani A, Gayowski T, Venkataramanan R "Pharmacokinetics of cefoperazone and sulbactam in liver transplant patients." J Clin Pharmacol 42 (2002):  644-50', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38248, 16028, 'Cefoperazone', 'Liver Diseases', 'Cefoperazone is primarily eliminated by hepatobiliary excretion.  In patients with impaired hepatic function and/or biliary obstruction, the half-life of cefoperazone is prolonged 2- to 4-fold but urinary excretion is increased.  At usual dosages, adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored if high dosages are used (i.e. > 4 g/day), and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, cefoperazone dosage should not exceed 1 to 2 grams per day without close monitoring of serum concentrations.', '2', 'Balant L, Dayer P, Rudhardt M, et al. "Cefoperazone: pharmacokinetics in humans with normal and impaired renal function and pharmacokinetics in rats." Clin Ther 3 (1980):  50-9|Neu HC "A review and summary of the pharmacokinetics of cefoperazone: a new, extended-spectrum B-lactam antibiotic." Ther Drug Monit 3 (1981):  121-8|Cochet B, Belaieff J, Allaz AF, et al. "Serum levels and urinary excretion of cefoperazone in patients with hepatic insufficiency." Infection 9 (1981):  s37-9|Bolton WK, Scheld WM, Spyker DA, Sande MA "Pharmacokinetics of cefoperazone in normal volunteers and subjects with renal insufficiency." Antimicrob Agents Chemother 19 (1981):  821-5|Boscia JA, Korzeniowski OM, Snepar R, et al. "Cefoperazone pharmacokinetics in normal subjects and patients with cirrhosis." Antimicrob Agents Chemother 23 (1983):  385-9|Greenfield RA, Gerber AU, Craig WA "Pharmacokinetics of cefoperazone in patients with normal and impaired hepataic and renal function." Rev Infect Dis 5 (1983):  s127-36|Saudek F, Moravek J, Modr Z "Cefoperazone pharmacokinetics in patients with liver cirrhosis: a predictive value of the ujoviridin test." Int J Clin Pharmacol Ther Toxicol 27 (1989):  82-7|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|Muder RR, Agarwala S, Mirani A, Gayowski T, Venkataramanan R "Pharmacokinetics of cefoperazone and sulbactam in liver transplant patients." J Clin Pharmacol 42 (2002):  644-50', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38249, 16051, 'Cefoperazone', 'Liver Diseases', 'Cefoperazone is primarily eliminated by hepatobiliary excretion.  In patients with impaired hepatic function and/or biliary obstruction, the half-life of cefoperazone is prolonged 2- to 4-fold but urinary excretion is increased.  At usual dosages, adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored if high dosages are used (i.e. > 4 g/day), and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, cefoperazone dosage should not exceed 1 to 2 grams per day without close monitoring of serum concentrations.', '2', 'Balant L, Dayer P, Rudhardt M, et al. "Cefoperazone: pharmacokinetics in humans with normal and impaired renal function and pharmacokinetics in rats." Clin Ther 3 (1980):  50-9|Neu HC "A review and summary of the pharmacokinetics of cefoperazone: a new, extended-spectrum B-lactam antibiotic." Ther Drug Monit 3 (1981):  121-8|Cochet B, Belaieff J, Allaz AF, et al. "Serum levels and urinary excretion of cefoperazone in patients with hepatic insufficiency." Infection 9 (1981):  s37-9|Bolton WK, Scheld WM, Spyker DA, Sande MA "Pharmacokinetics of cefoperazone in normal volunteers and subjects with renal insufficiency." Antimicrob Agents Chemother 19 (1981):  821-5|Boscia JA, Korzeniowski OM, Snepar R, et al. "Cefoperazone pharmacokinetics in normal subjects and patients with cirrhosis." Antimicrob Agents Chemother 23 (1983):  385-9|Greenfield RA, Gerber AU, Craig WA "Pharmacokinetics of cefoperazone in patients with normal and impaired hepataic and renal function." Rev Infect Dis 5 (1983):  s127-36|Saudek F, Moravek J, Modr Z "Cefoperazone pharmacokinetics in patients with liver cirrhosis: a predictive value of the ujoviridin test." Int J Clin Pharmacol Ther Toxicol 27 (1989):  82-7|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|Muder RR, Agarwala S, Mirani A, Gayowski T, Venkataramanan R "Pharmacokinetics of cefoperazone and sulbactam in liver transplant patients." J Clin Pharmacol 42 (2002):  644-50', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38250, 16052, 'Cefoperazone', 'Liver Diseases', 'Cefoperazone is primarily eliminated by hepatobiliary excretion.  In patients with impaired hepatic function and/or biliary obstruction, the half-life of cefoperazone is prolonged 2- to 4-fold but urinary excretion is increased.  At usual dosages, adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored if high dosages are used (i.e. > 4 g/day), and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, cefoperazone dosage should not exceed 1 to 2 grams per day without close monitoring of serum concentrations.', '2', 'Balant L, Dayer P, Rudhardt M, et al. "Cefoperazone: pharmacokinetics in humans with normal and impaired renal function and pharmacokinetics in rats." Clin Ther 3 (1980):  50-9|Neu HC "A review and summary of the pharmacokinetics of cefoperazone: a new, extended-spectrum B-lactam antibiotic." Ther Drug Monit 3 (1981):  121-8|Cochet B, Belaieff J, Allaz AF, et al. "Serum levels and urinary excretion of cefoperazone in patients with hepatic insufficiency." Infection 9 (1981):  s37-9|Bolton WK, Scheld WM, Spyker DA, Sande MA "Pharmacokinetics of cefoperazone in normal volunteers and subjects with renal insufficiency." Antimicrob Agents Chemother 19 (1981):  821-5|Boscia JA, Korzeniowski OM, Snepar R, et al. "Cefoperazone pharmacokinetics in normal subjects and patients with cirrhosis." Antimicrob Agents Chemother 23 (1983):  385-9|Greenfield RA, Gerber AU, Craig WA "Pharmacokinetics of cefoperazone in patients with normal and impaired hepataic and renal function." Rev Infect Dis 5 (1983):  s127-36|Saudek F, Moravek J, Modr Z "Cefoperazone pharmacokinetics in patients with liver cirrhosis: a predictive value of the ujoviridin test." Int J Clin Pharmacol Ther Toxicol 27 (1989):  82-7|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|Muder RR, Agarwala S, Mirani A, Gayowski T, Venkataramanan R "Pharmacokinetics of cefoperazone and sulbactam in liver transplant patients." J Clin Pharmacol 42 (2002):  644-50', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38251, 16057, 'Cefoperazone', 'Liver Diseases', 'Cefoperazone is primarily eliminated by hepatobiliary excretion.  In patients with impaired hepatic function and/or biliary obstruction, the half-life of cefoperazone is prolonged 2- to 4-fold but urinary excretion is increased.  At usual dosages, adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored if high dosages are used (i.e. > 4 g/day), and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, cefoperazone dosage should not exceed 1 to 2 grams per day without close monitoring of serum concentrations.', '2', 'Balant L, Dayer P, Rudhardt M, et al. "Cefoperazone: pharmacokinetics in humans with normal and impaired renal function and pharmacokinetics in rats." Clin Ther 3 (1980):  50-9|Neu HC "A review and summary of the pharmacokinetics of cefoperazone: a new, extended-spectrum B-lactam antibiotic." Ther Drug Monit 3 (1981):  121-8|Cochet B, Belaieff J, Allaz AF, et al. "Serum levels and urinary excretion of cefoperazone in patients with hepatic insufficiency." Infection 9 (1981):  s37-9|Bolton WK, Scheld WM, Spyker DA, Sande MA "Pharmacokinetics of cefoperazone in normal volunteers and subjects with renal insufficiency." Antimicrob Agents Chemother 19 (1981):  821-5|Boscia JA, Korzeniowski OM, Snepar R, et al. "Cefoperazone pharmacokinetics in normal subjects and patients with cirrhosis." Antimicrob Agents Chemother 23 (1983):  385-9|Greenfield RA, Gerber AU, Craig WA "Pharmacokinetics of cefoperazone in patients with normal and impaired hepataic and renal function." Rev Infect Dis 5 (1983):  s127-36|Saudek F, Moravek J, Modr Z "Cefoperazone pharmacokinetics in patients with liver cirrhosis: a predictive value of the ujoviridin test." Int J Clin Pharmacol Ther Toxicol 27 (1989):  82-7|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|Muder RR, Agarwala S, Mirani A, Gayowski T, Venkataramanan R "Pharmacokinetics of cefoperazone and sulbactam in liver transplant patients." J Clin Pharmacol 42 (2002):  644-50', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38252, 16060, 'Cefoperazone', 'Liver Diseases', 'Cefoperazone is primarily eliminated by hepatobiliary excretion.  In patients with impaired hepatic function and/or biliary obstruction, the half-life of cefoperazone is prolonged 2- to 4-fold but urinary excretion is increased.  At usual dosages, adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored if high dosages are used (i.e. > 4 g/day), and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, cefoperazone dosage should not exceed 1 to 2 grams per day without close monitoring of serum concentrations.', '2', 'Balant L, Dayer P, Rudhardt M, et al. "Cefoperazone: pharmacokinetics in humans with normal and impaired renal function and pharmacokinetics in rats." Clin Ther 3 (1980):  50-9|Neu HC "A review and summary of the pharmacokinetics of cefoperazone: a new, extended-spectrum B-lactam antibiotic." Ther Drug Monit 3 (1981):  121-8|Cochet B, Belaieff J, Allaz AF, et al. "Serum levels and urinary excretion of cefoperazone in patients with hepatic insufficiency." Infection 9 (1981):  s37-9|Bolton WK, Scheld WM, Spyker DA, Sande MA "Pharmacokinetics of cefoperazone in normal volunteers and subjects with renal insufficiency." Antimicrob Agents Chemother 19 (1981):  821-5|Boscia JA, Korzeniowski OM, Snepar R, et al. "Cefoperazone pharmacokinetics in normal subjects and patients with cirrhosis." Antimicrob Agents Chemother 23 (1983):  385-9|Greenfield RA, Gerber AU, Craig WA "Pharmacokinetics of cefoperazone in patients with normal and impaired hepataic and renal function." Rev Infect Dis 5 (1983):  s127-36|Saudek F, Moravek J, Modr Z "Cefoperazone pharmacokinetics in patients with liver cirrhosis: a predictive value of the ujoviridin test." Int J Clin Pharmacol Ther Toxicol 27 (1989):  82-7|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|Muder RR, Agarwala S, Mirani A, Gayowski T, Venkataramanan R "Pharmacokinetics of cefoperazone and sulbactam in liver transplant patients." J Clin Pharmacol 42 (2002):  644-50', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38253, 16296, 'Cefoperazone', 'Liver Diseases', 'Cefoperazone is primarily eliminated by hepatobiliary excretion.  In patients with impaired hepatic function and/or biliary obstruction, the half-life of cefoperazone is prolonged 2- to 4-fold but urinary excretion is increased.  At usual dosages, adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored if high dosages are used (i.e. > 4 g/day), and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, cefoperazone dosage should not exceed 1 to 2 grams per day without close monitoring of serum concentrations.', '2', 'Balant L, Dayer P, Rudhardt M, et al. "Cefoperazone: pharmacokinetics in humans with normal and impaired renal function and pharmacokinetics in rats." Clin Ther 3 (1980):  50-9|Neu HC "A review and summary of the pharmacokinetics of cefoperazone: a new, extended-spectrum B-lactam antibiotic." Ther Drug Monit 3 (1981):  121-8|Cochet B, Belaieff J, Allaz AF, et al. "Serum levels and urinary excretion of cefoperazone in patients with hepatic insufficiency." Infection 9 (1981):  s37-9|Bolton WK, Scheld WM, Spyker DA, Sande MA "Pharmacokinetics of cefoperazone in normal volunteers and subjects with renal insufficiency." Antimicrob Agents Chemother 19 (1981):  821-5|Boscia JA, Korzeniowski OM, Snepar R, et al. "Cefoperazone pharmacokinetics in normal subjects and patients with cirrhosis." Antimicrob Agents Chemother 23 (1983):  385-9|Greenfield RA, Gerber AU, Craig WA "Pharmacokinetics of cefoperazone in patients with normal and impaired hepataic and renal function." Rev Infect Dis 5 (1983):  s127-36|Saudek F, Moravek J, Modr Z "Cefoperazone pharmacokinetics in patients with liver cirrhosis: a predictive value of the ujoviridin test." Int J Clin Pharmacol Ther Toxicol 27 (1989):  82-7|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|Muder RR, Agarwala S, Mirani A, Gayowski T, Venkataramanan R "Pharmacokinetics of cefoperazone and sulbactam in liver transplant patients." J Clin Pharmacol 42 (2002):  644-50', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38254, 22387, 'Cefoperazone', 'Liver Diseases', 'Cefoperazone is primarily eliminated by hepatobiliary excretion.  In patients with impaired hepatic function and/or biliary obstruction, the half-life of cefoperazone is prolonged 2- to 4-fold but urinary excretion is increased.  At usual dosages, adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored if high dosages are used (i.e. > 4 g/day), and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, cefoperazone dosage should not exceed 1 to 2 grams per day without close monitoring of serum concentrations.', '2', 'Balant L, Dayer P, Rudhardt M, et al. "Cefoperazone: pharmacokinetics in humans with normal and impaired renal function and pharmacokinetics in rats." Clin Ther 3 (1980):  50-9|Neu HC "A review and summary of the pharmacokinetics of cefoperazone: a new, extended-spectrum B-lactam antibiotic." Ther Drug Monit 3 (1981):  121-8|Cochet B, Belaieff J, Allaz AF, et al. "Serum levels and urinary excretion of cefoperazone in patients with hepatic insufficiency." Infection 9 (1981):  s37-9|Bolton WK, Scheld WM, Spyker DA, Sande MA "Pharmacokinetics of cefoperazone in normal volunteers and subjects with renal insufficiency." Antimicrob Agents Chemother 19 (1981):  821-5|Boscia JA, Korzeniowski OM, Snepar R, et al. "Cefoperazone pharmacokinetics in normal subjects and patients with cirrhosis." Antimicrob Agents Chemother 23 (1983):  385-9|Greenfield RA, Gerber AU, Craig WA "Pharmacokinetics of cefoperazone in patients with normal and impaired hepataic and renal function." Rev Infect Dis 5 (1983):  s127-36|Saudek F, Moravek J, Modr Z "Cefoperazone pharmacokinetics in patients with liver cirrhosis: a predictive value of the ujoviridin test." Int J Clin Pharmacol Ther Toxicol 27 (1989):  82-7|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|Muder RR, Agarwala S, Mirani A, Gayowski T, Venkataramanan R "Pharmacokinetics of cefoperazone and sulbactam in liver transplant patients." J Clin Pharmacol 42 (2002):  644-50', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38255, 24726, 'Cefoperazone', 'Liver Diseases', 'Cefoperazone is primarily eliminated by hepatobiliary excretion.  In patients with impaired hepatic function and/or biliary obstruction, the half-life of cefoperazone is prolonged 2- to 4-fold but urinary excretion is increased.  At usual dosages, adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored if high dosages are used (i.e. > 4 g/day), and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, cefoperazone dosage should not exceed 1 to 2 grams per day without close monitoring of serum concentrations.', '2', 'Balant L, Dayer P, Rudhardt M, et al. "Cefoperazone: pharmacokinetics in humans with normal and impaired renal function and pharmacokinetics in rats." Clin Ther 3 (1980):  50-9|Neu HC "A review and summary of the pharmacokinetics of cefoperazone: a new, extended-spectrum B-lactam antibiotic." Ther Drug Monit 3 (1981):  121-8|Cochet B, Belaieff J, Allaz AF, et al. "Serum levels and urinary excretion of cefoperazone in patients with hepatic insufficiency." Infection 9 (1981):  s37-9|Bolton WK, Scheld WM, Spyker DA, Sande MA "Pharmacokinetics of cefoperazone in normal volunteers and subjects with renal insufficiency." Antimicrob Agents Chemother 19 (1981):  821-5|Boscia JA, Korzeniowski OM, Snepar R, et al. "Cefoperazone pharmacokinetics in normal subjects and patients with cirrhosis." Antimicrob Agents Chemother 23 (1983):  385-9|Greenfield RA, Gerber AU, Craig WA "Pharmacokinetics of cefoperazone in patients with normal and impaired hepataic and renal function." Rev Infect Dis 5 (1983):  s127-36|Saudek F, Moravek J, Modr Z "Cefoperazone pharmacokinetics in patients with liver cirrhosis: a predictive value of the ujoviridin test." Int J Clin Pharmacol Ther Toxicol 27 (1989):  82-7|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|Muder RR, Agarwala S, Mirani A, Gayowski T, Venkataramanan R "Pharmacokinetics of cefoperazone and sulbactam in liver transplant patients." J Clin Pharmacol 42 (2002):  644-50', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38256, 24727, 'Cefoperazone', 'Liver Diseases', 'Cefoperazone is primarily eliminated by hepatobiliary excretion.  In patients with impaired hepatic function and/or biliary obstruction, the half-life of cefoperazone is prolonged 2- to 4-fold but urinary excretion is increased.  At usual dosages, adjustments are generally not necessary in either renal or hepatobiliary impairment.  However, serum drug concentrations should be monitored if high dosages are used (i.e. > 4 g/day), and the dosage decreased accordingly if drug accumulation occurs.  In patients with both hepatic and severe renal impairment, cefoperazone dosage should not exceed 1 to 2 grams per day without close monitoring of serum concentrations.', '2', 'Balant L, Dayer P, Rudhardt M, et al. "Cefoperazone: pharmacokinetics in humans with normal and impaired renal function and pharmacokinetics in rats." Clin Ther 3 (1980):  50-9|Neu HC "A review and summary of the pharmacokinetics of cefoperazone: a new, extended-spectrum B-lactam antibiotic." Ther Drug Monit 3 (1981):  121-8|Cochet B, Belaieff J, Allaz AF, et al. "Serum levels and urinary excretion of cefoperazone in patients with hepatic insufficiency." Infection 9 (1981):  s37-9|Bolton WK, Scheld WM, Spyker DA, Sande MA "Pharmacokinetics of cefoperazone in normal volunteers and subjects with renal insufficiency." Antimicrob Agents Chemother 19 (1981):  821-5|Boscia JA, Korzeniowski OM, Snepar R, et al. "Cefoperazone pharmacokinetics in normal subjects and patients with cirrhosis." Antimicrob Agents Chemother 23 (1983):  385-9|Greenfield RA, Gerber AU, Craig WA "Pharmacokinetics of cefoperazone in patients with normal and impaired hepataic and renal function." Rev Infect Dis 5 (1983):  s127-36|Saudek F, Moravek J, Modr Z "Cefoperazone pharmacokinetics in patients with liver cirrhosis: a predictive value of the ujoviridin test." Int J Clin Pharmacol Ther Toxicol 27 (1989):  82-7|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|Muder RR, Agarwala S, Mirani A, Gayowski T, Venkataramanan R "Pharmacokinetics of cefoperazone and sulbactam in liver transplant patients." J Clin Pharmacol 42 (2002):  644-50', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38257, 2224, 'Cefoperazone', 'Heart Failure', 'Parenteral cefoperazone sodium contains approximately 34 mg (1.5 mEq) of sodium per each gram of cefoperazone activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38258, 2270, 'Cefoperazone', 'Heart Failure', 'Parenteral cefoperazone sodium contains approximately 34 mg (1.5 mEq) of sodium per each gram of cefoperazone activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38259, 2274, 'Cefoperazone', 'Heart Failure', 'Parenteral cefoperazone sodium contains approximately 34 mg (1.5 mEq) of sodium per each gram of cefoperazone activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38260, 2278, 'Cefoperazone', 'Heart Failure', 'Parenteral cefoperazone sodium contains approximately 34 mg (1.5 mEq) of sodium per each gram of cefoperazone activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38261, 2279, 'Cefoperazone', 'Heart Failure', 'Parenteral cefoperazone sodium contains approximately 34 mg (1.5 mEq) of sodium per each gram of cefoperazone activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38262, 6385, 'Cefoperazone', 'Heart Failure', 'Parenteral cefoperazone sodium contains approximately 34 mg (1.5 mEq) of sodium per each gram of cefoperazone activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38263, 16001, 'Cefoperazone', 'Heart Failure', 'Parenteral cefoperazone sodium contains approximately 34 mg (1.5 mEq) of sodium per each gram of cefoperazone activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38264, 16002, 'Cefoperazone', 'Heart Failure', 'Parenteral cefoperazone sodium contains approximately 34 mg (1.5 mEq) of sodium per each gram of cefoperazone activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38265, 16022, 'Cefoperazone', 'Heart Failure', 'Parenteral cefoperazone sodium contains approximately 34 mg (1.5 mEq) of sodium per each gram of cefoperazone activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38266, 16023, 'Cefoperazone', 'Heart Failure', 'Parenteral cefoperazone sodium contains approximately 34 mg (1.5 mEq) of sodium per each gram of cefoperazone activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38267, 16024, 'Cefoperazone', 'Heart Failure', 'Parenteral cefoperazone sodium contains approximately 34 mg (1.5 mEq) of sodium per each gram of cefoperazone activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38268, 16028, 'Cefoperazone', 'Heart Failure', 'Parenteral cefoperazone sodium contains approximately 34 mg (1.5 mEq) of sodium per each gram of cefoperazone activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38269, 16051, 'Cefoperazone', 'Heart Failure', 'Parenteral cefoperazone sodium contains approximately 34 mg (1.5 mEq) of sodium per each gram of cefoperazone activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38270, 16052, 'Cefoperazone', 'Heart Failure', 'Parenteral cefoperazone sodium contains approximately 34 mg (1.5 mEq) of sodium per each gram of cefoperazone activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38271, 16057, 'Cefoperazone', 'Heart Failure', 'Parenteral cefoperazone sodium contains approximately 34 mg (1.5 mEq) of sodium per each gram of cefoperazone activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38272, 16060, 'Cefoperazone', 'Heart Failure', 'Parenteral cefoperazone sodium contains approximately 34 mg (1.5 mEq) of sodium per each gram of cefoperazone activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38273, 16296, 'Cefoperazone', 'Heart Failure', 'Parenteral cefoperazone sodium contains approximately 34 mg (1.5 mEq) of sodium per each gram of cefoperazone activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38274, 22387, 'Cefoperazone', 'Heart Failure', 'Parenteral cefoperazone sodium contains approximately 34 mg (1.5 mEq) of sodium per each gram of cefoperazone activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38275, 24726, 'Cefoperazone', 'Heart Failure', 'Parenteral cefoperazone sodium contains approximately 34 mg (1.5 mEq) of sodium per each gram of cefoperazone activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38276, 24727, 'Cefoperazone', 'Heart Failure', 'Parenteral cefoperazone sodium contains approximately 34 mg (1.5 mEq) of sodium per each gram of cefoperazone activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38277, 2224, 'Cefoperazone', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38278, 2270, 'Cefoperazone', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38279, 2274, 'Cefoperazone', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38280, 2278, 'Cefoperazone', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38281, 2279, 'Cefoperazone', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38282, 6385, 'Cefoperazone', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38283, 16001, 'Cefoperazone', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38284, 16002, 'Cefoperazone', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38285, 16022, 'Cefoperazone', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38286, 16023, 'Cefoperazone', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38287, 16024, 'Cefoperazone', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38288, 16028, 'Cefoperazone', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38289, 16051, 'Cefoperazone', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38290, 16052, 'Cefoperazone', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38291, 16057, 'Cefoperazone', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38292, 16060, 'Cefoperazone', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38293, 16296, 'Cefoperazone', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38294, 22387, 'Cefoperazone', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38295, 24726, 'Cefoperazone', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38296, 24727, 'Cefoperazone', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38297, 2224, 'Cefoperazone', 'Alcoholic Intoxication', 'Disulfiram-like reactions may occur in patients who consume alcohol within 72 hours after administration of a cephalosporin antibiotic that contains an N-methylthiotetrazole (NMTT) side chain (cefamandole, cefmetazole, cefoperazone, cefotetan).  The reaction appears to result from accumulation of acetaldehyde due to inhibition of acetaldehyde dehydrogenase.  Therapy with cephalosporins containing the NMTT side chain should be administered cautiously in patients with a history of alcoholism.  Patients should be instructed to avoid alcohol-containing products during therapy and up to 72 hours after the last dose.', '2', 'Kline SS, Mauro VF, Forney RB Jr, et al. "Cefotetan-induced disulfiram-type reactions and hypoprothrombinemia." Antimicrob Agents Chemother 31 (1987):  1328-31|Freundt KJ, Kitson TM "Inactivation of aldehyde dehydrogenase by a putative metabolite of cefamandole." Infection 14 (1986):  44-7|Freundt KJ, Schreiner E, Christmann-Kleiss U "Cefamandole: a competitive inhibitor of aldehyde dehydrogenase." Infection 13 (1985):  91|McMahon FG "Disulfiram-like reaction to a cephalosporin." JAMA 243 (1980):  2397|Reeves DS, Davies AJ "Antabuse effect with cephalosporins." Lancet 2 (1980):  540|Brown KR, Guglielmo BJ, Pons VG, Jacobs RA "Theophylline elixir, moxalactam, and a disulfiram reaction." Ann Intern Med 97 (1982):  621-2|Umeda S, Arai T "Disulfiram-like reaction to moxalactam after celiac plexus alcohol block." Anesth Analg 64 (1985):  377|Foster TS, Raehl CL, Wilson HD "Disulfiram-like reaction associated with a parenteral cephalosporin." Am J Hosp Pharm 37 (1980):  858-9|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38298, 2270, 'Cefoperazone', 'Alcoholic Intoxication', 'Disulfiram-like reactions may occur in patients who consume alcohol within 72 hours after administration of a cephalosporin antibiotic that contains an N-methylthiotetrazole (NMTT) side chain (cefamandole, cefmetazole, cefoperazone, cefotetan).  The reaction appears to result from accumulation of acetaldehyde due to inhibition of acetaldehyde dehydrogenase.  Therapy with cephalosporins containing the NMTT side chain should be administered cautiously in patients with a history of alcoholism.  Patients should be instructed to avoid alcohol-containing products during therapy and up to 72 hours after the last dose.', '2', 'Kline SS, Mauro VF, Forney RB Jr, et al. "Cefotetan-induced disulfiram-type reactions and hypoprothrombinemia." Antimicrob Agents Chemother 31 (1987):  1328-31|Freundt KJ, Kitson TM "Inactivation of aldehyde dehydrogenase by a putative metabolite of cefamandole." Infection 14 (1986):  44-7|Freundt KJ, Schreiner E, Christmann-Kleiss U "Cefamandole: a competitive inhibitor of aldehyde dehydrogenase." Infection 13 (1985):  91|McMahon FG "Disulfiram-like reaction to a cephalosporin." JAMA 243 (1980):  2397|Reeves DS, Davies AJ "Antabuse effect with cephalosporins." Lancet 2 (1980):  540|Brown KR, Guglielmo BJ, Pons VG, Jacobs RA "Theophylline elixir, moxalactam, and a disulfiram reaction." Ann Intern Med 97 (1982):  621-2|Umeda S, Arai T "Disulfiram-like reaction to moxalactam after celiac plexus alcohol block." Anesth Analg 64 (1985):  377|Foster TS, Raehl CL, Wilson HD "Disulfiram-like reaction associated with a parenteral cephalosporin." Am J Hosp Pharm 37 (1980):  858-9|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38299, 2274, 'Cefoperazone', 'Alcoholic Intoxication', 'Disulfiram-like reactions may occur in patients who consume alcohol within 72 hours after administration of a cephalosporin antibiotic that contains an N-methylthiotetrazole (NMTT) side chain (cefamandole, cefmetazole, cefoperazone, cefotetan).  The reaction appears to result from accumulation of acetaldehyde due to inhibition of acetaldehyde dehydrogenase.  Therapy with cephalosporins containing the NMTT side chain should be administered cautiously in patients with a history of alcoholism.  Patients should be instructed to avoid alcohol-containing products during therapy and up to 72 hours after the last dose.', '2', 'Kline SS, Mauro VF, Forney RB Jr, et al. "Cefotetan-induced disulfiram-type reactions and hypoprothrombinemia." Antimicrob Agents Chemother 31 (1987):  1328-31|Freundt KJ, Kitson TM "Inactivation of aldehyde dehydrogenase by a putative metabolite of cefamandole." Infection 14 (1986):  44-7|Freundt KJ, Schreiner E, Christmann-Kleiss U "Cefamandole: a competitive inhibitor of aldehyde dehydrogenase." Infection 13 (1985):  91|McMahon FG "Disulfiram-like reaction to a cephalosporin." JAMA 243 (1980):  2397|Reeves DS, Davies AJ "Antabuse effect with cephalosporins." Lancet 2 (1980):  540|Brown KR, Guglielmo BJ, Pons VG, Jacobs RA "Theophylline elixir, moxalactam, and a disulfiram reaction." Ann Intern Med 97 (1982):  621-2|Umeda S, Arai T "Disulfiram-like reaction to moxalactam after celiac plexus alcohol block." Anesth Analg 64 (1985):  377|Foster TS, Raehl CL, Wilson HD "Disulfiram-like reaction associated with a parenteral cephalosporin." Am J Hosp Pharm 37 (1980):  858-9|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38300, 2278, 'Cefoperazone', 'Alcoholic Intoxication', 'Disulfiram-like reactions may occur in patients who consume alcohol within 72 hours after administration of a cephalosporin antibiotic that contains an N-methylthiotetrazole (NMTT) side chain (cefamandole, cefmetazole, cefoperazone, cefotetan).  The reaction appears to result from accumulation of acetaldehyde due to inhibition of acetaldehyde dehydrogenase.  Therapy with cephalosporins containing the NMTT side chain should be administered cautiously in patients with a history of alcoholism.  Patients should be instructed to avoid alcohol-containing products during therapy and up to 72 hours after the last dose.', '2', 'Kline SS, Mauro VF, Forney RB Jr, et al. "Cefotetan-induced disulfiram-type reactions and hypoprothrombinemia." Antimicrob Agents Chemother 31 (1987):  1328-31|Freundt KJ, Kitson TM "Inactivation of aldehyde dehydrogenase by a putative metabolite of cefamandole." Infection 14 (1986):  44-7|Freundt KJ, Schreiner E, Christmann-Kleiss U "Cefamandole: a competitive inhibitor of aldehyde dehydrogenase." Infection 13 (1985):  91|McMahon FG "Disulfiram-like reaction to a cephalosporin." JAMA 243 (1980):  2397|Reeves DS, Davies AJ "Antabuse effect with cephalosporins." Lancet 2 (1980):  540|Brown KR, Guglielmo BJ, Pons VG, Jacobs RA "Theophylline elixir, moxalactam, and a disulfiram reaction." Ann Intern Med 97 (1982):  621-2|Umeda S, Arai T "Disulfiram-like reaction to moxalactam after celiac plexus alcohol block." Anesth Analg 64 (1985):  377|Foster TS, Raehl CL, Wilson HD "Disulfiram-like reaction associated with a parenteral cephalosporin." Am J Hosp Pharm 37 (1980):  858-9|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38301, 2279, 'Cefoperazone', 'Alcoholic Intoxication', 'Disulfiram-like reactions may occur in patients who consume alcohol within 72 hours after administration of a cephalosporin antibiotic that contains an N-methylthiotetrazole (NMTT) side chain (cefamandole, cefmetazole, cefoperazone, cefotetan).  The reaction appears to result from accumulation of acetaldehyde due to inhibition of acetaldehyde dehydrogenase.  Therapy with cephalosporins containing the NMTT side chain should be administered cautiously in patients with a history of alcoholism.  Patients should be instructed to avoid alcohol-containing products during therapy and up to 72 hours after the last dose.', '2', 'Kline SS, Mauro VF, Forney RB Jr, et al. "Cefotetan-induced disulfiram-type reactions and hypoprothrombinemia." Antimicrob Agents Chemother 31 (1987):  1328-31|Freundt KJ, Kitson TM "Inactivation of aldehyde dehydrogenase by a putative metabolite of cefamandole." Infection 14 (1986):  44-7|Freundt KJ, Schreiner E, Christmann-Kleiss U "Cefamandole: a competitive inhibitor of aldehyde dehydrogenase." Infection 13 (1985):  91|McMahon FG "Disulfiram-like reaction to a cephalosporin." JAMA 243 (1980):  2397|Reeves DS, Davies AJ "Antabuse effect with cephalosporins." Lancet 2 (1980):  540|Brown KR, Guglielmo BJ, Pons VG, Jacobs RA "Theophylline elixir, moxalactam, and a disulfiram reaction." Ann Intern Med 97 (1982):  621-2|Umeda S, Arai T "Disulfiram-like reaction to moxalactam after celiac plexus alcohol block." Anesth Analg 64 (1985):  377|Foster TS, Raehl CL, Wilson HD "Disulfiram-like reaction associated with a parenteral cephalosporin." Am J Hosp Pharm 37 (1980):  858-9|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38302, 6385, 'Cefoperazone', 'Alcoholic Intoxication', 'Disulfiram-like reactions may occur in patients who consume alcohol within 72 hours after administration of a cephalosporin antibiotic that contains an N-methylthiotetrazole (NMTT) side chain (cefamandole, cefmetazole, cefoperazone, cefotetan).  The reaction appears to result from accumulation of acetaldehyde due to inhibition of acetaldehyde dehydrogenase.  Therapy with cephalosporins containing the NMTT side chain should be administered cautiously in patients with a history of alcoholism.  Patients should be instructed to avoid alcohol-containing products during therapy and up to 72 hours after the last dose.', '2', 'Kline SS, Mauro VF, Forney RB Jr, et al. "Cefotetan-induced disulfiram-type reactions and hypoprothrombinemia." Antimicrob Agents Chemother 31 (1987):  1328-31|Freundt KJ, Kitson TM "Inactivation of aldehyde dehydrogenase by a putative metabolite of cefamandole." Infection 14 (1986):  44-7|Freundt KJ, Schreiner E, Christmann-Kleiss U "Cefamandole: a competitive inhibitor of aldehyde dehydrogenase." Infection 13 (1985):  91|McMahon FG "Disulfiram-like reaction to a cephalosporin." JAMA 243 (1980):  2397|Reeves DS, Davies AJ "Antabuse effect with cephalosporins." Lancet 2 (1980):  540|Brown KR, Guglielmo BJ, Pons VG, Jacobs RA "Theophylline elixir, moxalactam, and a disulfiram reaction." Ann Intern Med 97 (1982):  621-2|Umeda S, Arai T "Disulfiram-like reaction to moxalactam after celiac plexus alcohol block." Anesth Analg 64 (1985):  377|Foster TS, Raehl CL, Wilson HD "Disulfiram-like reaction associated with a parenteral cephalosporin." Am J Hosp Pharm 37 (1980):  858-9|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38303, 16001, 'Cefoperazone', 'Alcoholic Intoxication', 'Disulfiram-like reactions may occur in patients who consume alcohol within 72 hours after administration of a cephalosporin antibiotic that contains an N-methylthiotetrazole (NMTT) side chain (cefamandole, cefmetazole, cefoperazone, cefotetan).  The reaction appears to result from accumulation of acetaldehyde due to inhibition of acetaldehyde dehydrogenase.  Therapy with cephalosporins containing the NMTT side chain should be administered cautiously in patients with a history of alcoholism.  Patients should be instructed to avoid alcohol-containing products during therapy and up to 72 hours after the last dose.', '2', 'Kline SS, Mauro VF, Forney RB Jr, et al. "Cefotetan-induced disulfiram-type reactions and hypoprothrombinemia." Antimicrob Agents Chemother 31 (1987):  1328-31|Freundt KJ, Kitson TM "Inactivation of aldehyde dehydrogenase by a putative metabolite of cefamandole." Infection 14 (1986):  44-7|Freundt KJ, Schreiner E, Christmann-Kleiss U "Cefamandole: a competitive inhibitor of aldehyde dehydrogenase." Infection 13 (1985):  91|McMahon FG "Disulfiram-like reaction to a cephalosporin." JAMA 243 (1980):  2397|Reeves DS, Davies AJ "Antabuse effect with cephalosporins." Lancet 2 (1980):  540|Brown KR, Guglielmo BJ, Pons VG, Jacobs RA "Theophylline elixir, moxalactam, and a disulfiram reaction." Ann Intern Med 97 (1982):  621-2|Umeda S, Arai T "Disulfiram-like reaction to moxalactam after celiac plexus alcohol block." Anesth Analg 64 (1985):  377|Foster TS, Raehl CL, Wilson HD "Disulfiram-like reaction associated with a parenteral cephalosporin." Am J Hosp Pharm 37 (1980):  858-9|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38304, 16002, 'Cefoperazone', 'Alcoholic Intoxication', 'Disulfiram-like reactions may occur in patients who consume alcohol within 72 hours after administration of a cephalosporin antibiotic that contains an N-methylthiotetrazole (NMTT) side chain (cefamandole, cefmetazole, cefoperazone, cefotetan).  The reaction appears to result from accumulation of acetaldehyde due to inhibition of acetaldehyde dehydrogenase.  Therapy with cephalosporins containing the NMTT side chain should be administered cautiously in patients with a history of alcoholism.  Patients should be instructed to avoid alcohol-containing products during therapy and up to 72 hours after the last dose.', '2', 'Kline SS, Mauro VF, Forney RB Jr, et al. "Cefotetan-induced disulfiram-type reactions and hypoprothrombinemia." Antimicrob Agents Chemother 31 (1987):  1328-31|Freundt KJ, Kitson TM "Inactivation of aldehyde dehydrogenase by a putative metabolite of cefamandole." Infection 14 (1986):  44-7|Freundt KJ, Schreiner E, Christmann-Kleiss U "Cefamandole: a competitive inhibitor of aldehyde dehydrogenase." Infection 13 (1985):  91|McMahon FG "Disulfiram-like reaction to a cephalosporin." JAMA 243 (1980):  2397|Reeves DS, Davies AJ "Antabuse effect with cephalosporins." Lancet 2 (1980):  540|Brown KR, Guglielmo BJ, Pons VG, Jacobs RA "Theophylline elixir, moxalactam, and a disulfiram reaction." Ann Intern Med 97 (1982):  621-2|Umeda S, Arai T "Disulfiram-like reaction to moxalactam after celiac plexus alcohol block." Anesth Analg 64 (1985):  377|Foster TS, Raehl CL, Wilson HD "Disulfiram-like reaction associated with a parenteral cephalosporin." Am J Hosp Pharm 37 (1980):  858-9|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38305, 16022, 'Cefoperazone', 'Alcoholic Intoxication', 'Disulfiram-like reactions may occur in patients who consume alcohol within 72 hours after administration of a cephalosporin antibiotic that contains an N-methylthiotetrazole (NMTT) side chain (cefamandole, cefmetazole, cefoperazone, cefotetan).  The reaction appears to result from accumulation of acetaldehyde due to inhibition of acetaldehyde dehydrogenase.  Therapy with cephalosporins containing the NMTT side chain should be administered cautiously in patients with a history of alcoholism.  Patients should be instructed to avoid alcohol-containing products during therapy and up to 72 hours after the last dose.', '2', 'Kline SS, Mauro VF, Forney RB Jr, et al. "Cefotetan-induced disulfiram-type reactions and hypoprothrombinemia." Antimicrob Agents Chemother 31 (1987):  1328-31|Freundt KJ, Kitson TM "Inactivation of aldehyde dehydrogenase by a putative metabolite of cefamandole." Infection 14 (1986):  44-7|Freundt KJ, Schreiner E, Christmann-Kleiss U "Cefamandole: a competitive inhibitor of aldehyde dehydrogenase." Infection 13 (1985):  91|McMahon FG "Disulfiram-like reaction to a cephalosporin." JAMA 243 (1980):  2397|Reeves DS, Davies AJ "Antabuse effect with cephalosporins." Lancet 2 (1980):  540|Brown KR, Guglielmo BJ, Pons VG, Jacobs RA "Theophylline elixir, moxalactam, and a disulfiram reaction." Ann Intern Med 97 (1982):  621-2|Umeda S, Arai T "Disulfiram-like reaction to moxalactam after celiac plexus alcohol block." Anesth Analg 64 (1985):  377|Foster TS, Raehl CL, Wilson HD "Disulfiram-like reaction associated with a parenteral cephalosporin." Am J Hosp Pharm 37 (1980):  858-9|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38306, 16023, 'Cefoperazone', 'Alcoholic Intoxication', 'Disulfiram-like reactions may occur in patients who consume alcohol within 72 hours after administration of a cephalosporin antibiotic that contains an N-methylthiotetrazole (NMTT) side chain (cefamandole, cefmetazole, cefoperazone, cefotetan).  The reaction appears to result from accumulation of acetaldehyde due to inhibition of acetaldehyde dehydrogenase.  Therapy with cephalosporins containing the NMTT side chain should be administered cautiously in patients with a history of alcoholism.  Patients should be instructed to avoid alcohol-containing products during therapy and up to 72 hours after the last dose.', '2', 'Kline SS, Mauro VF, Forney RB Jr, et al. "Cefotetan-induced disulfiram-type reactions and hypoprothrombinemia." Antimicrob Agents Chemother 31 (1987):  1328-31|Freundt KJ, Kitson TM "Inactivation of aldehyde dehydrogenase by a putative metabolite of cefamandole." Infection 14 (1986):  44-7|Freundt KJ, Schreiner E, Christmann-Kleiss U "Cefamandole: a competitive inhibitor of aldehyde dehydrogenase." Infection 13 (1985):  91|McMahon FG "Disulfiram-like reaction to a cephalosporin." JAMA 243 (1980):  2397|Reeves DS, Davies AJ "Antabuse effect with cephalosporins." Lancet 2 (1980):  540|Brown KR, Guglielmo BJ, Pons VG, Jacobs RA "Theophylline elixir, moxalactam, and a disulfiram reaction." Ann Intern Med 97 (1982):  621-2|Umeda S, Arai T "Disulfiram-like reaction to moxalactam after celiac plexus alcohol block." Anesth Analg 64 (1985):  377|Foster TS, Raehl CL, Wilson HD "Disulfiram-like reaction associated with a parenteral cephalosporin." Am J Hosp Pharm 37 (1980):  858-9|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38307, 16024, 'Cefoperazone', 'Alcoholic Intoxication', 'Disulfiram-like reactions may occur in patients who consume alcohol within 72 hours after administration of a cephalosporin antibiotic that contains an N-methylthiotetrazole (NMTT) side chain (cefamandole, cefmetazole, cefoperazone, cefotetan).  The reaction appears to result from accumulation of acetaldehyde due to inhibition of acetaldehyde dehydrogenase.  Therapy with cephalosporins containing the NMTT side chain should be administered cautiously in patients with a history of alcoholism.  Patients should be instructed to avoid alcohol-containing products during therapy and up to 72 hours after the last dose.', '2', 'Kline SS, Mauro VF, Forney RB Jr, et al. "Cefotetan-induced disulfiram-type reactions and hypoprothrombinemia." Antimicrob Agents Chemother 31 (1987):  1328-31|Freundt KJ, Kitson TM "Inactivation of aldehyde dehydrogenase by a putative metabolite of cefamandole." Infection 14 (1986):  44-7|Freundt KJ, Schreiner E, Christmann-Kleiss U "Cefamandole: a competitive inhibitor of aldehyde dehydrogenase." Infection 13 (1985):  91|McMahon FG "Disulfiram-like reaction to a cephalosporin." JAMA 243 (1980):  2397|Reeves DS, Davies AJ "Antabuse effect with cephalosporins." Lancet 2 (1980):  540|Brown KR, Guglielmo BJ, Pons VG, Jacobs RA "Theophylline elixir, moxalactam, and a disulfiram reaction." Ann Intern Med 97 (1982):  621-2|Umeda S, Arai T "Disulfiram-like reaction to moxalactam after celiac plexus alcohol block." Anesth Analg 64 (1985):  377|Foster TS, Raehl CL, Wilson HD "Disulfiram-like reaction associated with a parenteral cephalosporin." Am J Hosp Pharm 37 (1980):  858-9|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38308, 16028, 'Cefoperazone', 'Alcoholic Intoxication', 'Disulfiram-like reactions may occur in patients who consume alcohol within 72 hours after administration of a cephalosporin antibiotic that contains an N-methylthiotetrazole (NMTT) side chain (cefamandole, cefmetazole, cefoperazone, cefotetan).  The reaction appears to result from accumulation of acetaldehyde due to inhibition of acetaldehyde dehydrogenase.  Therapy with cephalosporins containing the NMTT side chain should be administered cautiously in patients with a history of alcoholism.  Patients should be instructed to avoid alcohol-containing products during therapy and up to 72 hours after the last dose.', '2', 'Kline SS, Mauro VF, Forney RB Jr, et al. "Cefotetan-induced disulfiram-type reactions and hypoprothrombinemia." Antimicrob Agents Chemother 31 (1987):  1328-31|Freundt KJ, Kitson TM "Inactivation of aldehyde dehydrogenase by a putative metabolite of cefamandole." Infection 14 (1986):  44-7|Freundt KJ, Schreiner E, Christmann-Kleiss U "Cefamandole: a competitive inhibitor of aldehyde dehydrogenase." Infection 13 (1985):  91|McMahon FG "Disulfiram-like reaction to a cephalosporin." JAMA 243 (1980):  2397|Reeves DS, Davies AJ "Antabuse effect with cephalosporins." Lancet 2 (1980):  540|Brown KR, Guglielmo BJ, Pons VG, Jacobs RA "Theophylline elixir, moxalactam, and a disulfiram reaction." Ann Intern Med 97 (1982):  621-2|Umeda S, Arai T "Disulfiram-like reaction to moxalactam after celiac plexus alcohol block." Anesth Analg 64 (1985):  377|Foster TS, Raehl CL, Wilson HD "Disulfiram-like reaction associated with a parenteral cephalosporin." Am J Hosp Pharm 37 (1980):  858-9|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38309, 16051, 'Cefoperazone', 'Alcoholic Intoxication', 'Disulfiram-like reactions may occur in patients who consume alcohol within 72 hours after administration of a cephalosporin antibiotic that contains an N-methylthiotetrazole (NMTT) side chain (cefamandole, cefmetazole, cefoperazone, cefotetan).  The reaction appears to result from accumulation of acetaldehyde due to inhibition of acetaldehyde dehydrogenase.  Therapy with cephalosporins containing the NMTT side chain should be administered cautiously in patients with a history of alcoholism.  Patients should be instructed to avoid alcohol-containing products during therapy and up to 72 hours after the last dose.', '2', 'Kline SS, Mauro VF, Forney RB Jr, et al. "Cefotetan-induced disulfiram-type reactions and hypoprothrombinemia." Antimicrob Agents Chemother 31 (1987):  1328-31|Freundt KJ, Kitson TM "Inactivation of aldehyde dehydrogenase by a putative metabolite of cefamandole." Infection 14 (1986):  44-7|Freundt KJ, Schreiner E, Christmann-Kleiss U "Cefamandole: a competitive inhibitor of aldehyde dehydrogenase." Infection 13 (1985):  91|McMahon FG "Disulfiram-like reaction to a cephalosporin." JAMA 243 (1980):  2397|Reeves DS, Davies AJ "Antabuse effect with cephalosporins." Lancet 2 (1980):  540|Brown KR, Guglielmo BJ, Pons VG, Jacobs RA "Theophylline elixir, moxalactam, and a disulfiram reaction." Ann Intern Med 97 (1982):  621-2|Umeda S, Arai T "Disulfiram-like reaction to moxalactam after celiac plexus alcohol block." Anesth Analg 64 (1985):  377|Foster TS, Raehl CL, Wilson HD "Disulfiram-like reaction associated with a parenteral cephalosporin." Am J Hosp Pharm 37 (1980):  858-9|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38310, 16052, 'Cefoperazone', 'Alcoholic Intoxication', 'Disulfiram-like reactions may occur in patients who consume alcohol within 72 hours after administration of a cephalosporin antibiotic that contains an N-methylthiotetrazole (NMTT) side chain (cefamandole, cefmetazole, cefoperazone, cefotetan).  The reaction appears to result from accumulation of acetaldehyde due to inhibition of acetaldehyde dehydrogenase.  Therapy with cephalosporins containing the NMTT side chain should be administered cautiously in patients with a history of alcoholism.  Patients should be instructed to avoid alcohol-containing products during therapy and up to 72 hours after the last dose.', '2', 'Kline SS, Mauro VF, Forney RB Jr, et al. "Cefotetan-induced disulfiram-type reactions and hypoprothrombinemia." Antimicrob Agents Chemother 31 (1987):  1328-31|Freundt KJ, Kitson TM "Inactivation of aldehyde dehydrogenase by a putative metabolite of cefamandole." Infection 14 (1986):  44-7|Freundt KJ, Schreiner E, Christmann-Kleiss U "Cefamandole: a competitive inhibitor of aldehyde dehydrogenase." Infection 13 (1985):  91|McMahon FG "Disulfiram-like reaction to a cephalosporin." JAMA 243 (1980):  2397|Reeves DS, Davies AJ "Antabuse effect with cephalosporins." Lancet 2 (1980):  540|Brown KR, Guglielmo BJ, Pons VG, Jacobs RA "Theophylline elixir, moxalactam, and a disulfiram reaction." Ann Intern Med 97 (1982):  621-2|Umeda S, Arai T "Disulfiram-like reaction to moxalactam after celiac plexus alcohol block." Anesth Analg 64 (1985):  377|Foster TS, Raehl CL, Wilson HD "Disulfiram-like reaction associated with a parenteral cephalosporin." Am J Hosp Pharm 37 (1980):  858-9|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38311, 16057, 'Cefoperazone', 'Alcoholic Intoxication', 'Disulfiram-like reactions may occur in patients who consume alcohol within 72 hours after administration of a cephalosporin antibiotic that contains an N-methylthiotetrazole (NMTT) side chain (cefamandole, cefmetazole, cefoperazone, cefotetan).  The reaction appears to result from accumulation of acetaldehyde due to inhibition of acetaldehyde dehydrogenase.  Therapy with cephalosporins containing the NMTT side chain should be administered cautiously in patients with a history of alcoholism.  Patients should be instructed to avoid alcohol-containing products during therapy and up to 72 hours after the last dose.', '2', 'Kline SS, Mauro VF, Forney RB Jr, et al. "Cefotetan-induced disulfiram-type reactions and hypoprothrombinemia." Antimicrob Agents Chemother 31 (1987):  1328-31|Freundt KJ, Kitson TM "Inactivation of aldehyde dehydrogenase by a putative metabolite of cefamandole." Infection 14 (1986):  44-7|Freundt KJ, Schreiner E, Christmann-Kleiss U "Cefamandole: a competitive inhibitor of aldehyde dehydrogenase." Infection 13 (1985):  91|McMahon FG "Disulfiram-like reaction to a cephalosporin." JAMA 243 (1980):  2397|Reeves DS, Davies AJ "Antabuse effect with cephalosporins." Lancet 2 (1980):  540|Brown KR, Guglielmo BJ, Pons VG, Jacobs RA "Theophylline elixir, moxalactam, and a disulfiram reaction." Ann Intern Med 97 (1982):  621-2|Umeda S, Arai T "Disulfiram-like reaction to moxalactam after celiac plexus alcohol block." Anesth Analg 64 (1985):  377|Foster TS, Raehl CL, Wilson HD "Disulfiram-like reaction associated with a parenteral cephalosporin." Am J Hosp Pharm 37 (1980):  858-9|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38312, 16060, 'Cefoperazone', 'Alcoholic Intoxication', 'Disulfiram-like reactions may occur in patients who consume alcohol within 72 hours after administration of a cephalosporin antibiotic that contains an N-methylthiotetrazole (NMTT) side chain (cefamandole, cefmetazole, cefoperazone, cefotetan).  The reaction appears to result from accumulation of acetaldehyde due to inhibition of acetaldehyde dehydrogenase.  Therapy with cephalosporins containing the NMTT side chain should be administered cautiously in patients with a history of alcoholism.  Patients should be instructed to avoid alcohol-containing products during therapy and up to 72 hours after the last dose.', '2', 'Kline SS, Mauro VF, Forney RB Jr, et al. "Cefotetan-induced disulfiram-type reactions and hypoprothrombinemia." Antimicrob Agents Chemother 31 (1987):  1328-31|Freundt KJ, Kitson TM "Inactivation of aldehyde dehydrogenase by a putative metabolite of cefamandole." Infection 14 (1986):  44-7|Freundt KJ, Schreiner E, Christmann-Kleiss U "Cefamandole: a competitive inhibitor of aldehyde dehydrogenase." Infection 13 (1985):  91|McMahon FG "Disulfiram-like reaction to a cephalosporin." JAMA 243 (1980):  2397|Reeves DS, Davies AJ "Antabuse effect with cephalosporins." Lancet 2 (1980):  540|Brown KR, Guglielmo BJ, Pons VG, Jacobs RA "Theophylline elixir, moxalactam, and a disulfiram reaction." Ann Intern Med 97 (1982):  621-2|Umeda S, Arai T "Disulfiram-like reaction to moxalactam after celiac plexus alcohol block." Anesth Analg 64 (1985):  377|Foster TS, Raehl CL, Wilson HD "Disulfiram-like reaction associated with a parenteral cephalosporin." Am J Hosp Pharm 37 (1980):  858-9|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38313, 16296, 'Cefoperazone', 'Alcoholic Intoxication', 'Disulfiram-like reactions may occur in patients who consume alcohol within 72 hours after administration of a cephalosporin antibiotic that contains an N-methylthiotetrazole (NMTT) side chain (cefamandole, cefmetazole, cefoperazone, cefotetan).  The reaction appears to result from accumulation of acetaldehyde due to inhibition of acetaldehyde dehydrogenase.  Therapy with cephalosporins containing the NMTT side chain should be administered cautiously in patients with a history of alcoholism.  Patients should be instructed to avoid alcohol-containing products during therapy and up to 72 hours after the last dose.', '2', 'Kline SS, Mauro VF, Forney RB Jr, et al. "Cefotetan-induced disulfiram-type reactions and hypoprothrombinemia." Antimicrob Agents Chemother 31 (1987):  1328-31|Freundt KJ, Kitson TM "Inactivation of aldehyde dehydrogenase by a putative metabolite of cefamandole." Infection 14 (1986):  44-7|Freundt KJ, Schreiner E, Christmann-Kleiss U "Cefamandole: a competitive inhibitor of aldehyde dehydrogenase." Infection 13 (1985):  91|McMahon FG "Disulfiram-like reaction to a cephalosporin." JAMA 243 (1980):  2397|Reeves DS, Davies AJ "Antabuse effect with cephalosporins." Lancet 2 (1980):  540|Brown KR, Guglielmo BJ, Pons VG, Jacobs RA "Theophylline elixir, moxalactam, and a disulfiram reaction." Ann Intern Med 97 (1982):  621-2|Umeda S, Arai T "Disulfiram-like reaction to moxalactam after celiac plexus alcohol block." Anesth Analg 64 (1985):  377|Foster TS, Raehl CL, Wilson HD "Disulfiram-like reaction associated with a parenteral cephalosporin." Am J Hosp Pharm 37 (1980):  858-9|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38314, 22387, 'Cefoperazone', 'Alcoholic Intoxication', 'Disulfiram-like reactions may occur in patients who consume alcohol within 72 hours after administration of a cephalosporin antibiotic that contains an N-methylthiotetrazole (NMTT) side chain (cefamandole, cefmetazole, cefoperazone, cefotetan).  The reaction appears to result from accumulation of acetaldehyde due to inhibition of acetaldehyde dehydrogenase.  Therapy with cephalosporins containing the NMTT side chain should be administered cautiously in patients with a history of alcoholism.  Patients should be instructed to avoid alcohol-containing products during therapy and up to 72 hours after the last dose.', '2', 'Kline SS, Mauro VF, Forney RB Jr, et al. "Cefotetan-induced disulfiram-type reactions and hypoprothrombinemia." Antimicrob Agents Chemother 31 (1987):  1328-31|Freundt KJ, Kitson TM "Inactivation of aldehyde dehydrogenase by a putative metabolite of cefamandole." Infection 14 (1986):  44-7|Freundt KJ, Schreiner E, Christmann-Kleiss U "Cefamandole: a competitive inhibitor of aldehyde dehydrogenase." Infection 13 (1985):  91|McMahon FG "Disulfiram-like reaction to a cephalosporin." JAMA 243 (1980):  2397|Reeves DS, Davies AJ "Antabuse effect with cephalosporins." Lancet 2 (1980):  540|Brown KR, Guglielmo BJ, Pons VG, Jacobs RA "Theophylline elixir, moxalactam, and a disulfiram reaction." Ann Intern Med 97 (1982):  621-2|Umeda S, Arai T "Disulfiram-like reaction to moxalactam after celiac plexus alcohol block." Anesth Analg 64 (1985):  377|Foster TS, Raehl CL, Wilson HD "Disulfiram-like reaction associated with a parenteral cephalosporin." Am J Hosp Pharm 37 (1980):  858-9|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38315, 24726, 'Cefoperazone', 'Alcoholic Intoxication', 'Disulfiram-like reactions may occur in patients who consume alcohol within 72 hours after administration of a cephalosporin antibiotic that contains an N-methylthiotetrazole (NMTT) side chain (cefamandole, cefmetazole, cefoperazone, cefotetan).  The reaction appears to result from accumulation of acetaldehyde due to inhibition of acetaldehyde dehydrogenase.  Therapy with cephalosporins containing the NMTT side chain should be administered cautiously in patients with a history of alcoholism.  Patients should be instructed to avoid alcohol-containing products during therapy and up to 72 hours after the last dose.', '2', 'Kline SS, Mauro VF, Forney RB Jr, et al. "Cefotetan-induced disulfiram-type reactions and hypoprothrombinemia." Antimicrob Agents Chemother 31 (1987):  1328-31|Freundt KJ, Kitson TM "Inactivation of aldehyde dehydrogenase by a putative metabolite of cefamandole." Infection 14 (1986):  44-7|Freundt KJ, Schreiner E, Christmann-Kleiss U "Cefamandole: a competitive inhibitor of aldehyde dehydrogenase." Infection 13 (1985):  91|McMahon FG "Disulfiram-like reaction to a cephalosporin." JAMA 243 (1980):  2397|Reeves DS, Davies AJ "Antabuse effect with cephalosporins." Lancet 2 (1980):  540|Brown KR, Guglielmo BJ, Pons VG, Jacobs RA "Theophylline elixir, moxalactam, and a disulfiram reaction." Ann Intern Med 97 (1982):  621-2|Umeda S, Arai T "Disulfiram-like reaction to moxalactam after celiac plexus alcohol block." Anesth Analg 64 (1985):  377|Foster TS, Raehl CL, Wilson HD "Disulfiram-like reaction associated with a parenteral cephalosporin." Am J Hosp Pharm 37 (1980):  858-9|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38316, 24727, 'Cefoperazone', 'Alcoholic Intoxication', 'Disulfiram-like reactions may occur in patients who consume alcohol within 72 hours after administration of a cephalosporin antibiotic that contains an N-methylthiotetrazole (NMTT) side chain (cefamandole, cefmetazole, cefoperazone, cefotetan).  The reaction appears to result from accumulation of acetaldehyde due to inhibition of acetaldehyde dehydrogenase.  Therapy with cephalosporins containing the NMTT side chain should be administered cautiously in patients with a history of alcoholism.  Patients should be instructed to avoid alcohol-containing products during therapy and up to 72 hours after the last dose.', '2', 'Kline SS, Mauro VF, Forney RB Jr, et al. "Cefotetan-induced disulfiram-type reactions and hypoprothrombinemia." Antimicrob Agents Chemother 31 (1987):  1328-31|Freundt KJ, Kitson TM "Inactivation of aldehyde dehydrogenase by a putative metabolite of cefamandole." Infection 14 (1986):  44-7|Freundt KJ, Schreiner E, Christmann-Kleiss U "Cefamandole: a competitive inhibitor of aldehyde dehydrogenase." Infection 13 (1985):  91|McMahon FG "Disulfiram-like reaction to a cephalosporin." JAMA 243 (1980):  2397|Reeves DS, Davies AJ "Antabuse effect with cephalosporins." Lancet 2 (1980):  540|Brown KR, Guglielmo BJ, Pons VG, Jacobs RA "Theophylline elixir, moxalactam, and a disulfiram reaction." Ann Intern Med 97 (1982):  621-2|Umeda S, Arai T "Disulfiram-like reaction to moxalactam after celiac plexus alcohol block." Anesth Analg 64 (1985):  377|Foster TS, Raehl CL, Wilson HD "Disulfiram-like reaction associated with a parenteral cephalosporin." Am J Hosp Pharm 37 (1980):  858-9|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38317, 0, 'Cefotetan', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38318, 0, 'Cefotetan', 'Hypoprothrombinemias', 'Hypoprothrombinemia, with or without bleeding, has been reported rarely with various cephalosporins, particularly those containing an N-methylthiotetrazole (NMTT) side chain (cefamandole, cefmetazole, cefoperazone, cefotetan).  The sulfhydryl group of this side chain is suspected of interfering with the hepatic synthesis of prothrombin.  Risk factors include advanced age, debility, vitamin K deficiency, malnutrition, malabsorption, and severe renal or hepatobiliary impairment.  Therapy with cephalosporins containing the NMTT side chain should be administered cautiously in patients with any of these risk factors and/or significant active bleeding or a hemorrhagic diathesis.  Prophylactic administration of vitamin K may be indicated in some patients, especially when intestinal sterilization and surgical procedures are performed.', '3', 'Lerner PI, Lubin A "Coagulopathy with cefazolin in uremia." N Engl J Med 290 (1974):  1324|Fujita Y, Inoue S, Yorifuji R, et al. "Effects of cefotaxime on blood coagulation in patients with renal insufficiency." Drugs 35 (1988):  196-8|Kline SS, Mauro VF, Forney RB Jr, et al. "Cefotetan-induced disulfiram-type reactions and hypoprothrombinemia." Antimicrob Agents Chemother 31 (1987):  1328-31|Holt J "Hypoprothrombinemia and bleeding diathesis associated with cefotetan therapy in surgical patients." Arch Surg 123 (1988):  523|Conjura A, Bell W, Lipsky JJ "Cefotetan and hypoprothrombinemia." Ann Intern Med 108 (1988):  643|Kaiser CW, McAuliffe JD, Barth RJ, Lynch JA "Hypoprothrombinemia and hemorrhage in a surgical patient treated with cefotetan." Arch Surg 126 (1991):  524-5|Wurtz RM, Sande MA "Cefotetan and coagulopathy." J Infect Dis 160 (1989):  555-6|Shimada K, Matsuda T, Inamatsu T, Urayama K "Bleeding secondary to vitamin K deficiency in patients receiving parenteral cephem antibiotics." J Antimicrob Chemother 14 (1984):  325-30|Fass RJ, Copelan EA, Brandt JT, Moeschberger ML, Ashton JJ "Platelet-mediated bleeding caused by broad-spectrum penicillins." J Infect Dis 155 (1987):  1242-8|Sanburg AL, Hughes JD, Nichols C "Antibiotic-induced hypoprothrombinaemia." Med J Aust 143 (1985):  387-8|Alitalo R, Ruutu M, Valtonen V, et al. "Hypoprothrombinaemia and bleeding during administration of cefamandole and cefoperazone." Ann Clin Res 17 (1985):  116-9|Bertino JS, Kozak AJ, Reese RE, Chiarello LA "Hypoprothrombinemia associated with cefamandole use in a rural teaching hospital." Arch Intern Med 146 (1986):  1125-8|Yangco BG, Palumbo JA, Nolen T, et al. "Comparative multicentre evaluation of the safety and efficacy of ceftazidime versus cefamandole for pneumonia." J Antimicrob Chemother 18 (1986):  521-9|O''Donnell D "Hypoprothrombinaemia associated with use of cephamandole." Aust N Z J Surg 61 (1991):  471-2|Tibbitts JS, Lipsky JJ "Effect of biliary diversion on the ability of cefamandole to inhibit vitamin K metabolism." Drug Metabol Drug Interact 7 (1989):  149-60|Cristiano P "Hypoprothrombinemia associated with cefoperazone treatment." Drug Intell Clin Pharm 18 (1984):  314-6|Meisel S "Hypoprothrombinemia due to cefoperazone." Drug Intell Clin Pharm 18 (1984):  316|Parker SW, Baxter J, Beam TR "Cefoperazone-induced coagulopathy." Lancet 1 (1984):  1016|Andrassy K, Koderisch J, Fritz S, et al. "Alteration of hemostasis associated with cefoperazone treatment." Infection 14 (1986):  27-31|Mueller RJ, Green D, Phair JP "Hypoprothrombinemia associated with cefoperazone therapy." South Med J 80 (1987):  1360-2|Brown RB, Klar J, Lemeshow S, Teres D, Pastides H, Sands M "Enhanced bleeding with cefoxitin or moxalactam." Arch Intern Med 146 (1986):  2159-64|Shenkenberg TD, Mackowiak PA, Smith JW "Coagulopathy and hemorrhage associated with cefoperazone therapy in a patient with renal failure." South Med J 78 (1985):  488-9|D''Elia JA, Kaldany A, Miller DG, et al. "Moxalactam bleeding and renal insufficiency." JAMA 249 (1983):  1565|Clark J, Hochman R, Rolla A, et al. "Coagulopathy associated with the use of cephalosporin or moxalactam antibiotics in acute and chronic renal failure." Clin Exp Dial Apheresis 7 (1983):  177-90|Shimanda K, Matsuda T, Inamatsu T, Urayama K "Bleeding secondary to vitamin K deficiency in patients receiving parenteral cephem antibiotics." J Antimicrob Chemother 14 (1984):  325-30|Sanburg AL, Hughes JD, Nichols C "Antibiotic-induced hypoprothrombinaemia." Med J Aust 143 (1985):  387-8|Natelson EA, Brown CH, 3d  Bradshaw MW, Alfrey CP, Jr  Williams TW, Jr "Influence of cephalosporin antibiotics on blood coagulation and platelet function." Antimicrob Agents Chemother 9 (1976):  91-3|Freedy HR, Cetnarowski AB, Lumish RM, Schafer FJ "Cefoperazone-induced coagulopathy." Drug Intell Clin Pharm 20 (1986):  281-3|Osborne JC "Hypoprothrombinemia and bleeding due to cefoperazone." Ann Intern Med 102 (1985):  721-2|Haubenstock A, Schmidt P, Zazgornik J, Balcke P, Kopsa H "Hypoprothrombinaemic bleeding associated with ceftriaxone." Lancet 1 (1983):  1215-6|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|Shearer MJ, Bechtold H, Andrassy K, Koderisch J, McCarthy PT, Trenk D, Jahnchen E, Ritz E "Mechanism of cephalosporin-induced hypoprothrombinemia: relation to cephalosporin side chain, vitamin K metabolism, and vitamin K status." J Clin Pharmacol 28 (1988):  88-95|Riancho JA, Olmos JM, Sedano C "Life-threatening bleeding in a patient treated with cefonicid." Ann Intern Med 123 (1995):  472-3|Breen GA, Stpeter WL "Hypoprothrombinemia associated with cefmetazole." Ann Pharmacother 31 (1997):  180-4', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38319, 0, 'Cefotetan', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased, and the half-lives prolonged, in patients with impaired renal function.  Neurotoxic reactions (e.g., encephalopathy, asterixis, myoclonus, seizures, coma) have been reported in such patients treated parenterally with these agents.  Dosage adjustments may be necessary, and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Staphcillin (methicillin)." Apothecon Inc  (2002):|"Product Information. Pfizerpen (penicillin)." Roerig Division  (2001):|"Product Information. Pipracil (piperacillin)." Lederle Laboratories  (2001):|"Product Information. Ticar (ticarcillin)." SmithKline Beecham  (2001):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38320, 0, 'Cefotetan', 'Heart Failure', 'Parenteral cefotetan disodium contains approximately 80 mg (3.5 mEq) of sodium per each gram of cefotetan activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38321, 0, 'Cefotetan', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38322, 0, 'Cefotetan', 'Alcoholic Intoxication', 'Disulfiram-like reactions may occur in patients who consume alcohol within 72 hours after administration of a cephalosporin antibiotic that contains an N-methylthiotetrazole (NMTT) side chain (cefamandole, cefmetazole, cefoperazone, cefotetan).  The reaction appears to result from accumulation of acetaldehyde due to inhibition of acetaldehyde dehydrogenase.  Therapy with cephalosporins containing the NMTT side chain should be administered cautiously in patients with a history of alcoholism.  Patients should be instructed to avoid alcohol-containing products during therapy and up to 72 hours after the last dose.', '2', 'Kline SS, Mauro VF, Forney RB Jr, et al. "Cefotetan-induced disulfiram-type reactions and hypoprothrombinemia." Antimicrob Agents Chemother 31 (1987):  1328-31|Freundt KJ, Kitson TM "Inactivation of aldehyde dehydrogenase by a putative metabolite of cefamandole." Infection 14 (1986):  44-7|Freundt KJ, Schreiner E, Christmann-Kleiss U "Cefamandole: a competitive inhibitor of aldehyde dehydrogenase." Infection 13 (1985):  91|McMahon FG "Disulfiram-like reaction to a cephalosporin." JAMA 243 (1980):  2397|Reeves DS, Davies AJ "Antabuse effect with cephalosporins." Lancet 2 (1980):  540|Brown KR, Guglielmo BJ, Pons VG, Jacobs RA "Theophylline elixir, moxalactam, and a disulfiram reaction." Ann Intern Med 97 (1982):  621-2|Umeda S, Arai T "Disulfiram-like reaction to moxalactam after celiac plexus alcohol block." Anesth Analg 64 (1985):  377|Foster TS, Raehl CL, Wilson HD "Disulfiram-like reaction associated with a parenteral cephalosporin." Am J Hosp Pharm 37 (1980):  858-9|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38323, 0, 'Cefotetan', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38324, 0, 'Cefotetan', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38325, 0, 'Ceftizoxime', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38326, 0, 'Ceftizoxime', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased, and the half-lives prolonged, in patients with impaired renal function.  Neurotoxic reactions (e.g., encephalopathy, asterixis, myoclonus, seizures, coma) have been reported in such patients treated parenterally with these agents.  Dosage adjustments may be necessary, and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Staphcillin (methicillin)." Apothecon Inc  (2002):|"Product Information. Pfizerpen (penicillin)." Roerig Division  (2001):|"Product Information. Pipracil (piperacillin)." Lederle Laboratories  (2001):|"Product Information. Ticar (ticarcillin)." SmithKline Beecham  (2001):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38327, 0, 'Ceftizoxime', 'Heart Failure', 'Parenteral ceftizoxime sodium contains approximately 60 mg (2.6 mEq) of sodium per each gram of ceftizoxime activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.', '2', '"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38328, 0, 'Ceftizoxime', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38329, 0, 'Ceftizoxime', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38330, 0, 'Ceftizoxime', 'Epilepsy', 'Cephalosporins have been implicated in triggering seizures.  Nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported with cephalosporins particularly in patients with a history of epilepsy and/or when recommended dosages of cephalosporins were exceeded due to renal impairment.  Adjust dosing based on creatinine clearance.  Anticonvulsant therapy should be continued in patients with known seizure disorders.  If CNS adverse reactions including seizures occur, patients should undergo a neurological evaluation to determine whether treatment should be discontinued.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38331, 29956, 'Ceftaroline fosamil', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38332, 29957, 'Ceftaroline fosamil', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38333, 29956, 'Ceftaroline fosamil', 'Kidney Diseases', 'A dosage adjustment is required in adult patients with moderate or severe renal impairment, and in patients with end-stage renal disease, including patients on hemodialysis.  The manufacturer states that there is insufficient information to recommend a dosage regimen for pediatric patients with renal impairment.', '2', '"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38334, 29957, 'Ceftaroline fosamil', 'Kidney Diseases', 'A dosage adjustment is required in adult patients with moderate or severe renal impairment, and in patients with end-stage renal disease, including patients on hemodialysis.  The manufacturer states that there is insufficient information to recommend a dosage regimen for pediatric patients with renal impairment.', '2', '"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38335, 29956, 'Ceftaroline fosamil', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38336, 29957, 'Ceftaroline fosamil', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38337, 0, 'Cefradine', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38338, 0, 'Cefradine', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased and the half-lives prolonged in patients with impaired renal function.  Dosage adjustments may be necessary and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy, since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', 'Bergan T "Pharmacokinetic comparison of oral bacampicillin and parenteral ampicillin." Antimicrob Agents Chemother 13 (1978):  971-4|Ehrnebo M, Nilsson SO, Boreus LO "Pharmacokinetics of ampicillin and its prodrugs bacampicillin and pivampicillin in man." J Pharmacokinet Biopharm 7 (1979):  429-51|Humbert G, Spyker DA, Fillastre JP, Leroy A "Pharmacokinetics of amoxicillin: dosage nomogram for patients with impaired renal function." Antimicrob Agents Chemother 15 (1979):  28-33|Bloch R, Szwed JJ, Sloan RS, Luft FC "Pharmacokinetics of cefaclor in normal subjects and patients with chronic renal failure." Antimicrob Agents Chemother 12 (1977):  730-2|Santoro J, Agarwal BN, Martinelli R, et al. "Pharmacology of cefaclor in normal volunteers and patients with renal failure." Antimicrob Agents Chemother 13 (1978):  951-4|Spyker DA, Thomas BL, Sande MA, Bolton WK "Pharmacokinetics of cefaclor and caphalexin: dosage nomograms for impaired renal function." Antimicrob Agents Chemother 14 (1978):  172-7|Gartenberg G, Meyers BR, Hirschman SZ, Srulevitch E "Pharmacokinetics of cefaclor in patients with stable renal impairment, and patients undergoing haemodialysis." J Antimicrob Chemother 5 (1979):  465-70|Fillastre JP, Leroy A, Humbert G, Godin M "Cefaclor pharmacokinetics and renal impairment." J Antimicrob Chemother 6 (1980):  155-6|Berman SJ, Boughton WH, Sugihara JG, et al. "Pharmacokinetics of cefaclor in patients with end stage renal disease and during hemodialysis." Antimicrob Agents Chemother 14 (1978):  281-3|Spyker DA, Gober LL, Scheld WM, et al. "Pharmacokinetics of cefaclor in renal failure: effects of multiple doses and hemodialysis." Antimicrob Agents Chemother 21 (1982):  278-81|Pommer W, Krause PH, Berg PA, et al. "Acute interstitial nephritis and non-oliguric renal failure after cefaclor treatment." Klin Wochenschr 64 (1986):  290-3|Guay DR, Meatherall RC, Harding GK, Brown GR "Pharmacokinetics of cefixime (CL 284,635; FK 027) in healthy subjects and patients with renal insufficiency." Antimicrob Agents Chemother 30 (1986):  485-90|Dhib M, Moulin B, Leroy A, et al. "Relationship between renal function and disposition of oral cefixime." Eur J Clin Pharmacol 41 (1991):  579-83|Shyu WC, Pittman KA, Wilber RB, et al. "Pharmacokinetics of cefprozil in healthy subjects and patients with renal impairment." J Clin Pharmacol 31 (1991):  362-71|Humbert G, Leroy A, Fillastre JP, Godin M "Pharmacokinetics of cefadroxil in normal subjects and in patients with renal insufficiency." Chemotherapy 25 (1979):  189-95|Leroy A, Humbert G, Godin M, Fillastre JP "Pharmacokinetics of cefadroxil in patients with impaired renal function." J Antimicrob Chemother 10 (1982):  39-46|Kabins SA, Kelner B, Walton E, Goldstein E "Cephalexin therapy as related to renal function." Am J Med Sci 259 (1970):  133-42|Kunin CM, Finkelberg Z "Oral cephalexin and ampicillin: antimicrobial activity, recovery in urine, and persistence in blood of uremic patients." Ann Intern Med 72 (1970):  349-56|Yamasaku F, Tsuchida R, Usuda Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Bailey RR, Gower PE, Dash CH "The effect of impairment of renal function and haemodialysis on serum and urine levels of cephalexin." Postgrad Med J 46 (1970):  60-4|Regamey C, Humair L "Pharmacokinetics of cephalexin in renal insufficiency." Postgrad Med J 47 Supp) (1971):  69-77|Reisberg BE, Mandelbaum JM "Cephalexin: absorption and excretion as related to renal function and hemodialysis." Infect Immun 3 (1971):  540-3|Kirby WM, de Maine JB, Serrill WS "Pharmacokinetics of the cephalosporins in healthy volunteers and uremic patients." Postgrad Med J 47 Suppl (1971):  41-6|Brogard JM, Pinget M, Dorner M, Lavillaureix J "Determination of cefalexin pharmacokinetics and dosage adjustments in relation to renal function." J Clin Pharmacol 15 (1975):  666-73|Chow M, Quintiliani R, Cunha BA, et al. "Pharmacokinetics of high-dose oral cephalosporins." J Clin Pharmacol 19 (1979):  185-94|Finkelstein ER, Quintiliani R, Nightingale CH "Pharmacokinetics of oral cephalosporins." J Pediatr 93 (1978):  902|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-99|Hori R, Okumura K, Nihira H, et al. "A new dosing regimen in renal insufficiency: application to cephalexin." Clin Pharmacol Ther 38 (1985):  290-5|St Peter JV, Borin MT, Hughes GS, et al. "Disposition of cefpodoxime proxetil in healthy volunteers and patients with impaired renal function." Antimicrob Agents Chemother 36 (1992):  126-31|Gibaldi M, Perrier D "Drug distribution and renal failure." J Clin Pharmacol 12 (1972):  201-4|Hoffman TA, Cestero R, Bullock WE "Pharmacodynamics of carbenicillin in hepatic and renal failure." Ann Intern Med 73 (1970):  173-8|Latos DL, Bryan CS, Stone WJ "Carbenicillin therapy in patients with normal and impaired renal function." Clin Pharmacol Ther 17 (1975):  692-700|Arancibia A, Droguett MT, Fuentes G, et al. "Pharmacokinetics of amoxicillin in subjects with normal and impaired renal function." Int J Clin Pharmacol Ther Toxicol 20 (1982):  447-53|Sjovall J, Westerlund D, Alvan G "Renal excretion of intravenously infused amoxycillin and ampicillin." Br J Clin Pharmacol 19 (1985):  191-201|Jackson EA, McLeod DC "Pharmacokinetics and dosing of antimicrobial agents in renal impairment, part I." Am J Hosp Pharm 31 (1974):  36-52|Bailey RR, Eastwood JB, Vaughan RB "The pharmacokinetics of an oral form of carbenicillin in patients with renal failure." Postgrad Med J 48 (1972):  422-5|Nelson JD, Reimold EW "Carbenicillin pharmacokinetics in an anephric patient." Lancet 1 (1973):  486-7|Nakano H, Sasaki K, Mizoguchi M, Ishibe T, Nihira H "Absorption and excretion of carbenicillin indanyl sodium in patients with reduced kidney function." Chemotherapy 23 (1977):  299-308|Hoffler D, Koeppe P, Corcilius M, Przyklink A "Cefpodoxime proxetil in patients with endstage renal failure on hemodialysis." Infection 18 (1990):  157-62|Yamasaku F, Tsuchida R, Usada Y "A study of the kinetics of cephalosporins in renal impairment." Postgrad Med J Suppl (1970):  57-9|Standiford HC, Jordan MC, Kirby WM "Clinical pharmacology of carbenicillin compared with other penicillins." J Infect Dis 122 (1970):  s9-13|Andriole VT "Pharmacokinetics of cephalosporins in patients with normal or reduced renal function." J Infect Dis 137 (1978):  s88-97|Schwinghammer TL, Norden CW, Gill E "Pharmacokinetics of cephradine administered intravenously and orally to young and elderly subjects." J Clin Pharmacol 30 (1990):  893-9|Solomon AE, Briggs JD "The administration of cephradine to patients in renal failure." Br J Clin Pharmacol 2 (1975):  443-8|Neu HC "The pharmacokinetics of bacampicillin." Rev Infect Dis 3 (1981):  110-6|Braga PC, Fraschini F, Ceccarelli G, Scaglione F, Scarpazza G "Clinical pharmacokinetic evaluation of bacampicillin." Clin Ther 4 (1981):  32-42|DeSante KA, Zeckel ML "Pharmacokinetic profile of loracarbef." Am J Med 92 (1992):  s16-9|"Product Information. Polymox (amoxicillin)." Bristol-Myers Squibb, Princeton, NJ.|"Product Information. Spectrobid (bacampicillin)." Roerig Division  (2002):|"Product Information. Geocillin (carbenicillin)." Roerig Division  (2002):|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|Therasse DG, Farlow DS, Davidson RL, et al. "Effect of renal dysfunction on the pharmacokinetics of loracarbef." Clin Pharmacol Ther 54 (1993):  311-6|Granero L, Gimeno MJ, Torresmolina F, Chesajimenez J, Peris JE "Studies on the renal excretion mechanisms of cefadroxil." Drug Metab Dispos 22 (1994):  447-50|Hyslop DL "Cefaclor safety profile: a ten-year review." Clin Ther 11 Suppl A (1988):  83-94|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|Nix DE, Symonds WT, Hyatt JM, et al. "Comparative pharmacokinetics of oral ceftibuten, cefixime, cefaclor, and cefuroxime axetil in healthy volunteers." Pharmacotherapy 17 (1997):  121-5|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|Guay DRP "Ceftibuten: A new expanded-spectrum oral cephalosporin." Ann Pharmacother 31 (1997):  1022-33|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38339, 0, 'Cefradine', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38340, 0, 'Cenobamate', 'Short Qt Syndrome', 'Cenobamate causes QT interval shortening.  The use of this drug is contraindicated in patients with familial short QT syndrome, as it is associated with an increased risk of sudden death and ventricular arrhythmias, particularly ventricular fibrillation.', '3', '"Product Information. Xcopri (cenobamate)." SK Life Science, Inc.  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38341, 0, 'Cenobamate', 'Depressive Disorder', 'Antiepileptic drugs (AEDs) have been associated with an increased risk of suicidal thoughts or behavior in patients taking these drugs for any indication.  Pooled analyses of 199 placebo-controlled clinical studies involving the use of 11 different AEDs showed that patients receiving AEDs had approximately twice the risk of suicidal thinking or behavior compared to patients receiving placebo.  AEDs should be administered cautiously in patients with depression or other psychiatric disorders.  The risk of suicidal thoughts and behavior should be carefully assessed against the risk of untreated illness, bearing in mind that epilepsy and many other conditions for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior.  Patients, caregivers, and families should be alert to the emergence or worsening of signs and symptoms of depression, any unusual changes in mood or behavior, or the emergence of suicidal thoughts or behavior.  If patients have symptoms of suicidal ideation or behavior, a dosage reduction or treatment discontinuation should be considered.', '2', '"Product Information. Tegretol (carbamazepine)." Novartis Pharmaceuticals  (2002):|"Product Information. Klonopin (clonazepam)." Roche Laboratories  (2001):|"Product Information. Dilantin (phenytoin)." Parke-Davis  (2001):|"Product Information. Cerebyx (fosphenytoin)." Parke-Davis  (2001):|"Product Information. Mysoline (primidone)." Elan Pharmaceuticals  (2001):|"Product Information. Lyrica (pregabalin)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Sabril (vigabatrin)." Lundbeck Inc  (2009):|"Product Information. Potiga (ezogabine)." GlaxoSmithKline  (2011):|"Product Information. Qsymia (phentermine-topiramate)." Vivus Inc  (2012):|"Product Information. Fycompa (perampanel)." Eisai Inc  (2012):|"Product Information. Briviact (brivaracetam)." UCB Pharma Inc  (2016):|"Product Information. Diacomit (stiripentol)." Biocodex USA  (2018):|"Product Information. Epidiolex (cannabidiol)." Greenwich Biosciences LLC  (2018):|"Product Information. Xcopri (cenobamate)." SK Life Science, Inc.  (2020):|"Product Information. Fintepla (fenfluramine)." Zogenix, Inc  (2020):|"Product Information. Ztalmy (ganaxolone)." Marinus Pharmaceuticals, Inc  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38342, 0, 'Cenobamate', 'Liver Diseases', 'Cenobamate should be used with caution in patients with mild to moderate hepatic dysfunction.  Consider a dosage reduction in these patients, with a maximum recommended dosage of 200 mg once a day.  The use in patients with severe hepatic dysfunction is not recommended.', '2', '"Product Information. Xcopri (cenobamate)." SK Life Science, Inc.  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38343, 0, 'Cenobamate', 'Kidney Diseases', 'Cenobamate should be used with caution and dosage reduction may be considered in patients with renal dysfunction.  The use in patients with end-stage renal disease undergoing dialysis is not recommended.', '2', '"Product Information. Xcopri (cenobamate)." SK Life Science, Inc.  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38344, 0, 'Agalsidase beta', 'Heart Failure', 'Appropriate medical support measures should be readily available when agalsidase beta is administered due to the potential for severe infusion-associated reactions.  Compromised cardiac function may predispose patients to a higher risk of severe complications from infusion-associated reactions; patients with compromised cardiac function should be monitored closely if administered agalsidase beta.', '2', '"Product Information. Fabrazyme (agalsidase beta)." Genzyme Corporation  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38345, 2233, 'Ceftazidime', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38346, 2281, 'Ceftazidime', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38347, 2284, 'Ceftazidime', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38348, 2301, 'Ceftazidime', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38349, 2302, 'Ceftazidime', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38350, 2303, 'Ceftazidime', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38351, 2444, 'Ceftazidime', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38352, 2445, 'Ceftazidime', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38353, 5113, 'Ceftazidime', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38354, 6801, 'Ceftazidime', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38355, 6802, 'Ceftazidime', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38356, 10438, 'Ceftazidime', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38357, 10439, 'Ceftazidime', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38358, 16013, 'Ceftazidime', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38359, 16014, 'Ceftazidime', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38360, 16015, 'Ceftazidime', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38361, 16062, 'Ceftazidime', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38362, 16080, 'Ceftazidime', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38363, 16194, 'Ceftazidime', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38364, 19339, 'Ceftazidime', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38365, 19340, 'Ceftazidime', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38366, 19341, 'Ceftazidime', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38367, 19355, 'Ceftazidime', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38368, 19356, 'Ceftazidime', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38369, 20922, 'Ceftazidime', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38370, 21317, 'Ceftazidime', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38371, 22394, 'Ceftazidime', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38372, 22395, 'Ceftazidime', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38373, 23346, 'Ceftazidime', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38374, 23347, 'Ceftazidime', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38375, 28976, 'Ceftazidime', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38376, 28977, 'Ceftazidime', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38377, 29784, 'Ceftazidime', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38378, 29785, 'Ceftazidime', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38379, 29786, 'Ceftazidime', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38380, 2233, 'Ceftazidime', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased, and the half-lives prolonged, in patients with impaired renal function.  Neurotoxic reactions (e.g., encephalopathy, asterixis, myoclonus, seizures, coma) have been reported in such patients treated parenterally with these agents.  Dosage adjustments may be necessary, and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Staphcillin (methicillin)." Apothecon Inc  (2002):|"Product Information. Pfizerpen (penicillin)." Roerig Division  (2001):|"Product Information. Pipracil (piperacillin)." Lederle Laboratories  (2001):|"Product Information. Ticar (ticarcillin)." SmithKline Beecham  (2001):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38381, 2281, 'Ceftazidime', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased, and the half-lives prolonged, in patients with impaired renal function.  Neurotoxic reactions (e.g., encephalopathy, asterixis, myoclonus, seizures, coma) have been reported in such patients treated parenterally with these agents.  Dosage adjustments may be necessary, and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Staphcillin (methicillin)." Apothecon Inc  (2002):|"Product Information. Pfizerpen (penicillin)." Roerig Division  (2001):|"Product Information. Pipracil (piperacillin)." Lederle Laboratories  (2001):|"Product Information. Ticar (ticarcillin)." SmithKline Beecham  (2001):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38382, 2284, 'Ceftazidime', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased, and the half-lives prolonged, in patients with impaired renal function.  Neurotoxic reactions (e.g., encephalopathy, asterixis, myoclonus, seizures, coma) have been reported in such patients treated parenterally with these agents.  Dosage adjustments may be necessary, and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Staphcillin (methicillin)." Apothecon Inc  (2002):|"Product Information. Pfizerpen (penicillin)." Roerig Division  (2001):|"Product Information. Pipracil (piperacillin)." Lederle Laboratories  (2001):|"Product Information. Ticar (ticarcillin)." SmithKline Beecham  (2001):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38383, 2301, 'Ceftazidime', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased, and the half-lives prolonged, in patients with impaired renal function.  Neurotoxic reactions (e.g., encephalopathy, asterixis, myoclonus, seizures, coma) have been reported in such patients treated parenterally with these agents.  Dosage adjustments may be necessary, and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Staphcillin (methicillin)." Apothecon Inc  (2002):|"Product Information. Pfizerpen (penicillin)." Roerig Division  (2001):|"Product Information. Pipracil (piperacillin)." Lederle Laboratories  (2001):|"Product Information. Ticar (ticarcillin)." SmithKline Beecham  (2001):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38384, 2302, 'Ceftazidime', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased, and the half-lives prolonged, in patients with impaired renal function.  Neurotoxic reactions (e.g., encephalopathy, asterixis, myoclonus, seizures, coma) have been reported in such patients treated parenterally with these agents.  Dosage adjustments may be necessary, and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Staphcillin (methicillin)." Apothecon Inc  (2002):|"Product Information. Pfizerpen (penicillin)." Roerig Division  (2001):|"Product Information. Pipracil (piperacillin)." Lederle Laboratories  (2001):|"Product Information. Ticar (ticarcillin)." SmithKline Beecham  (2001):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38385, 2303, 'Ceftazidime', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased, and the half-lives prolonged, in patients with impaired renal function.  Neurotoxic reactions (e.g., encephalopathy, asterixis, myoclonus, seizures, coma) have been reported in such patients treated parenterally with these agents.  Dosage adjustments may be necessary, and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Staphcillin (methicillin)." Apothecon Inc  (2002):|"Product Information. Pfizerpen (penicillin)." Roerig Division  (2001):|"Product Information. Pipracil (piperacillin)." Lederle Laboratories  (2001):|"Product Information. Ticar (ticarcillin)." SmithKline Beecham  (2001):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38386, 2444, 'Ceftazidime', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased, and the half-lives prolonged, in patients with impaired renal function.  Neurotoxic reactions (e.g., encephalopathy, asterixis, myoclonus, seizures, coma) have been reported in such patients treated parenterally with these agents.  Dosage adjustments may be necessary, and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Staphcillin (methicillin)." Apothecon Inc  (2002):|"Product Information. Pfizerpen (penicillin)." Roerig Division  (2001):|"Product Information. Pipracil (piperacillin)." Lederle Laboratories  (2001):|"Product Information. Ticar (ticarcillin)." SmithKline Beecham  (2001):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38387, 2445, 'Ceftazidime', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased, and the half-lives prolonged, in patients with impaired renal function.  Neurotoxic reactions (e.g., encephalopathy, asterixis, myoclonus, seizures, coma) have been reported in such patients treated parenterally with these agents.  Dosage adjustments may be necessary, and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Staphcillin (methicillin)." Apothecon Inc  (2002):|"Product Information. Pfizerpen (penicillin)." Roerig Division  (2001):|"Product Information. Pipracil (piperacillin)." Lederle Laboratories  (2001):|"Product Information. Ticar (ticarcillin)." SmithKline Beecham  (2001):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38388, 5113, 'Ceftazidime', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased, and the half-lives prolonged, in patients with impaired renal function.  Neurotoxic reactions (e.g., encephalopathy, asterixis, myoclonus, seizures, coma) have been reported in such patients treated parenterally with these agents.  Dosage adjustments may be necessary, and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Staphcillin (methicillin)." Apothecon Inc  (2002):|"Product Information. Pfizerpen (penicillin)." Roerig Division  (2001):|"Product Information. Pipracil (piperacillin)." Lederle Laboratories  (2001):|"Product Information. Ticar (ticarcillin)." SmithKline Beecham  (2001):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38389, 6801, 'Ceftazidime', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased, and the half-lives prolonged, in patients with impaired renal function.  Neurotoxic reactions (e.g., encephalopathy, asterixis, myoclonus, seizures, coma) have been reported in such patients treated parenterally with these agents.  Dosage adjustments may be necessary, and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Staphcillin (methicillin)." Apothecon Inc  (2002):|"Product Information. Pfizerpen (penicillin)." Roerig Division  (2001):|"Product Information. Pipracil (piperacillin)." Lederle Laboratories  (2001):|"Product Information. Ticar (ticarcillin)." SmithKline Beecham  (2001):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38390, 6802, 'Ceftazidime', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased, and the half-lives prolonged, in patients with impaired renal function.  Neurotoxic reactions (e.g., encephalopathy, asterixis, myoclonus, seizures, coma) have been reported in such patients treated parenterally with these agents.  Dosage adjustments may be necessary, and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Staphcillin (methicillin)." Apothecon Inc  (2002):|"Product Information. Pfizerpen (penicillin)." Roerig Division  (2001):|"Product Information. Pipracil (piperacillin)." Lederle Laboratories  (2001):|"Product Information. Ticar (ticarcillin)." SmithKline Beecham  (2001):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38391, 10438, 'Ceftazidime', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased, and the half-lives prolonged, in patients with impaired renal function.  Neurotoxic reactions (e.g., encephalopathy, asterixis, myoclonus, seizures, coma) have been reported in such patients treated parenterally with these agents.  Dosage adjustments may be necessary, and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Staphcillin (methicillin)." Apothecon Inc  (2002):|"Product Information. Pfizerpen (penicillin)." Roerig Division  (2001):|"Product Information. Pipracil (piperacillin)." Lederle Laboratories  (2001):|"Product Information. Ticar (ticarcillin)." SmithKline Beecham  (2001):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38392, 10439, 'Ceftazidime', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased, and the half-lives prolonged, in patients with impaired renal function.  Neurotoxic reactions (e.g., encephalopathy, asterixis, myoclonus, seizures, coma) have been reported in such patients treated parenterally with these agents.  Dosage adjustments may be necessary, and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Staphcillin (methicillin)." Apothecon Inc  (2002):|"Product Information. Pfizerpen (penicillin)." Roerig Division  (2001):|"Product Information. Pipracil (piperacillin)." Lederle Laboratories  (2001):|"Product Information. Ticar (ticarcillin)." SmithKline Beecham  (2001):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38393, 16013, 'Ceftazidime', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased, and the half-lives prolonged, in patients with impaired renal function.  Neurotoxic reactions (e.g., encephalopathy, asterixis, myoclonus, seizures, coma) have been reported in such patients treated parenterally with these agents.  Dosage adjustments may be necessary, and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Staphcillin (methicillin)." Apothecon Inc  (2002):|"Product Information. Pfizerpen (penicillin)." Roerig Division  (2001):|"Product Information. Pipracil (piperacillin)." Lederle Laboratories  (2001):|"Product Information. Ticar (ticarcillin)." SmithKline Beecham  (2001):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38394, 16014, 'Ceftazidime', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased, and the half-lives prolonged, in patients with impaired renal function.  Neurotoxic reactions (e.g., encephalopathy, asterixis, myoclonus, seizures, coma) have been reported in such patients treated parenterally with these agents.  Dosage adjustments may be necessary, and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Staphcillin (methicillin)." Apothecon Inc  (2002):|"Product Information. Pfizerpen (penicillin)." Roerig Division  (2001):|"Product Information. Pipracil (piperacillin)." Lederle Laboratories  (2001):|"Product Information. Ticar (ticarcillin)." SmithKline Beecham  (2001):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38395, 16015, 'Ceftazidime', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased, and the half-lives prolonged, in patients with impaired renal function.  Neurotoxic reactions (e.g., encephalopathy, asterixis, myoclonus, seizures, coma) have been reported in such patients treated parenterally with these agents.  Dosage adjustments may be necessary, and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Staphcillin (methicillin)." Apothecon Inc  (2002):|"Product Information. Pfizerpen (penicillin)." Roerig Division  (2001):|"Product Information. Pipracil (piperacillin)." Lederle Laboratories  (2001):|"Product Information. Ticar (ticarcillin)." SmithKline Beecham  (2001):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38396, 16062, 'Ceftazidime', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased, and the half-lives prolonged, in patients with impaired renal function.  Neurotoxic reactions (e.g., encephalopathy, asterixis, myoclonus, seizures, coma) have been reported in such patients treated parenterally with these agents.  Dosage adjustments may be necessary, and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Staphcillin (methicillin)." Apothecon Inc  (2002):|"Product Information. Pfizerpen (penicillin)." Roerig Division  (2001):|"Product Information. Pipracil (piperacillin)." Lederle Laboratories  (2001):|"Product Information. Ticar (ticarcillin)." SmithKline Beecham  (2001):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38397, 16080, 'Ceftazidime', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased, and the half-lives prolonged, in patients with impaired renal function.  Neurotoxic reactions (e.g., encephalopathy, asterixis, myoclonus, seizures, coma) have been reported in such patients treated parenterally with these agents.  Dosage adjustments may be necessary, and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Staphcillin (methicillin)." Apothecon Inc  (2002):|"Product Information. Pfizerpen (penicillin)." Roerig Division  (2001):|"Product Information. Pipracil (piperacillin)." Lederle Laboratories  (2001):|"Product Information. Ticar (ticarcillin)." SmithKline Beecham  (2001):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38398, 16194, 'Ceftazidime', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased, and the half-lives prolonged, in patients with impaired renal function.  Neurotoxic reactions (e.g., encephalopathy, asterixis, myoclonus, seizures, coma) have been reported in such patients treated parenterally with these agents.  Dosage adjustments may be necessary, and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Staphcillin (methicillin)." Apothecon Inc  (2002):|"Product Information. Pfizerpen (penicillin)." Roerig Division  (2001):|"Product Information. Pipracil (piperacillin)." Lederle Laboratories  (2001):|"Product Information. Ticar (ticarcillin)." SmithKline Beecham  (2001):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38399, 19339, 'Ceftazidime', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased, and the half-lives prolonged, in patients with impaired renal function.  Neurotoxic reactions (e.g., encephalopathy, asterixis, myoclonus, seizures, coma) have been reported in such patients treated parenterally with these agents.  Dosage adjustments may be necessary, and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Staphcillin (methicillin)." Apothecon Inc  (2002):|"Product Information. Pfizerpen (penicillin)." Roerig Division  (2001):|"Product Information. Pipracil (piperacillin)." Lederle Laboratories  (2001):|"Product Information. Ticar (ticarcillin)." SmithKline Beecham  (2001):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38400, 19340, 'Ceftazidime', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased, and the half-lives prolonged, in patients with impaired renal function.  Neurotoxic reactions (e.g., encephalopathy, asterixis, myoclonus, seizures, coma) have been reported in such patients treated parenterally with these agents.  Dosage adjustments may be necessary, and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Staphcillin (methicillin)." Apothecon Inc  (2002):|"Product Information. Pfizerpen (penicillin)." Roerig Division  (2001):|"Product Information. Pipracil (piperacillin)." Lederle Laboratories  (2001):|"Product Information. Ticar (ticarcillin)." SmithKline Beecham  (2001):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38401, 19341, 'Ceftazidime', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased, and the half-lives prolonged, in patients with impaired renal function.  Neurotoxic reactions (e.g., encephalopathy, asterixis, myoclonus, seizures, coma) have been reported in such patients treated parenterally with these agents.  Dosage adjustments may be necessary, and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Staphcillin (methicillin)." Apothecon Inc  (2002):|"Product Information. Pfizerpen (penicillin)." Roerig Division  (2001):|"Product Information. Pipracil (piperacillin)." Lederle Laboratories  (2001):|"Product Information. Ticar (ticarcillin)." SmithKline Beecham  (2001):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38402, 19355, 'Ceftazidime', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased, and the half-lives prolonged, in patients with impaired renal function.  Neurotoxic reactions (e.g., encephalopathy, asterixis, myoclonus, seizures, coma) have been reported in such patients treated parenterally with these agents.  Dosage adjustments may be necessary, and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Staphcillin (methicillin)." Apothecon Inc  (2002):|"Product Information. Pfizerpen (penicillin)." Roerig Division  (2001):|"Product Information. Pipracil (piperacillin)." Lederle Laboratories  (2001):|"Product Information. Ticar (ticarcillin)." SmithKline Beecham  (2001):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38403, 19356, 'Ceftazidime', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased, and the half-lives prolonged, in patients with impaired renal function.  Neurotoxic reactions (e.g., encephalopathy, asterixis, myoclonus, seizures, coma) have been reported in such patients treated parenterally with these agents.  Dosage adjustments may be necessary, and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Staphcillin (methicillin)." Apothecon Inc  (2002):|"Product Information. Pfizerpen (penicillin)." Roerig Division  (2001):|"Product Information. Pipracil (piperacillin)." Lederle Laboratories  (2001):|"Product Information. Ticar (ticarcillin)." SmithKline Beecham  (2001):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38404, 20922, 'Ceftazidime', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased, and the half-lives prolonged, in patients with impaired renal function.  Neurotoxic reactions (e.g., encephalopathy, asterixis, myoclonus, seizures, coma) have been reported in such patients treated parenterally with these agents.  Dosage adjustments may be necessary, and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Staphcillin (methicillin)." Apothecon Inc  (2002):|"Product Information. Pfizerpen (penicillin)." Roerig Division  (2001):|"Product Information. Pipracil (piperacillin)." Lederle Laboratories  (2001):|"Product Information. Ticar (ticarcillin)." SmithKline Beecham  (2001):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38405, 21317, 'Ceftazidime', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased, and the half-lives prolonged, in patients with impaired renal function.  Neurotoxic reactions (e.g., encephalopathy, asterixis, myoclonus, seizures, coma) have been reported in such patients treated parenterally with these agents.  Dosage adjustments may be necessary, and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Staphcillin (methicillin)." Apothecon Inc  (2002):|"Product Information. Pfizerpen (penicillin)." Roerig Division  (2001):|"Product Information. Pipracil (piperacillin)." Lederle Laboratories  (2001):|"Product Information. Ticar (ticarcillin)." SmithKline Beecham  (2001):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38406, 22394, 'Ceftazidime', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased, and the half-lives prolonged, in patients with impaired renal function.  Neurotoxic reactions (e.g., encephalopathy, asterixis, myoclonus, seizures, coma) have been reported in such patients treated parenterally with these agents.  Dosage adjustments may be necessary, and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Staphcillin (methicillin)." Apothecon Inc  (2002):|"Product Information. Pfizerpen (penicillin)." Roerig Division  (2001):|"Product Information. Pipracil (piperacillin)." Lederle Laboratories  (2001):|"Product Information. Ticar (ticarcillin)." SmithKline Beecham  (2001):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38407, 22395, 'Ceftazidime', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased, and the half-lives prolonged, in patients with impaired renal function.  Neurotoxic reactions (e.g., encephalopathy, asterixis, myoclonus, seizures, coma) have been reported in such patients treated parenterally with these agents.  Dosage adjustments may be necessary, and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Staphcillin (methicillin)." Apothecon Inc  (2002):|"Product Information. Pfizerpen (penicillin)." Roerig Division  (2001):|"Product Information. Pipracil (piperacillin)." Lederle Laboratories  (2001):|"Product Information. Ticar (ticarcillin)." SmithKline Beecham  (2001):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38408, 23346, 'Ceftazidime', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased, and the half-lives prolonged, in patients with impaired renal function.  Neurotoxic reactions (e.g., encephalopathy, asterixis, myoclonus, seizures, coma) have been reported in such patients treated parenterally with these agents.  Dosage adjustments may be necessary, and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Staphcillin (methicillin)." Apothecon Inc  (2002):|"Product Information. Pfizerpen (penicillin)." Roerig Division  (2001):|"Product Information. Pipracil (piperacillin)." Lederle Laboratories  (2001):|"Product Information. Ticar (ticarcillin)." SmithKline Beecham  (2001):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38409, 23347, 'Ceftazidime', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased, and the half-lives prolonged, in patients with impaired renal function.  Neurotoxic reactions (e.g., encephalopathy, asterixis, myoclonus, seizures, coma) have been reported in such patients treated parenterally with these agents.  Dosage adjustments may be necessary, and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Staphcillin (methicillin)." Apothecon Inc  (2002):|"Product Information. Pfizerpen (penicillin)." Roerig Division  (2001):|"Product Information. Pipracil (piperacillin)." Lederle Laboratories  (2001):|"Product Information. Ticar (ticarcillin)." SmithKline Beecham  (2001):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38410, 28976, 'Ceftazidime', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased, and the half-lives prolonged, in patients with impaired renal function.  Neurotoxic reactions (e.g., encephalopathy, asterixis, myoclonus, seizures, coma) have been reported in such patients treated parenterally with these agents.  Dosage adjustments may be necessary, and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Staphcillin (methicillin)." Apothecon Inc  (2002):|"Product Information. Pfizerpen (penicillin)." Roerig Division  (2001):|"Product Information. Pipracil (piperacillin)." Lederle Laboratories  (2001):|"Product Information. Ticar (ticarcillin)." SmithKline Beecham  (2001):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38411, 28977, 'Ceftazidime', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased, and the half-lives prolonged, in patients with impaired renal function.  Neurotoxic reactions (e.g., encephalopathy, asterixis, myoclonus, seizures, coma) have been reported in such patients treated parenterally with these agents.  Dosage adjustments may be necessary, and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Staphcillin (methicillin)." Apothecon Inc  (2002):|"Product Information. Pfizerpen (penicillin)." Roerig Division  (2001):|"Product Information. Pipracil (piperacillin)." Lederle Laboratories  (2001):|"Product Information. Ticar (ticarcillin)." SmithKline Beecham  (2001):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38412, 29784, 'Ceftazidime', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased, and the half-lives prolonged, in patients with impaired renal function.  Neurotoxic reactions (e.g., encephalopathy, asterixis, myoclonus, seizures, coma) have been reported in such patients treated parenterally with these agents.  Dosage adjustments may be necessary, and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Staphcillin (methicillin)." Apothecon Inc  (2002):|"Product Information. Pfizerpen (penicillin)." Roerig Division  (2001):|"Product Information. Pipracil (piperacillin)." Lederle Laboratories  (2001):|"Product Information. Ticar (ticarcillin)." SmithKline Beecham  (2001):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38413, 29785, 'Ceftazidime', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased, and the half-lives prolonged, in patients with impaired renal function.  Neurotoxic reactions (e.g., encephalopathy, asterixis, myoclonus, seizures, coma) have been reported in such patients treated parenterally with these agents.  Dosage adjustments may be necessary, and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Staphcillin (methicillin)." Apothecon Inc  (2002):|"Product Information. Pfizerpen (penicillin)." Roerig Division  (2001):|"Product Information. Pipracil (piperacillin)." Lederle Laboratories  (2001):|"Product Information. Ticar (ticarcillin)." SmithKline Beecham  (2001):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38414, 29786, 'Ceftazidime', 'Kidney Diseases', 'Most beta-lactam antibiotics are eliminated by the kidney as unchanged drug and, in some cases, also as metabolites.  The serum concentrations of beta-lactam antibiotics and their metabolites may be increased, and the half-lives prolonged, in patients with impaired renal function.  Neurotoxic reactions (e.g., encephalopathy, asterixis, myoclonus, seizures, coma) have been reported in such patients treated parenterally with these agents.  Dosage adjustments may be necessary, and modifications should be based on the degree of renal impairment as well as severity of infection in accordance with the individual product package labeling.  Renal function tests should be performed periodically during prolonged and/or high-dose therapy since nephrotoxicity and alterations in renal function have occasionally been associated with the use of these drugs.', '2', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Zefazone (cefmetazole)." Pharmacia and Upjohn  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Staphcillin (methicillin)." Apothecon Inc  (2002):|"Product Information. Pfizerpen (penicillin)." Roerig Division  (2001):|"Product Information. Pipracil (piperacillin)." Lederle Laboratories  (2001):|"Product Information. Ticar (ticarcillin)." SmithKline Beecham  (2001):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38415, 2233, 'Ceftazidime', 'Heart Failure', 'Fortaz, Tazicef, and Tazidime (brands of parenteral ceftazidime pentahydrate) are formulated with sodium carbonate and contain approximately 53 mg (2.3 mEq) of sodium per each gram of ceftazidime activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.  Ceptaz, another brand of ceftazidime, is formulated with l-arginine and contains no sodium.', '2', '"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Ceptaz (ceftazidime)." Glaxo Wellcome  (2001):|"Product Information. Tazidime (ceftazidime)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38416, 2281, 'Ceftazidime', 'Heart Failure', 'Fortaz, Tazicef, and Tazidime (brands of parenteral ceftazidime pentahydrate) are formulated with sodium carbonate and contain approximately 53 mg (2.3 mEq) of sodium per each gram of ceftazidime activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.  Ceptaz, another brand of ceftazidime, is formulated with l-arginine and contains no sodium.', '2', '"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Ceptaz (ceftazidime)." Glaxo Wellcome  (2001):|"Product Information. Tazidime (ceftazidime)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38417, 2284, 'Ceftazidime', 'Heart Failure', 'Fortaz, Tazicef, and Tazidime (brands of parenteral ceftazidime pentahydrate) are formulated with sodium carbonate and contain approximately 53 mg (2.3 mEq) of sodium per each gram of ceftazidime activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.  Ceptaz, another brand of ceftazidime, is formulated with l-arginine and contains no sodium.', '2', '"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Ceptaz (ceftazidime)." Glaxo Wellcome  (2001):|"Product Information. Tazidime (ceftazidime)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38418, 2301, 'Ceftazidime', 'Heart Failure', 'Fortaz, Tazicef, and Tazidime (brands of parenteral ceftazidime pentahydrate) are formulated with sodium carbonate and contain approximately 53 mg (2.3 mEq) of sodium per each gram of ceftazidime activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.  Ceptaz, another brand of ceftazidime, is formulated with l-arginine and contains no sodium.', '2', '"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Ceptaz (ceftazidime)." Glaxo Wellcome  (2001):|"Product Information. Tazidime (ceftazidime)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38419, 2302, 'Ceftazidime', 'Heart Failure', 'Fortaz, Tazicef, and Tazidime (brands of parenteral ceftazidime pentahydrate) are formulated with sodium carbonate and contain approximately 53 mg (2.3 mEq) of sodium per each gram of ceftazidime activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.  Ceptaz, another brand of ceftazidime, is formulated with l-arginine and contains no sodium.', '2', '"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Ceptaz (ceftazidime)." Glaxo Wellcome  (2001):|"Product Information. Tazidime (ceftazidime)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38420, 2303, 'Ceftazidime', 'Heart Failure', 'Fortaz, Tazicef, and Tazidime (brands of parenteral ceftazidime pentahydrate) are formulated with sodium carbonate and contain approximately 53 mg (2.3 mEq) of sodium per each gram of ceftazidime activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.  Ceptaz, another brand of ceftazidime, is formulated with l-arginine and contains no sodium.', '2', '"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Ceptaz (ceftazidime)." Glaxo Wellcome  (2001):|"Product Information. Tazidime (ceftazidime)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38421, 2444, 'Ceftazidime', 'Heart Failure', 'Fortaz, Tazicef, and Tazidime (brands of parenteral ceftazidime pentahydrate) are formulated with sodium carbonate and contain approximately 53 mg (2.3 mEq) of sodium per each gram of ceftazidime activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.  Ceptaz, another brand of ceftazidime, is formulated with l-arginine and contains no sodium.', '2', '"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Ceptaz (ceftazidime)." Glaxo Wellcome  (2001):|"Product Information. Tazidime (ceftazidime)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38422, 2445, 'Ceftazidime', 'Heart Failure', 'Fortaz, Tazicef, and Tazidime (brands of parenteral ceftazidime pentahydrate) are formulated with sodium carbonate and contain approximately 53 mg (2.3 mEq) of sodium per each gram of ceftazidime activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.  Ceptaz, another brand of ceftazidime, is formulated with l-arginine and contains no sodium.', '2', '"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Ceptaz (ceftazidime)." Glaxo Wellcome  (2001):|"Product Information. Tazidime (ceftazidime)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38423, 5113, 'Ceftazidime', 'Heart Failure', 'Fortaz, Tazicef, and Tazidime (brands of parenteral ceftazidime pentahydrate) are formulated with sodium carbonate and contain approximately 53 mg (2.3 mEq) of sodium per each gram of ceftazidime activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.  Ceptaz, another brand of ceftazidime, is formulated with l-arginine and contains no sodium.', '2', '"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Ceptaz (ceftazidime)." Glaxo Wellcome  (2001):|"Product Information. Tazidime (ceftazidime)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38424, 6801, 'Ceftazidime', 'Heart Failure', 'Fortaz, Tazicef, and Tazidime (brands of parenteral ceftazidime pentahydrate) are formulated with sodium carbonate and contain approximately 53 mg (2.3 mEq) of sodium per each gram of ceftazidime activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.  Ceptaz, another brand of ceftazidime, is formulated with l-arginine and contains no sodium.', '2', '"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Ceptaz (ceftazidime)." Glaxo Wellcome  (2001):|"Product Information. Tazidime (ceftazidime)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38425, 6802, 'Ceftazidime', 'Heart Failure', 'Fortaz, Tazicef, and Tazidime (brands of parenteral ceftazidime pentahydrate) are formulated with sodium carbonate and contain approximately 53 mg (2.3 mEq) of sodium per each gram of ceftazidime activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.  Ceptaz, another brand of ceftazidime, is formulated with l-arginine and contains no sodium.', '2', '"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Ceptaz (ceftazidime)." Glaxo Wellcome  (2001):|"Product Information. Tazidime (ceftazidime)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38426, 10438, 'Ceftazidime', 'Heart Failure', 'Fortaz, Tazicef, and Tazidime (brands of parenteral ceftazidime pentahydrate) are formulated with sodium carbonate and contain approximately 53 mg (2.3 mEq) of sodium per each gram of ceftazidime activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.  Ceptaz, another brand of ceftazidime, is formulated with l-arginine and contains no sodium.', '2', '"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Ceptaz (ceftazidime)." Glaxo Wellcome  (2001):|"Product Information. Tazidime (ceftazidime)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38427, 10439, 'Ceftazidime', 'Heart Failure', 'Fortaz, Tazicef, and Tazidime (brands of parenteral ceftazidime pentahydrate) are formulated with sodium carbonate and contain approximately 53 mg (2.3 mEq) of sodium per each gram of ceftazidime activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.  Ceptaz, another brand of ceftazidime, is formulated with l-arginine and contains no sodium.', '2', '"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Ceptaz (ceftazidime)." Glaxo Wellcome  (2001):|"Product Information. Tazidime (ceftazidime)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38428, 16013, 'Ceftazidime', 'Heart Failure', 'Fortaz, Tazicef, and Tazidime (brands of parenteral ceftazidime pentahydrate) are formulated with sodium carbonate and contain approximately 53 mg (2.3 mEq) of sodium per each gram of ceftazidime activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.  Ceptaz, another brand of ceftazidime, is formulated with l-arginine and contains no sodium.', '2', '"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Ceptaz (ceftazidime)." Glaxo Wellcome  (2001):|"Product Information. Tazidime (ceftazidime)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38429, 16014, 'Ceftazidime', 'Heart Failure', 'Fortaz, Tazicef, and Tazidime (brands of parenteral ceftazidime pentahydrate) are formulated with sodium carbonate and contain approximately 53 mg (2.3 mEq) of sodium per each gram of ceftazidime activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.  Ceptaz, another brand of ceftazidime, is formulated with l-arginine and contains no sodium.', '2', '"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Ceptaz (ceftazidime)." Glaxo Wellcome  (2001):|"Product Information. Tazidime (ceftazidime)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38430, 16015, 'Ceftazidime', 'Heart Failure', 'Fortaz, Tazicef, and Tazidime (brands of parenteral ceftazidime pentahydrate) are formulated with sodium carbonate and contain approximately 53 mg (2.3 mEq) of sodium per each gram of ceftazidime activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.  Ceptaz, another brand of ceftazidime, is formulated with l-arginine and contains no sodium.', '2', '"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Ceptaz (ceftazidime)." Glaxo Wellcome  (2001):|"Product Information. Tazidime (ceftazidime)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38431, 16062, 'Ceftazidime', 'Heart Failure', 'Fortaz, Tazicef, and Tazidime (brands of parenteral ceftazidime pentahydrate) are formulated with sodium carbonate and contain approximately 53 mg (2.3 mEq) of sodium per each gram of ceftazidime activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.  Ceptaz, another brand of ceftazidime, is formulated with l-arginine and contains no sodium.', '2', '"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Ceptaz (ceftazidime)." Glaxo Wellcome  (2001):|"Product Information. Tazidime (ceftazidime)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38432, 16080, 'Ceftazidime', 'Heart Failure', 'Fortaz, Tazicef, and Tazidime (brands of parenteral ceftazidime pentahydrate) are formulated with sodium carbonate and contain approximately 53 mg (2.3 mEq) of sodium per each gram of ceftazidime activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.  Ceptaz, another brand of ceftazidime, is formulated with l-arginine and contains no sodium.', '2', '"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Ceptaz (ceftazidime)." Glaxo Wellcome  (2001):|"Product Information. Tazidime (ceftazidime)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38433, 16194, 'Ceftazidime', 'Heart Failure', 'Fortaz, Tazicef, and Tazidime (brands of parenteral ceftazidime pentahydrate) are formulated with sodium carbonate and contain approximately 53 mg (2.3 mEq) of sodium per each gram of ceftazidime activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.  Ceptaz, another brand of ceftazidime, is formulated with l-arginine and contains no sodium.', '2', '"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Ceptaz (ceftazidime)." Glaxo Wellcome  (2001):|"Product Information. Tazidime (ceftazidime)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38434, 19339, 'Ceftazidime', 'Heart Failure', 'Fortaz, Tazicef, and Tazidime (brands of parenteral ceftazidime pentahydrate) are formulated with sodium carbonate and contain approximately 53 mg (2.3 mEq) of sodium per each gram of ceftazidime activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.  Ceptaz, another brand of ceftazidime, is formulated with l-arginine and contains no sodium.', '2', '"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Ceptaz (ceftazidime)." Glaxo Wellcome  (2001):|"Product Information. Tazidime (ceftazidime)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38435, 19340, 'Ceftazidime', 'Heart Failure', 'Fortaz, Tazicef, and Tazidime (brands of parenteral ceftazidime pentahydrate) are formulated with sodium carbonate and contain approximately 53 mg (2.3 mEq) of sodium per each gram of ceftazidime activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.  Ceptaz, another brand of ceftazidime, is formulated with l-arginine and contains no sodium.', '2', '"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Ceptaz (ceftazidime)." Glaxo Wellcome  (2001):|"Product Information. Tazidime (ceftazidime)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38436, 19341, 'Ceftazidime', 'Heart Failure', 'Fortaz, Tazicef, and Tazidime (brands of parenteral ceftazidime pentahydrate) are formulated with sodium carbonate and contain approximately 53 mg (2.3 mEq) of sodium per each gram of ceftazidime activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.  Ceptaz, another brand of ceftazidime, is formulated with l-arginine and contains no sodium.', '2', '"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Ceptaz (ceftazidime)." Glaxo Wellcome  (2001):|"Product Information. Tazidime (ceftazidime)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38437, 19355, 'Ceftazidime', 'Heart Failure', 'Fortaz, Tazicef, and Tazidime (brands of parenteral ceftazidime pentahydrate) are formulated with sodium carbonate and contain approximately 53 mg (2.3 mEq) of sodium per each gram of ceftazidime activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.  Ceptaz, another brand of ceftazidime, is formulated with l-arginine and contains no sodium.', '2', '"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Ceptaz (ceftazidime)." Glaxo Wellcome  (2001):|"Product Information. Tazidime (ceftazidime)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38438, 19356, 'Ceftazidime', 'Heart Failure', 'Fortaz, Tazicef, and Tazidime (brands of parenteral ceftazidime pentahydrate) are formulated with sodium carbonate and contain approximately 53 mg (2.3 mEq) of sodium per each gram of ceftazidime activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.  Ceptaz, another brand of ceftazidime, is formulated with l-arginine and contains no sodium.', '2', '"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Ceptaz (ceftazidime)." Glaxo Wellcome  (2001):|"Product Information. Tazidime (ceftazidime)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38439, 20922, 'Ceftazidime', 'Heart Failure', 'Fortaz, Tazicef, and Tazidime (brands of parenteral ceftazidime pentahydrate) are formulated with sodium carbonate and contain approximately 53 mg (2.3 mEq) of sodium per each gram of ceftazidime activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.  Ceptaz, another brand of ceftazidime, is formulated with l-arginine and contains no sodium.', '2', '"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Ceptaz (ceftazidime)." Glaxo Wellcome  (2001):|"Product Information. Tazidime (ceftazidime)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38440, 21317, 'Ceftazidime', 'Heart Failure', 'Fortaz, Tazicef, and Tazidime (brands of parenteral ceftazidime pentahydrate) are formulated with sodium carbonate and contain approximately 53 mg (2.3 mEq) of sodium per each gram of ceftazidime activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.  Ceptaz, another brand of ceftazidime, is formulated with l-arginine and contains no sodium.', '2', '"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Ceptaz (ceftazidime)." Glaxo Wellcome  (2001):|"Product Information. Tazidime (ceftazidime)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38441, 22394, 'Ceftazidime', 'Heart Failure', 'Fortaz, Tazicef, and Tazidime (brands of parenteral ceftazidime pentahydrate) are formulated with sodium carbonate and contain approximately 53 mg (2.3 mEq) of sodium per each gram of ceftazidime activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.  Ceptaz, another brand of ceftazidime, is formulated with l-arginine and contains no sodium.', '2', '"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Ceptaz (ceftazidime)." Glaxo Wellcome  (2001):|"Product Information. Tazidime (ceftazidime)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38442, 22395, 'Ceftazidime', 'Heart Failure', 'Fortaz, Tazicef, and Tazidime (brands of parenteral ceftazidime pentahydrate) are formulated with sodium carbonate and contain approximately 53 mg (2.3 mEq) of sodium per each gram of ceftazidime activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.  Ceptaz, another brand of ceftazidime, is formulated with l-arginine and contains no sodium.', '2', '"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Ceptaz (ceftazidime)." Glaxo Wellcome  (2001):|"Product Information. Tazidime (ceftazidime)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38443, 23346, 'Ceftazidime', 'Heart Failure', 'Fortaz, Tazicef, and Tazidime (brands of parenteral ceftazidime pentahydrate) are formulated with sodium carbonate and contain approximately 53 mg (2.3 mEq) of sodium per each gram of ceftazidime activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.  Ceptaz, another brand of ceftazidime, is formulated with l-arginine and contains no sodium.', '2', '"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Ceptaz (ceftazidime)." Glaxo Wellcome  (2001):|"Product Information. Tazidime (ceftazidime)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38444, 23347, 'Ceftazidime', 'Heart Failure', 'Fortaz, Tazicef, and Tazidime (brands of parenteral ceftazidime pentahydrate) are formulated with sodium carbonate and contain approximately 53 mg (2.3 mEq) of sodium per each gram of ceftazidime activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.  Ceptaz, another brand of ceftazidime, is formulated with l-arginine and contains no sodium.', '2', '"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Ceptaz (ceftazidime)." Glaxo Wellcome  (2001):|"Product Information. Tazidime (ceftazidime)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38445, 28976, 'Ceftazidime', 'Heart Failure', 'Fortaz, Tazicef, and Tazidime (brands of parenteral ceftazidime pentahydrate) are formulated with sodium carbonate and contain approximately 53 mg (2.3 mEq) of sodium per each gram of ceftazidime activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.  Ceptaz, another brand of ceftazidime, is formulated with l-arginine and contains no sodium.', '2', '"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Ceptaz (ceftazidime)." Glaxo Wellcome  (2001):|"Product Information. Tazidime (ceftazidime)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38446, 28977, 'Ceftazidime', 'Heart Failure', 'Fortaz, Tazicef, and Tazidime (brands of parenteral ceftazidime pentahydrate) are formulated with sodium carbonate and contain approximately 53 mg (2.3 mEq) of sodium per each gram of ceftazidime activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.  Ceptaz, another brand of ceftazidime, is formulated with l-arginine and contains no sodium.', '2', '"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Ceptaz (ceftazidime)." Glaxo Wellcome  (2001):|"Product Information. Tazidime (ceftazidime)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38447, 29784, 'Ceftazidime', 'Heart Failure', 'Fortaz, Tazicef, and Tazidime (brands of parenteral ceftazidime pentahydrate) are formulated with sodium carbonate and contain approximately 53 mg (2.3 mEq) of sodium per each gram of ceftazidime activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.  Ceptaz, another brand of ceftazidime, is formulated with l-arginine and contains no sodium.', '2', '"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Ceptaz (ceftazidime)." Glaxo Wellcome  (2001):|"Product Information. Tazidime (ceftazidime)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38448, 29785, 'Ceftazidime', 'Heart Failure', 'Fortaz, Tazicef, and Tazidime (brands of parenteral ceftazidime pentahydrate) are formulated with sodium carbonate and contain approximately 53 mg (2.3 mEq) of sodium per each gram of ceftazidime activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.  Ceptaz, another brand of ceftazidime, is formulated with l-arginine and contains no sodium.', '2', '"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Ceptaz (ceftazidime)." Glaxo Wellcome  (2001):|"Product Information. Tazidime (ceftazidime)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38449, 29786, 'Ceftazidime', 'Heart Failure', 'Fortaz, Tazicef, and Tazidime (brands of parenteral ceftazidime pentahydrate) are formulated with sodium carbonate and contain approximately 53 mg (2.3 mEq) of sodium per each gram of ceftazidime activity.  The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.  Ceptaz, another brand of ceftazidime, is formulated with l-arginine and contains no sodium.', '2', '"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Ceptaz (ceftazidime)." Glaxo Wellcome  (2001):|"Product Information. Tazidime (ceftazidime)." Lilly, Eli and Company  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38450, 2233, 'Ceftazidime', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38451, 2281, 'Ceftazidime', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38452, 2284, 'Ceftazidime', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38453, 2301, 'Ceftazidime', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38454, 2302, 'Ceftazidime', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38455, 2303, 'Ceftazidime', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38456, 2444, 'Ceftazidime', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38457, 2445, 'Ceftazidime', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38458, 5113, 'Ceftazidime', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38459, 6801, 'Ceftazidime', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38460, 6802, 'Ceftazidime', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38461, 10438, 'Ceftazidime', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38462, 10439, 'Ceftazidime', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38463, 16013, 'Ceftazidime', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38464, 16014, 'Ceftazidime', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38465, 16015, 'Ceftazidime', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38466, 16062, 'Ceftazidime', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38467, 16080, 'Ceftazidime', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38468, 16194, 'Ceftazidime', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38469, 19339, 'Ceftazidime', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38470, 19340, 'Ceftazidime', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38471, 19341, 'Ceftazidime', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38472, 19355, 'Ceftazidime', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38473, 19356, 'Ceftazidime', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38474, 20922, 'Ceftazidime', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38475, 21317, 'Ceftazidime', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38476, 22394, 'Ceftazidime', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38477, 22395, 'Ceftazidime', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38478, 23346, 'Ceftazidime', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38479, 23347, 'Ceftazidime', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38480, 28976, 'Ceftazidime', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38481, 28977, 'Ceftazidime', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38482, 29784, 'Ceftazidime', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38483, 29785, 'Ceftazidime', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38484, 29786, 'Ceftazidime', 'Diseases requiring dialysis', 'Most cephalosporin antibiotics are removed by hemodialysis.  Doses should either be scheduled for administration after dialysis or supplemental doses be given after dialysis.  Cefonicid, cefixime, and ceftriaxone are not significantly removed by hemodialysis.', '2', '"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Monocid (cefonicid)." SmithKline Beecham  (2002):|"Product Information. Cefobid (cefoperazone)." Roerig Division  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Tazicef (ceftazidime)." SmithKline Beecham  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Rocephin (ceftriaxone)." Roche Laboratories  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Velosef (cephradine)." Apothecon Inc  (2002):|"Product Information. Keflin (cephalothin)." Lilly, Eli and Company  (2002):|"Product Information. Cefadyl (cephapirin)." Apothecon Inc  (2002):|"Product Information. Lorabid (loracarbef)." Lilly, Eli and Company  (2002):|"Product Information. Mandol (cefamandole)." Lilly, Eli and Company  (2001):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38485, 2233, 'Ceftazidime', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38486, 2281, 'Ceftazidime', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38487, 2284, 'Ceftazidime', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38488, 2301, 'Ceftazidime', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38489, 2302, 'Ceftazidime', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38490, 2303, 'Ceftazidime', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38491, 2444, 'Ceftazidime', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38492, 2445, 'Ceftazidime', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38493, 5113, 'Ceftazidime', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38494, 6801, 'Ceftazidime', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38495, 6802, 'Ceftazidime', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38496, 10438, 'Ceftazidime', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38497, 10439, 'Ceftazidime', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38498, 16013, 'Ceftazidime', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38499, 16014, 'Ceftazidime', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (38500, 16015, 'Ceftazidime', 'Liver Diseases', 'Cases of hepatitis have been reported with the use of certain cephalosporins.  Transient rise in AST, ALT, and alkaline phosphatase levels have also been observed.  Caution and monitoring is recommended when these agents are prescribed to patients with hepatic disorders.', '2', '"Product Information. Vantin (cefpodoxime)." Pharmacia and Upjohn|"Product Information. Ceclor (cefaclor)." Lilly, Eli and Company  (2002):|"Product Information. Duricef (cefadroxil)." Bristol-Myers Squibb  (2002):|"Product Information. Ancef (cefazolin)." SmithKline Beecham  (2002):|"Product Information. Kefzol (cefazolin)." Lilly, Eli and Company  (2002):|"Product Information. Suprax (cefixime)." Lupin Pharmaceuticals Inc  (2002):|"Product Information. Claforan (cefotaxime)." Hoechst Marion Roussel  (2002):|"Product Information. Cefotan (cefotetan)." Stuart Pharmaceuticals  (2002):|"Product Information. Mefoxin (cefoxitin)." Merck & Co., Inc  (2002):|"Product Information. Cefzil (cefprozil)." Bristol-Myers Squibb  (2002):|"Product Information. Fortaz (ceftazidime)." Glaxo Wellcome  (2002):|"Product Information. Cefizox (ceftizoxime)." Fujisawa  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Keflex (cephalexin)." Dista Products Company  (2002):|"Product Information. Cedax (ceftibuten)." Schering-Plough  (2001):|"Product Information. Maxipime (cefepime)." Bristol-Myers Squibb  (2001):|"Product Information. Omnicef (cefdinir)." Parke-Davis  (2001):|"Product Information. Ceclor CD (cefaclor)." Dura Pharmaceuticals  (2001):|"Product Information. Spectracef (cefditoren)." TAP Pharmaceuticals Inc  (2001):', 'DDInter', 0);
